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A major challenge of platinum anticancer therapy lies in overcoming the severe 
side-effects associated with treatment. Photoactivatable Pt
IV
 azido complexes, 
which are stable in the dark and reduced to cytotoxic Pt
II
 species upon irradiation, 
have recently emerged as a potential site-specific treatment. This thesis is 




 azido complexes as potential 
cytotoxic and photochemotherapeutic agents. 
Pt
II
 azido complexes such as [Pt(en)(N3)2] were shown to bind to both 
5'-guanosine monophosphate (5'-GMP) and glutathione, at a much reduced rate 
compared with their Pt
II
 chlorido analogues. Interestingly, and unexpectedly, these 
Pt
II
 azido complexes showed moderate cytotoxicity towards the A2780 cancer cell 
line (IC50 21–47 µM). Binding to 5'-GMP was observed to occur more rapidly 
upon irradiation with UVA light, although the extent of binding was low and the 
complexes did not demonstrate phototoxicity towards HaCaT keratinocytes. 
The pendant hydroxyl group of a Pt
II
 azido complex was functionalised with a 
fluorescent probe; conjugation to one axial hydroxyl ligand of a Pt
IV
 azido 
complex was also achieved. The latter conjugate showed a rapid increase in 
fluorescence intensity upon irradiation, resulting from loss of the axial ligands 
upon photoreduction. The functionalisation of quantum dots with Pt
II
 complexes 
was also investigated. Water soluble CdSe-ZnS quantum dots were synthesised 
and derivatised with an amine ligand to which platinum was bound. Conjugation 
of apo-transferrin to quantum dots was also achieved, with subsequent platinum 
binding yielding a conjugate with improved aqueous solubility and fluorescence 
properties. However, the conjugate was inactive towards the A2780 cancer cell 
line, likely due to surface modifications preventing cellular internalisation. Pt
II
 
chlorido and azido conjugates with a porphyrin were synthesised and found to 
show differing behaviour upon irradiation with visible light; evidence of hydrogen 
peroxide generation from the chlorido complex was much reduced in the case of 
ii 
 
the azido complex; it is suggested this may result from quenching of reactive 
oxygen species by the azide anion released upon irradiation. 
Pt
II
 chlorido and azido complexes of highly coloured azo ligands were synthesised 
in an attempt to shift the wavelength of activation into the visible region. TD-DFT 
calculations allowed frontier orbital analysis and assignment of the transitions in 
the absorption spectra. Irradiation of the Pt
II
 azido complexes with UVA or 
broadband visible light led to their decomposition; one water-soluble complex 
was found to show moderate cytotoxicity and phototoxicity; in addition, its 
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This thesis is concerned with the design of photoactivatable platinum complexes 
and their potential application as anticancer agents. In this Chapter, an 
introduction to platinum drugs in clinical use and the current research in this area 
is given, followed by a discussion of photochemistry with emphasis on metal 
complexes and its use in medicine. An introduction to the previous work in the 
area of photoactivatable platinum anticancer complexes is then given. 
 
1.2 Metal-based Drugs 
It is now apparent that around 24 elements are essential to human life,[1] with 
inorganic elements playing crucial roles in many biological processes. The rich 
redox and coordination chemistry of a number of transition metals is utilised in 
many catalytic and electron transfer processes; it has been estimated that the 
activity of around 12% of all enzymes can be attributed to metal centres.[2]   
Metal ions are electron deficient and thus show affinity for electron rich 
biomolecules such as proteins and DNA. However, their reactivity is very much 
dependent upon speciation, and with scope to vary the coordination number, 
geometry, oxidation state, thermodynamic and kinetic stability of metal 
complexes, interest is increasing in their potential medicinal applications. 
The use of metals in medicine dates back to antiquity; it is believed the use of 
gold as a therapeutic agent began in Ancient China around 2500 BC,[3] whilst the 
antimicrobial properties of silver compounds were recognised by the Romans.[4] 
The last century has seen the use of bismuth compounds in the treatment of 
gastrointestinal disorders,[5] as well as the development of gold complexes in the 
treatment of rheumatoid arthritis;[6] both of which are still in use today. However, 
the field of medicinal inorganic chemistry was sparked by the discovery, in 1969, 
of the anticancer activity of cis-[Pt(NH3)2Cl2] (cisplatin).
[7] Since platinum 
anticancer agents are a focus of this work they shall be discussed in detail below, 




however it is important to note the development of this field in the last forty years. 
A wide range of inorganic and organometallic complexes are in clinical use or are 
under investigation as therapeutic agents, including those of gadolinium as 
imaging contrast agents,[8] vanadium as insulin mimetics,[9] and titanium,[10] 
ruthenium,[11] gallium[12] and gold[13] as anticancer agents, among others. 
 
1.3 Platinum Anticancer Agents 
Cancer is a term for a group of over 100 diseases characterised by abnormal cell 
growth. Cancers typically acquire six hallmark capabilities: a self-sufficiency in 
growth signals with insensitivity to anti-growth signals, sustained angiogenesis 
(growth of blood vessels), a limitless replicative potential, the evasion of 
apoptosis and the ability to invade other tissues.[14] The treatment of cancer 
includes surgery, external or internal radiotherapy (using X-rays or a radioactive 
source, respectively) and/or chemotherapy with cytotoxic drugs, of which there 
are several types:[15] DNA alkylating agents, antimetabolites, mitotic and 
topoisomerase inhibitors, hormone treatments and cytotoxic antibiotics. Although 
not strictly alkylating agents, platinum drugs are related to the first class, and 
since their routine use began thirty years ago have become the world’s best selling 
anticancer agents; it is estimated that over 70% of cancer patients receive a 
platinum drug as part of their treatment.[16] 
  
1.3.1 Cisplatin 
The biological activity of cisplatin was serendipitously discovered by Barnett 
Rosenberg in 1969 who, studying the effect of electric fields on E. coli, noted 
abnormal filamentous growth attributed to platinum complexes formed from the 
electrode.[17] Several such complexes were then tested and found to have potent 
anticancer activity,[7] resulting in cisplatin entering clinical trials in 1971. 
Following FDA approval in 1978, it is now used in the treatment of ovarian, 





cervical, bladder, small-cell lung and head and neck cancers,[18] and has 
revolutionised the treatment of testicular cancer; rendering a disease which once 






Figure 1.1  The structure of cisplatin, the first platinum anticancer agent. 
 
Cisplatin is administered by infusion or intravenous injection, following which the 
high extracellular chloride concentration (~100 mM) prevents hydrolysis of the 
two chlorido ligands during distribution throughout the body. For many years, 
uptake into cells was believed to occur via passive diffusion,[20] however in recent 
years evidence has mounted for the involvement of a number of active transport 
processes,[21] the most important of which involves the copper transporter protein 
CTR1. This was shown to be a major determinant of the initial influx of platinum 
drugs, with one experiment showing its loss reduces cisplatin influx by 81% in the 
first five minutes of exposure, and renders cells resistant to even high 
concentrations of the drug.[22] It has been suggested that CTR1 employs a 
different mechanism for the transport of copper and cisplatin,[23] and although the 
mechanism has yet to be elucidated, the interaction of platinum complexes with a 
methionine motif found in this protein has been reported.[24] 
Upon entry into the cytoplasm, where the chloride concentration falls to ~25 mM, 
cisplatin becomes hydrolysed to the mono- and diaqua species 
cis-[Pt(NH3)2(H2O)Cl]
+ and cis-[Pt(NH3)2(H2O)2]
2+, and it is the binding of these 
to DNA which results in a cytotoxic effect.[25] Hydrolysis is the rate-limiting step 
in this interaction, with half-lives for loss of the first and second chloride 




determined as 1.9 h and 2.1 h respectively (310 K).[26] The preferred binding site 
on DNA is the N7 of guanine residues, since this is the most electron rich site and, 
additionally, allows for hydrogen bonding interactions between the amine N–H of 
cisplatin and the O6 of guanine.[27] The major DNA adducts formed are 
1,2-d(GpG) intrastrand cross-links between two adjacent guanines (Figure 1.2), 
accounting for 65% of the total, with other adducts including 1,2-d(ApG) (25%) 
and 1,3-d(GpNpG) (5–10%) intrastrand links, with a small percentage of 




Figure 1.2  Two representations of the 1,2-d(GpG) adduct formed by the 
interaction of cisplatin with duplex DNA. Adapted from reference 25.  
 
The formation of platinum adducts significantly alters the structure of DNA, with 
studies revealing destabilisation of the duplex, unwinding and bending. 1,2-
Intrastrand cross-links were shown to unwind the DNA duplex in the locality of 
the platination site, inducing a bend towards the major groove and a widened, 
shallow minor groove.[29]  




Several classes of protein can bind to the exposed minor groove surface, the most 
studied of which are the high-mobility group (HMG) box proteins. Following 
binding, the protein inserts a phenylalanine side chain between the two guanine 
bases in the platinated cross-link,[30] and may serve to shield the cross-link from 
repair, ultimately leading to apoptosis. However, the exact mechanism by which 
platinum–DNA adducts trigger apoptosis is unclear; they are known to modulate 
several signal transduction pathways, which may lead to replication arrest, 
transcription inhibition and cell cycle arrest,[31] although much work is needed in 
order to gain further understanding of these processes. 
 
1.3.2 Platinum Anticancer Agents in Clinical Use 
Despite the success of cisplatin there are a number of problems associated with its 
use, namely poor saline solubility and resistance as well as toxic side effects 
including nausea and vomiting, nephro- and neurotoxicity. Whilst the former can 
be partially managed with antiemetics, and nephrotoxicity with hydration therapy, 
neurotoxicity is dose-limiting and may be severe enough to necessitate withdrawal 
of treatment.[31] Consequently, the search for new platinum drugs to circumvent 
such effects is extensive and ongoing; although despite the synthesis of thousands 
of complexes, around 35 have undergone clinical testing with only five approved 
for clinical use.[32] These are discussed in the following sections. 
 
1.3.2.1 Carboplatin 
The toxicity of cisplatin has been attributed in part to its high reactivity, resulting 
from the lability of the Pt–Cl bonds. It was hypothesised that the incorporation of 
a more stable leaving group would render the complex less reactive towards 
biomolecules, thereby minimising side-reactions and lowering toxicity yet 
retaining antitumour efficacy. This led to the development of the second 




generation drug carboplatin, containing the chelating 1,1-
cyclobutanedicarboxylato ligand (Figure 1.3). 
Despite its introduction as early as the 1980s, the nature of the interaction of 
carboplatin with DNA is yet to be fully elucidated and two main mechanisms 
have been proposed:[33] the aquation hypothesis, involving hydrolysis of the 
chelating ligand and subsequent reaction with DNA in a similar fashion to 
cisplatin, or the activation hypothesis, involving biological activation (for 
example, enzymatically or by reaction with thiols) to a species which can then 
react with DNA.[34] Additionally, direct reactions with DNA have also been 
suggested due to unexpectedly rapid reactions with 5'-GMP.[35] Although there is 
a lack of evidence for these latter theories, they are consistent with the observed 
activity of carboplatin despite its chemical inertness.  
Therapeutically, an increased dose relative to cisplatin is required, however whilst 
a 100-fold greater concentration is necessary to achieve the same rate of DNA 
platination as cisplatin in vitro, only a 4–20 fold increase is needed to achieve the 
same in patients.[36] Furthermore, such doses of carboplatin are comparatively 
well-tolerated. Nausea, vomiting and neurotoxicity are markedly reduced and 
nephrotoxicity is absent at standard doses; instead, the dose-limiting toxicity of 
carboplatin is myelosuppression (a reduction in bone marrow function). As a 
result of this higher tolerance, carboplatin has largely replaced cisplatin in clinical 
use where possible.  
However, compared with cisplatin, carboplatin shows somewhat reduced efficacy 
in head and neck, bladder and oesophageal cancers, although is comparable in 
ovarian and both small-cell and non-small-cell lung cancers;[32] thus showing no 
real increase in the range of sensitive tumours. This is attributed to the fact that 
both complexes form similar DNA adducts, since these are largely dictated by the 
non-leaving am(m)ino ligands, which are ammonia groups in both cases. 
 





The third generation drug oxaliplatin was approved for use in major European 
countries in 1999, followed by the United States in 2002.[37] This complex 
contains a 1,2-diaminocyclohexane (DACH) ligand as the non-leaving group 
(Figure 1.3), hence the Pt–DNA adducts formed differ from those of cisplatin and 
carboplatin; although 1,2-d(GpG) cross-links are still the major platinated species, 
the bulky DACH ligand confers differing chemical and steric characteristics to the 
adducts. This is likely to result in differential recognition and protein binding to 
these adducts compared with those of cisplatin and carboplatin, implicated in the 
fact that oxaliplatin shows potency in tumours that are resistant to these drugs. It 
is now the first line treatment for metastatic colorectal cancer, and has recently 
undergone Phase III trials for the treatment of pancreatic cancer,[37] a notoriously 
difficult cancer to treat. However, the difference in tumour specificity could also 
be related to a difference in uptake. Studies have determined that organic cation 
transporters (OCTs) markedly increase cellular accumulation of oxaliplatin, but 
not cisplatin or carboplatin, and that the cytotoxicity of oxaliplatin is reduced 
upon administration with an OCT inhibitor. It is suggested that an organic group 
on the non-leaving ligand is required for selective uptake by OCTs.[38] 
Tolerance to oxaliplatin is similar to that of carboplatin, with sensory neuropathy 
the dose-limiting toxicity, as is common with all DACH-containing complexes.[19] 
Oxaliplatin is now the best selling of all platinum anticancer agents and has 
become a blockbuster drug, with sales of over $1.6 billion in 2005/2006.[21] 
 
1.3.2.3 Nedaplatin, Lobaplatin and Heptaplatin 
Three other platinum complexes have also gained regionally limited approval. 
Nedaplatin is approved for use in Japan in the treatment of lung, ovarian and 
colorectal cancers; however shows major cross-resistance with cisplatin.[39] 
Lobaplatin is used in China to treat metastatic breast and small-cell lung 







tumours,[40] with heptaplatin used in South Korea for gastric cancers.[41] However, 
their toxicities remain similar to that of carboplatin and, although effective in a 
slightly wider range of tumours, they again do little to circumvent the problem of 
















Figure 1.3  Five platinum compounds approved for use in cancer treatment.  
 
1.3.3 Resistance to Platinum Anticancer Agents 
The second- and third generation platinum drugs discussed here show some 
improvements over cisplatin; these include greater water solubility, a slightly 
broader spectrum of activity and, in particular, a reduction in toxic side effects. 




However, they do little to circumvent another major problem of platinum 
chemotherapy: that of resistance. This can be either inherent, or acquired 
following initial treatment, and can occur by several different mechanisms.  
Reduced drug accumulation is commonly reported in platinum-resistant cell lines, 
and is believed to result from a decrease in uptake rather than an increase in 
efflux.[42] Reasons behind this are unclear; in addition to the copper transporter 
CTR1, a number of other transporters are likely to be capable of accommodating 
cisplatin uptake, and studies of sensitive and resistant cell lines have not been able 
to identify a single one whose decreased presence on the plasma membrane 
significantly contributes to a reduction in accumulation.[43] However, there are 
also arguments for the role of increased efflux, with evidence of extrusion after 
chelation by glutathione and in an unknown form via the copper efflux system.[43] 
A major resistance mechanism involves the deactivation of complexes prior to 
reaching their active site of DNA; in fact, it has been estimated that only 1% of 
intracellular platinum reaches the nucleus.[44] The high affinity of platinum for 
sulfur donor ligands results in binding to intracellular thiols, with the cysteine-
containing tripeptide glutathione, present in millimolar concentrations within 
cells, believed to play an important role in deactivation. There have been many 
reports showing that the toxicity of platinum drugs decreases with increasing 
cellular glutathione levels,[45] however reducing these levels with drugs such as 
buthionine sulfoximine has led to only low to moderate increases in cisplatin 
sensitivity.[46] Furthermore, recent work has suggested that higher molecular 
weight thiols may be of greater importance than glutathione in deactivation 
reactions. Experiments involving the incubation of cisplatin with whole cell 
extracts revealed that two-thirds of the resulting platinum adducts had a molecular 
mass >3 kDa, and Pt(glutathione)2 species could not account for more than 20% 
of the total platinum adducts.[47]  The high molecular weight adducts could not be 
identified due to the sheer abundance of proteins in the cell with which platinum 
could react, however the likely role of metallothioneins in deactivation is well-
documented.[48] These metal-binding proteins are sulfur rich, containing twenty 




cysteine residues, and incorporation of platinum into the metallothionein structure 
is an efficient means of sequestering these drugs. 
Resistance can also arise from the increased tolerance to, or repair of, Pt–DNA 
adducts. The recognition of such adducts can either lead to induction of apoptosis 
by activation of the appropriate signalling pathways, as discussed in section 1.3.1, 
or to damage repair, which will increase the probability of cell survival. Adducts 
are primarily removed by nucleotide excision repair (NER), in which the damaged 
DNA segment is excised by hydrolysis of the backbone phosphodiester bonds, 
followed by replacement of the missing nucleotides by DNA polymerase.[49] It is 
known that cells deficient in NER are more sensitive to platinum drugs, and that 
repair is enhanced in platinum-resistant cell lines.[50] In addition, mismatch repair 
and recombinatorial repair mechanisms have also been implicated;[25] it has been 
suggested that the latter may also be active against the small proportion of 
interstrand cross-links. However, studies have indicated that an enhancement of 
DNA repair is not sufficient to render cells resistant to platinum drugs in the 
absence of other resistance mechanisms.[50] 
 
1.3.4 The Design of New Platinum Anticancer Agents 
In the years following the development of cisplatin, Cleare and Hoeschele 
published a set of structure-activity relationships[51] which focused the research 
efforts in this field onto complexes similar in nature to cisplatin; namely 
cis-[PtA2X2], where A = amine possessing at least one N–H bond, and 
X = anionic leaving group with intermediate binding strength (e.g. chloride). 
However, whilst thousands of complexes have been screened, only five have 
entered clinical use, and no drug has yet emerged in which the range of sensitive 
tumours is much greater, and the toxicity significantly lower, than that of 
cisplatin. It is becoming increasingly apparent that in order to overcome these 
problems, new design concepts are needed.  Hence in recent years the emphasis 
has shifted and many recent complexes violate these rules; they are designed to 




have a different mechanism of action, mode of activation, or platination profile to 
cisplatin in attempts to produce a more effective platinum anticancer agent. Some 
examples are discussed below. 
 
1.3.4.1 Sterically Hindered Complexes 
cis–[Pt(NH3)(2-picoline)Cl2] (picoplatin) was designed in an attempt to reduce 
drug deactivation by intracellular thiols.[52] The methyl group of the 2-picoline 
ring lies over the top of the platinum square plane, providing steric hindrance to 
the formation of a trigonal bipyramidal intermediate necessary in substitution 
reactions. The hydrolysis rates of picoplatin are two to three times slower than 
those of cisplatin,[52] with the rate of reaction towards glutathione also reduced, 
and the influence of the 2-picoline ring highlighted by comparison with the 3-
picoline analogue.[53] Although reaction rates with DNA were also decreased, the 
extent of platination by this complex was shown to be similar to that of 
cisplatin.[54] It was suggested that DNA adducts may be recognised differently to 
those of cisplatin by the excision repair systems, which could explain the 
observed lack of cross-resistance. Picoplatin shows in vitro toxicity intermediate 
between that of cisplatin and carboplatin,[55] and is currently undergoing Phase III 
clinical trials for the treatment of small-cell lung cancer.[21]  
 
1.3.4.2 Trans Complexes 
It had been observed in early studies of platinum complexes that 
trans-[Pt(NH3)2Cl2] (transplatin) was inactive.
[56] This was partially attributed to 
its lack of ability to form 1,2-d(GpG) intrastrand cross-links, responsible for the 
activity of its isomer cisplatin, although stable monoadducts are formed. 
Furthermore, transplatin is kinetically much more reactive to nucleophiles in both 
the dichloro and monoaqua forms than is cisplatin, reacting up to 1000 times 
faster with glutathione. Such high activity is likely to result in rapid deactivation 




prior to reaching DNA. However, by varying the nature of the amine ligands, 
several classes of active trans complexes have been identified; three shall be 
discussed here.  
The complex trans-[Pt(E-iminoether)2Cl2] (Figure 1.4) forms monofunctional 
adducts at the N7 of guanine residues; experiments with single-stranded 
oligonucleotides, which were subsequently hybridised, suggested the local 
distortion of DNA and bending towards the minor groove, with a lack of adduct 
recognition by HMG proteins.[57] The monofunctional adducts can readily cross-
link proteins, enhancing the ability to terminate DNA polymerisation and 
inhibiting removal of the adduct by nucleotide excision repair. However, more 
recent studies suggested that trans-[Pt(E-iminoether)2Cl2] does not interact with 
short duplexes lacking terminal guanine residues, as a result of the steric demand 
of the iminoether groups. The replacement of one iminoether group with NH3 
allowed for binding at central guanines, whilst retaining the toxicity of the bis-
iminoether complex.[58] It has also been suggested that the steric bulk of the 
iminoether ligand may retard any deactivation reactions with thiol-containing 
biomolecules. These imino complexes have shown good activity in a range of cell 
lines.[59] 
Trans-PtII complexes with branched chain aliphatic amines also show very 
promising cytotoxicity. Trans-[Pt(dimethylamine)(isopropylamine)Cl2] (Figure 
1.4) has been shown to form mainly interstrand cross-links with DNA, between a 
guanine residue and its complementary cytosine, and induce apoptosis.[60] Recent 
work suggests that hydrolysis rates of this and two related branched-amine 
complexes are rapid (half-lives 1.3–3.5 h at 298 K), however the extent of 
hydrolysis is low: <1% at equilibrium.[61] It was noted that more sterically 
hindered complexes hydrolyse more slowly, and a lower extent of hydrolysis at 
equilibrium appears to correlate with higher cytotoxicity, suggesting more 
efficient DNA targeting. The effect of replacing one aliphatic amine with various 
pyridyl moieties has also been investigated, with the cytotoxicity very much 
dependent upon the substituents on the pyridyl ring.[62] 




In the last few years, trans complexes with N2O2 donor sets have been 
investigated,[63] where the chlorido groups are replaced by carboxylates to 
improve aqueous solubility (Figure 1.4). Like carboplatin, these complexes are 
surprisingly stable to hydrolysis, although their toxicity is similar to that of the 
chlorido analogues.[64] The use of carboxylate ligands appears to result in 
increased cellular accumulation, furthermore there is much scope to fine-tune the 







Figure 1.4   Three trans-platinum complexes currently under investigation.  
Left: an iminoether complex, middle: a complex with branched chain aliphatic 
amines, right: a complex containing the N2O2 donor set. 
 
1.3.4.3 Multinuclear Complexes 
Multiplatinum complexes have been under investigation since the late 1980s. The 
rationale behind their development was the belief that complexes structurally 
dissimilar to cisplatin could form markedly different DNA adducts, potentially 
leading to differences in recognition and repair, and activity in a wider range of 
tumour types.  
The most successful and widely studied is the trinuclear complex BBR3464 
(Figure 1.5), in which the platinum centres are separated by diaminohexane 
linkers, and the two terminal platinums bind one chlorido ligand each. This 
complex has a high affinity for DNA due to its positive charge, and binds rapidly 




forming 1,4-interstrand cross-links involving two guanine residues. These adducts 
do not significantly distort DNA, suggesting recognition by HMG proteins is 
poor; in addition, their flexibility renders them less likely to be recognised and 
removed by the nucleotide excision repair system.[65] However, these complexes 
are able to induce conformational changes in DNA, particularly from B-type to Z-
type and A-type.[66] Cell tests reveal BBR3464 to be highly cytotoxic, showing 
mean IC50 values more than one order of magnitude lower than cisplatin in an 
assay of seven cell lines,[67] with evidence that the drug can overcome both 
acquired and inherent cisplatin resistance.[68] However, BBR3464 is also highly 
toxic to healthy cells, with the maximum tolerated dose at least 60 times lower 
than that of cisplatin.[66] Nephro- and neurotoxicity are not observed, and the 
dose-limiting toxicity is neutropenia (a reduction in the number of white blood 
cells). BBR3464 has undergone a number of clinical trials over the past ten years, 
including recent Phase II trials for gastric adenocarcinoma, ovarian and small-cell 
lung cancer; however, the results were not substantially different from those of 
cisplatin, possibly resulting from extensive binding and degradation by human 
plasma proteins.[66] 
Triplatin NC (Figure 1.5) is a more recent trinuclear complex in which the 
chlorido ligands are replaced by diaminohexane groups. This increases the overall 
charge on the complex to +8 and introduces further hydrogen bonding capability, 
but removes the ability to form coordination bonds with DNA. Instead, this 
complex shows an unprecedented non-covalent interaction known as the 
“phosphate clamp”, binding to the phosphate oxygens of the backbone.[69] This 
complex shows micromolar activity against a human ovarian cancer cell line,[70] 



















Figure 1.5   The multinuclear platinum complexes BBR3464 and TriplatinNC. 
 
1.3.4.4  PtIV Complexes 
The cytotoxicity of PtIV complexes has been recognised since the early work on 
cisplatin,[17] and over the years research interest in this area has increased with the 
recognition that PtIV complexes can offer several advantages over those of PtII. 
Firstly, PtIV complexes are much more kinetically inert, and as such the 
probability of deactivating side-reactions, a major problem with PtII complexes, is 
greatly reduced. They are also generally more lipophilic than those of PtII, 
allowing for greater diffusion through cell membranes with less reliance upon 
facilitated transport mechanisms for cellular uptake. Furthermore, the addition of 
two “axial”[71] ligands gives great scope for structural variation and modifying the 
properties of the complex. 
It is widely accepted that PtIV complexes act as prodrugs and must be reduced to 
PtII in order to exert a cytotoxic effect; their reduction potentials are therefore of 
great importance. The axial ligands have the greatest influence on this property, 
determined by their size and electron withdrawing ability.[72] Complexes with 
axial chlorido ligands are the most readily reduced, followed by 




acetato/carboxylato, and those with axial hydroxyl groups have the lowest relative 
reduction potential and therefore are the least readily reduced.[73] 
There have been some attempts to correlate these reduction potentials with DNA 
binding ability, cellular reduction rates and cytotoxicity. The most readily reduced 
complexes showed increased DNA binding ability,[74] and the proportions of three 
PtIV complexes reduced intracellularly, two hours after administration, was found 
to correlate with their reduction potentials.[75] Correlations with cytotoxicity 
cannot be so readily drawn, since dramatic changes in lipophilicity, uptake and 
reactivity will occur upon reduction, which can occur either intra- or 
extracellularly. 
The location of reduction, nature of the reducing species, and the overall fate of 
the complex depends upon the PtIV complex in question. There are a number of 
biomolecules available in the bloodstream and in cells capable of effecting such a 
reduction, such as glutathione, ascorbate, metallothioneins and even 
nucleotides.[72] It is suggested that complexes with axial chlorido groups, such as 
[Pt(1,2-diaminocyclohexane)Cl4] (tetraplatin, Figure 1.6), are rapidly reduced 
extracellularly to form PtII biotransformation products.[76] Those with axial acetato 
groups, such as cis,cis,trans-[Pt(NH3)(cyclohexylamine)Cl2(OAc)2] (satraplatin, 
Figure 1.6) are likely to be reduced at a lesser rate in the bloodstream, allowing 
for a small degree of hydrolysis of the chlorido ligands.[72] In vivo metabolism of 
satraplatin is not well understood; although the major metabolite is the PtII 
analogue formed by loss of the axial acetato groups, at least six biotransformation 
products, both PtIV and PtII, have been identified.[77] Recent research has shown 
that the reduction of satraplatin can be mediated by haem proteins, consistent with 
the shorter half-life observed in whole blood extracts compared with plasma 
alone.[78] Complexes with lower reduction potentials, such as cis,cis,trans-
[Pt(isopropylamine)2Cl2(OH)2] (iproplatin, Figure 1.6) are likely to remain in the 
PtIV state until reduced intracellularly, likely by glutathione. One study shows a 
positive correlation between iproplatin and tetraplatin cytotoxicity and cellular 
glutathione levels, and suggests the more significant correlation for iproplatin 






arises since its high reduction potential would necessitate a strong reducing agent 
such as glutathione, whereas tetraplatin could also be reduced by weaker 





Figure 1.6  Three PtIV complexes which have been investigated in clinical trials. 
 
The three aforementioned PtIV complexes have all entered clinical trials. 
Tetraplatin had showed high activity both in vivo and in vitro to a number of cell 
lines,[32] likely due to increased cellular accumulation (four-fold compared with 
cisplatin).[80] However, four different Phase I trials revealed severe and 
irreversible neurotoxicity, and trials were discontinued. Iproplatin reached 
Phase III clinical trials for ovarian cancer, but was ultimately abandoned due to 
lower activity compared with cisplatin. Satraplatin, an orally-administered drug, 
first entered clinical trials over 15 years ago and has recently completed Phase III 
trials in combination with prednisolone for the treatment of hormone-refractory 
prostate cancer. However, results failed to show a significant increase in overall 
survival compared with cisplatin,[81] and an FDA application for drug approval 
was withdrawn. However, given its convenience of administration, mild toxicity 
profile and lack of cross-resistance with cisplatin, further clinical trials involving 
satraplatin may be likely. 
PtIV complexes remain an active area of research. Recent developments include 
new insights into the reaction of iproplatin with glutathione; this was previously 




believed to involve reduction to the PtII chlorido species, however formation of a 
PtII bis-glutathione complex has been demonstrated.[82] A new class of PtIV 
complexes with long-chain carboxylate ligands has shown very high toxicity, with 
IC50 values in the low micromolar and even nanomolar range.
[83] Furthermore, an 
increasingly attractive strategy is the incorporation of bioactive moieties into the 
axial ligands, which would be released upon reduction; this could aid in targeting 
or give complexes with a dual mode of action, and is explored further in Section 
1.3.4.5. 
 
1.3.4.5 Functionalisation and Targeting of Platinum Anticancer Complexes 
The drawbacks of current platinum anticancer complexes include the lack of 
selectivity for cancerous over healthy cells (a problem common to the majority of 
anticancer agents), and deactivation of the drugs before reaching their intended 
site of DNA. The idea of incorporating a moiety that can increase selectivity, 
either for cancer cells or for a particular cellular target, is becoming an 
increasingly attractive strategy in drug design. There are many examples of such 
approaches applied to platinum complexes in the literature, hence only a few shall 
be considered here. 
Attention has recently focused upon novel methods of delivery of cytotoxic 
platinum complexes, aiming to increase selective uptake into cancer cells. A 
liposomal formulation of cisplatin, known as lipoplatin (Figure 1.7), is among the 
most widely studied. The liposomes in which cisplatin is encapsulated (average 
size 110 nm) are coated with hydrophilic polyethylene glycol (PEG) chains, hence 
are able to evade removal by macrophages, and show a long in vivo retention time 
(>100 h). Since tumours are often hyperpermeable to macromolecules due to their 
compromised vasculature (the EPR effect), lipoplatin shows accumulation in both 
primary and metastatic tumour tissue up to 200 times greater than in surrounding 
healthy tissue. As of 2008, lipoplatin was involved in three Phase III clinical 
trials, two against non-small-cell lung cancer and a third for head and neck 





cancers. The results of previous trials have suggested a vast reduction in side 
effects compared with other platinum drugs and an improved spectrum of activity, 
and further Phase III trials are planned. Additional delivery methods have 
included the use of dendrimers, polymers and micellar systems.[84] More recently, 
the encapsulation of cisplatin into the cavity of the iron binding protein apoferritin 
was reported (Figure 1.7).[85] The resulting conjugate showed a 4.5-fold increase 
in cellular uptake relative to cisplatin alone, and appeared to release the toxic 
moiety slowly over time. Au-Fe3O4 nanoparticles have also been used as target-
specific nanocarriers of a toxic platinum moiety, targeted to Her-2 breast cancer 









Figure 1.7  Schematic diagrams of two novel methods for the delivery of 
platinum anticancer complexes. In both cases, the platinum complexes are 
represented by the yellow colour. Adapted from references 32 and 85.  
  
Many studies have investigated the attachment of DNA-targeting species, such as 
intercalators, to cytotoxic PtII complexes. Construction of the intercalating moiety 
to enable platinum binding allows the synthesis of complexes with a potentially 
bifunctional mode of DNA interaction; furthermore, changes in the nature of 
DNA adducts may result in complexes with a different activity profile to cisplatin. 
The complex [Pt(en)Cl(ACRAMTU-S)](NO3)2, (ACRAMTU = [2-(acridin-9-




ylamino)ethyl]-1,3-dimethylthiourea), denoted Pt–ACRAMTU and depicted in 
Figure 1.8, was found to interact with DNA via a dual mechanism involving 
intercalation of the ACRAMTU moiety and monofunctional platination. Contrary 
to cisplatin, platination occurs at the guanine N7 and adenine N3 sites, and is 
directed towards the minor groove by the sequence and groove specificity of the 
intercalator.[87] In another recent example, a targeted interaction with G-
quadruplex DNA was achieved with a platinum–quinacridine hybrid complex, 
which showed a dual noncovalent and covalent binding mode to further stabilise 
the G-quadruplex structure.[88] 
 
 
Figure 1.8  The structures of two platinum-intercalator complexes.  
Top: Pt–ACRAMTU, and bottom: a Pt-quinacridine complex to target G-
quadruplex DNA. 
+




Other studies have shown the effects of varying the linker length between an 
intercalator (9-aminoacridine-4-carboxamide) and a platinum moiety 
([Pt(en)Cl2]); compounds with shorter linker chain lengths were found to show 
greater alteration of sequence specificity than those in which the linker was 
longer, where the platination profile was more similar to cisplatin.[89] 
An additional strategy gaining increasing interest is the functionalisation of the 
axial ligands of PtIV complexes. Since the reduction of these complexes involves 
loss of the axial ligands, intracellular reduction should release these along with a 
toxic platinum complex; a wide range of ligands could potentially be employed to 
give targeted complexes or those with a dual mode of action. 
In one such example, Lippard et al synthesised a series of estrogen-tethered PtIV 
complexes (Figure 1.9),[90] since it is known that exposure to the hormone 
sensitises estrogen-receptor positive (ER(+)) cells towards cisplatin treatment, via 
overexpression of a protein shielding the platinated adduct from repair. The 
complexes were found to selectively induce overexpression in ER(+) and not 
ER(–) cells, and were consequently more toxic to the former cell line. 
Lippard et al have also synthesised a PtIV conjugate functionalising both axial 
ligands independently: one with a targeting species, a folate derivative exploiting 
the overexpression of the folate receptor on a variety of tumour cells, and the 
second with a delivery aid, a single-walled carbon nanotube to aid internalisation 
into cells (Figure 1.9). Cell entry via endocytosis was confirmed, as well as 
reduction to a cytotoxic PtII species able to cross-link DNA. 
Dyson et al employed the ligand ethacrynic acid (Figure 1.9), a known inhibitor 
of the enzyme glutathione-S-transferase, which catalyses the conjugation of 
cisplatin to glutathione.[91] The greater cytotoxicity of these conjugates compared 
with cisplatin was suggested to arise from the release of the inhibitor upon 






























Figure 1.9  PtIV complexes with functionalised axial ligands. 
Top: An estrogen conjugate, middle: a complex containing a carbon nanotube and 
a folate derivative, and bottom: a complex containing ethacrynic acid. 
 
Many of the strategies described above are designed with the aim of minimising 
activity in healthy cells, and thus reducing toxic side effects associated with 
treatment. This was also the rationale behind the development of photoactivatable 
platinum anticancer complexes, with which this thesis is concerned. Prior to 
discussion of previous work on these complexes, some background to 
photochemistry and its use in medicine will be given. 
 





Photochemistry is concerned with the effects of light on chemical systems, and is 
discussed here with reference to coordination compounds. This section considers 
the formation of excited states and different types of electronic transition, 
followed by deactivation pathways to the ground state. The photochemistry of 
platinum complexes is then discussed. 
 
During the interaction of light with a complex, photoexcitation can occur if the 
difference in energy between the ground state and an excited state matches that of 
the incident photon. The transition dipole moment is a transient dipolar 
polarisation created by this interaction, and the intensity of the transition is 
proportional to the square of this term. 
 
Transitions with a nonzero transition dipole moment therefore have nonzero 
intensity, and are designated allowed transitions, whilst in forbidden transitions 
the dipole moment is zero, with the magnitude governed by selection rules.  
  
– The spin selection rule declares that transitions between states of different 
multiplicity are forbidden; i.e. the relative orientations of spins in the complex 
must not change. 
– The Laporte, or symmetry selection rule declares that transitions between states 
of equal parity are forbidden; for example d–d transitions in metal complexes. 
 
The intensity of the transition can be quantified by the amount of light absorbed, 
according to the Beer-Lambert Law: 
A = ε c l 
where A is absorbance, c is the concentration (M), ε is the molar extinction 
coefficient (M-1 cm-1) and l is the pathlength of the light beam (cm).  
Absorbance is defined as A = log10(I/I0), where I0 is the incident light intensity 
and I the transmitted intensity. 




1.4.1 Types of Electronic Transition 
Electronic transitions are classified according to the localisation of the electron 
density and its change during the transition. There are four main types of 
transition, as described below. 
 
– Transitions between molecular orbitals (MOs) based on the central (metal) atom 
in a complex, subdivided into ligand field (LF) transitions (e.g. d–d), Rydberg 
transitions (populating an orbital of higher quantum number), and inter-valence 
charge transfer transitions (between metal atoms in polymetallic complexes). 
– Ligand based transitions; either intraligand (ILCT), where the two MOs are 
based on the same ligand, or ligand-to-ligand charge transfer transitions (LLCT), 
involving two different ligands of the same complex. 
– Transitions involving charge transfer between orbitals that are primarily ligand 
in character and those primarily metal in character, classified according to 
direction: Ligand-to-metal charge transfer (LMCT) or Metal-to-ligand charge 
transfer (MLCT). 
– Transitions between complex and solvent; charge-transfer-to-solvent (CTTS). 
 
Ligand field transitions correspond to a redistribution of electrons in partially 
filled d orbitals; since this does not involve a change in parity, these transitions 
are formally forbidden in octahedral complexes. However, they often occur, albeit 
weakly, since the Laporte selection rule can be relaxed in one of two ways: firstly 
the complex may deviate from perfect symmetry, due to the differing nature of its 
ligands or environmental distortions, and secondly the complex can undergo 
asymmetric vibration, also destroying the centre of symmetry. 
 
The direction of charge transfer transitions (metal-to-ligand or ligand-to-metal) 
depends on the relative energy of the orbitals and their population; for example, if 
the ligand orbitals are filled and those of the metal are not, an LMCT may arise, 




conversely if the metal is electron rich (in a low oxidation state) and the ligand 
has low-lying, accessible empty orbitals, an MLCT may result.  
Since charge-transfer transitions are formally allowed they give rise to much more 
intense bands in absorption spectra, and this is one means of identifying such a 
transition. Another is that charge-transfer transitions typically display 
solvatochromism, a shift in transition frequency with solvent polarity; this is 
characteristic of transitions in which a large shift of electron density occurs. 
 
Intraligand charge-transfer transitions can occur in complexes containing organic 
ligands with multiple bonds. These transitions are both spin- and orbital-allowed, 
and hence give rise to intense bands in the spectra, the position of which do not 
depend significantly on the metal or other ligands in the complex. 
 
1.4.2 Deactivation from Excited States  
Generation of an excited singlet state typically populates the higher vibrational 
levels of that state, from which the complex rapidly relaxes back to the lowest 
level by a process known as vibrational relaxation. From here, several processes 
are possible: either photophysical, which regenerate the ground state of the 
complex, or photochemical, in which reactions occur in the excited state to 
generate new products. 
 
1.4.2.1 Photophysical Deactivation and Luminescence 
Photophysical deactivation pathways can either be non-radiative, in which the 
excitation energy is dissipated to the solvent as heat, or radiative, where relaxation 
to the ground state is accompanied by emission of a photon (luminescence). The 
loss of energy to molecular rotation, vibrations and heat means the photon emitted 
is of lower energy than that absorbed, hence complexes are often excited in the 
























ISC – Intersystem Crossing
IC – Internal Conversion
UV region but emit in the visible. This difference in energy is known as the 














Figure 1.10 A Jablonski diagram summarising the potential deactivation 
pathways of a complex in an excited state. 
  
There are two main luminescent processes: fluorescence and phosphorescence, 
which differ in the nature of the excited state from which the emission occurs. 
Where this is a singlet state (usually S1), the process is known as fluorescence. 
Being a formally allowed process, the emission rate is rapid and fluorescence 
lifetimes are short, typically around 10 ns. Molecules in the S1 excited state can 
also undergo spin conversion to the first triplet state, T1, via intersystem crossing; 
emission from this state is termed phosphorescence. As the transition from T1 to 
S0 is spin forbidden, the rate of relaxation from the triplet state is much reduced 




compared with the singlet, and as a result phosphorescence lifetimes are of the 
order of milliseconds or seconds.  
A decrease in intensity of fluorescence is known as quenching, and can be 
induced by many processes. A common process is collisional quenching, in which 
the fluorophore is deactivated upon contact with another molecule in solution. 
Molecular oxygen is a good example of a quencher, hence many samples show 
fluorescence only in degassed solutions. The mechanism of quenching depends 
upon the molecules involved, and can include electron transfer and increased 
intersystem crossing. The latter is typically seen in the presence of heavy metals, 
which are known to be excellent quenchers. Heavy atoms, either within the 
fluorophore or in close contact, increase the rate of intersystem crossing to the 
triplet state by strengthening spin-orbit coupling. This radiationless transition to 
the triplet state completes with the emissive transition from S1 to S0, hence 
quenching the fluorescence. 
 
1.4.2.2 Photochemical Reactions of Coordination Compounds 
A photochemical reaction is a process in which part of the excited state energy is 
used to produce a chemical change in the complex. In certain cases, 
photochemical reactions compete efficiently with photophysical decay pathways 
to dissipate the energy gained upon excitation. The reactivity of the excited state 
is different from that of the ground state, and otherwise inaccessible products can 
often be formed upon irradiation. The main photoreactions can be classified as 
photoredox, photoisomerisation and photosubstitution, and are discussed below. 
 
 a) Photoredox reactions 
Although several reactions can be classified as photoredox, this section shall 
consider only addition and elimination reactions. These involve a change in 
oxidation state of the central atom and in coordination number of the complex, 




and often involve the formation of intermediates, so do not always result in a 
stable product.  
Oxidative addition reactions occur in metal complexes with vacant coordination 
sites and a low oxidation state, and involve the insertion of a metal into a covalent 
bond. They can occur photochemically when the Lewis acidity of the central atom 
is increased upon excitation. Reductive elimination reactions involve the 
elimination of two ligands adjacent in the coordination sphere of the metal, and 
are favoured where the new bond formed between them is strong, such as in the 
case of N2 produced from reductive elimination of azido ligands. LMCT 
transitions are often implicated in photochemical reductive eliminations. 
 
b) Photoisomerisation reactions 
Reactions leading to isomerisation of a substrate can occur by several mechanisms 
including bond rotation, skeletal rearrangement or atom or group transfer, and the 
cis-trans photoisomerisation of square planar complexes is thought to involve 
both tetrahedral and trigonal intermediates. Studies of PtII complexes indicate that 
the photoactive states are mostly spin-forbidden ligand-field states, and that 
photoisomerisations occur from the lowest triplet state. Photochemical 
isomerisation reactions can give mixtures rich in thermodynamically unstable 
isomers. 
 
c) Photosubstitution reactions 
These reactions involve an exchange of ligands on the central metal atom with 
retention of coordination number. Photochemical substitutions can form different 
products to those accessible thermally, and occur up to 14 orders of magnitude 
faster. Substitution generally occurs from ligand-field triplet excited states, and 
can be achieved by irradiation in the region of ligand-field transitions; for d6 
configurations, this often results in the labilisation of all ligands, with substitution 




of one. Photosubstitution is also often induced concurrently with photoredox 
reactions upon irradiating in the region of charge-transfer transitions.  
 
1.4.3 Photochemistry of Platinum Complexes 
The photochemistry of platinum complexes is extensive and varied, with much of 
the work concerned with the luminescent properties of square planar PtII 
complexes, which shall not be discussed here. This section will concentrate on the 
chemistry of platinum azide complexes, and the photoreduction of PtIV 
complexes, due to their relevance to this work. 
As discussed in section 1.4.2.2, the fate of a complex upon irradiation is 
dependent upon the transitions accessible given the energy of the incident light. 
Lower energy ligand-field transitions can induce photoisomerisation or 
substitution reactions, whilst ligand-to-metal charge transfer transitions typically 
result in photoreduction.  
 
c) Platinum Azide Complexes 
The photoactivity of the azide (N3) moiety is well demonstrated in both organic 
and inorganic compounds,[95] and it has been stated that almost any transition 
metal azide complex is light sensitive, regardless of oxidation state.[96] Metal 
azido complexes can undergo a variety of photoreactions,[95] including 
photosubstitution, photoisomerisation, formation of a nitrido (≡N) complex with a 
two-electron oxidation of the central metal, or oxidation of the azide anion to a 
radical with a one-electron reduction of the metal. 
An example of the latter reaction, the photoinduced, reductive transelimination of 
nitrogen from a PtIV azido complex, was first reported in 1978.[97] 
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Irradiation into the LMCT (N3 → Pt) band was accomplished with UVA light 
(314 nm), and the elimination reaction was shown to involve the formation of two 
azide radicals and no PtIII intermediate. 
 
This was followed by reports of successive reductive eliminations from [Pt(N3)6]
2-
In this case, irradiation into the LMCT band induces cleavage of two ligands from 
the metal in a one-photon, two-electron elimination to yield a PtII species. 
Subsequent irradiation of this species induces further elimination and a reduction 





The photoreduction of the PtII complex cis-[Pt(N3)2(PPh3)2] yields a Pt
0 complex 
as shown below, and conversion to the trans isomer is also seen. It is of interest 
that this photoreduction occurs at wavelengths above 350 nm, since only ligand-
field transitions are present in this region, and these would be expected to give 




PtII diazido complexes of α-diimine ligands have also been found to act as 
efficient photosensitisers in the production of singlet oxygen (1O2), with the 
excited states arising from MLCT transitions implicated in the mechanism.[99] The 




efficiency was found to be dependent upon the nature of the α-diimine ligand,[100] 
and quantum yields comparable with haematoporphyrin, a known sensitiser for 
singlet oxygen.[99] 
 
d) Photoreduction of PtIV Complexes 
The photochemical reduction of PtIV to PtII is reasonably well documented, and 
can show some interesting features. For example, as in the case of 
[Pt(PPh3)2(N3)2]
2–, the photoreduction of [PtCl6]
2– occurs at all wavelengths at 
which the complex absorbs light, even in regions where only ligand-field 
transitions are present.[101] The ability to effect reductions at significantly lower 
energy than would be expected could be of benefit in many applications.  
A recent investigation into several PtIV complexes with bipyridine ligands, such as 
trans-[Pt(bipy)(MeNH2)2Cl2]Cl2, found that such complexes undergo initial 
hydrolysis of chloride, followed by photoisomerisation and reduction in daylight. 
This was accompanied by formation of HOCl, presumably arising from the 
reductive elimination of the axial ligands, and this study served to highlight the 
importance of considering photochemical reactions of PtIV complexes when 
considering any potential applications.[102] 
The photochemistry of PtIV complexes has been exploited in the sensitisation of 
TiO2 surfaces. TiO2 is a known photocatalyst, and modification with [PtCl6]
2- 
allows for activation with visible wavelengths. The photosensitisation mechanism 
is believed to involve an electron injection from the photogenerated PtIII 
intermediate to titanium dioxide, leading to the formation of reactive oxygen 
species. Cell tests have indicated the platinum-modified TiO2 is phototoxic to a 
murine macrophage cell line.[103] 
 
  




1.5 Photochemistry in Medicine 
The use of light in the treatment of disease dates back over 4000 years to the 
Ancient Egyptians, who combined the ingestion of psoralen-containing plants 
with exposure to sunlight in the treatment of the skin disorder vitiligo; the same 
active ingredient is used worldwide today in phototherapy for the treatment of 
psoriasis.[104] However, the field of modern phototherapy did not begin until the 
1960s, with the observation that a porphyrin could be used as a photosensitiser in 
the destruction of tumour tissue.[105] 
The use of light in medicine is an attractive prospect, since site-selective 
irradiation allows for targeting of the therapeutic effect. However, there are 
several factors that can limit its application, and must be considered in the design 
of photoactive drugs.  
The wavelengths at which the drug can be activated is perhaps the most important 
consideration. The use of UV light below 300 nm is not possible, since these 
wavelengths induce extensive damage to tissues, DNA and proteins. Higher 
wavelengths are less damaging, but penetration through tissues is poor below 
around 600 nm, as a result of absorption by biomolecules such as haemoglobin, 
cytochromes and melanin, and scattering by organelles. Light in the region of 
600–1000 nm shows the deepest penetration through tissue[106] (Figure 1.11) and 
is known as the “therapeutic window”; it is these wavelengths which are most 
suitable for phototherapy. In addition, the dosage of light required to produce a 
therapeutic effect must also be taken into account. 
There are also practical considerations: whilst irradiation of the skin is easily 
achievable, other parts of the body are less accessible and this has limited the use 
of phototherapy to date. However, advances in laser technology have begun to 
circumvent this problem, and it is now possible to irradiate various parts of the 
body including the lung, bladder, cervix, colon and oesophagus. Furthermore, the 
rapid developments in fibre optic technologies in recent years will soon allow 


























Figure 1.11  The skin penetration depths of different wavelengths of light.[106,107] 
 
1.5.1 Photodynamic Therapy 
Photodynamic therapy (PDT) is a treatment involving the selective damage of 
tissue using a photosensitising drug, light and oxygen. It is currently used in the 
treatment of accessible cancers including those of the skin, mouth, oesophagus 
and bladder, as well as several inflammatory skin conditions, and the eye disease 
age-related macular degeneration.  
Following administration of the photosensitiser (intravenously for most cancers 
and topically for skin conditions), irradiation in the target region with an 
appropriate wavelength of light excites the photosensitiser to a singlet excited 




state. From here, it can undergo intersystem crossing to a triplet state. Relaxation 
to the ground state is spin-forbidden, favouring the transfer of energy to molecular 
oxygen. This regenerates the ground state of the photosensitiser and forms singlet 
oxygen, 1O2, responsible for the cytotoxicity. Although this mechanism is 
predominant, interactions of the photosensitiser with biomolecules, and 
subsequent reactions of both can lead to the generation of other reactive oxygen 
species, such as superoxide anions (O2
–), superoxide radicals (O2
•) and hydroxyl 
radicals (OH•).[105]  
Singlet oxygen is a very reactive species that induces cell death via rapid and 
indiscriminate reactions with biomolecules. Its lifetime in aqueous solutions is 
very low, around 2 µs; it therefore has a very limited spatial range of activity, 
likely confined to the cell in which it was created, and hence damage to healthy 
tissue is minimised. Although direct cell effects are the main cause of cell death, 
research has indicated that a significant proportion also die following irradiation, 
since an induced shutdown of vasculature deprives them of oxygen and nutrients, 
and mitochondrially-controlled apoptosis has also been implicated.[105]  
The photosensitisers employed are typically porphyrins or porphyrin-like 
molecules such as chlorins, with a strong absorbance in the visible region and the 
ability to accumulate preferentially inside tumour cells, and all are very efficient 
singlet oxygen generators. The first approved photosensitiser, Photofrin®, is a 
mixture of haematoporphyrin derivatives of varying linkages, lengths and 
stereochemistries (Figure 1.12), with an absorption maximum around 630 nm, and 
can be activated to a depth of about 5 mm in tissue. Foscan®, a chlorin derivative, 
requires a much lower drug and light dose to achieve similar responses to 
photofrin, and has a shorter retention time in the body.[104,105]  
More recently, the lanthanide complex lutetium texaphyrin (Lutrin) has also been 
approved for use in cervical, prostate and brain tumours, with several other 
potential new photosensitisers in clinical trials.[108] Other metal complexes, which 
are phototoxic by a different mechanism to that of photodynamic therapy, are 
discussed in Section 1.5.2. 





















Figure 1.12  Two drugs in clinical use for photodynamic therapy. 
 
PDT is non-invasive, and is typically well-tolerated by patients. The targeted 
treatment also means that the incidence of side effects common to chemotherapy 
can be minimised.  
 
 
Figure 1.13  Patients receiving photodynamic therapy. Images courtesy of Dr 
Sam Eljamel, Ninewells Hospital, Dundee. 




However, the disadvantages of PDT include sensitivity to sunlight, which can 
persist for weeks after treatment, and its reliance on oxygen, since many tumour 
cells are known to be hypoxic. 
 
1.5.2 Phototoxic Metal Complexes 
In the development of metal complexes as potential anticancer agents, one design 
concept receiving increasing interest in recent years is that of photoactivation. 
The complex cis-[Ru(bipy)2(NH3)2]
2+ (bipy = 2,2-bipyridine), upon irradiation 
with λ < 400 nm, was found to undergo sequential loss of the ammonia ligands in 
aqueous solution to form the bis-aqua complex; in the presence of 9-ethylguanine, 
bisadducts of this species were formed. This complex was also found to be 
phototoxic to human skin fibroblasts (Hs-27).[109] A dinuclear Ru
II arene complex, 
[{(η6-indan)RuCl}2(µ-2,3-dpp)](PF6)2 (2,3-dpp = 2,3-bis(2-pyridyl)pyrazine) was 
found to undergo indan loss upon irradiation with UVA light in aqueous solution, 
with an increase in the fluorescence of this arene. DNA binding was also 
markedly increased upon irradiation, with the formation of both mono- and 
bifunctional adducts; additionally, the photoreaction appeared independent of 
oxygen.[110] 
The dinuclear rhodium complex cis-[Rh2(µ-O2CCH3)2(dppz)(bipy)]
2+ 
(dppz = dipyrido[3,2-a:2’,3’-c]phenazine) is one of several rhodium complexes 
investigated for phototoxicity. This complex shows low toxicity in the dark, but a 
79% increase in toxicity upon irradiation with visible light, similar to that of 
haematoporphyrin, with efficient photocleavage demonstrated upon 
irradiation.[111]  
The group of Chakravarty has investigated the DNA-photocleavage properties of 
several different metal complexes. A series of copper complexes of the formula 
[Cu(L-arg)(B)Cl]Cl, where B is a heterocyclic base such as pyridine, were shown 
to effectively cleave DNA upon irradiation with UVA (365 nm) or red (647.1 nm) 




light in a metal-assisted photoexcitation process forming singlet oxygen.[112] 
Similarly, the vanadium complex [VOCl(dppz)2]Cl
[113] also cleaved DNA by a 
similar mechanism involving singlet oxygen upon irradiation with UVA light, but 
with near-IR wavelengths (≥ 750 nm), the involvement of only OH• radicals was 
found. This complex was found to be non-toxic in the dark, but phototoxic upon 
irradiation with both UVA and visible light, although IC50 values were lower for 
the former. Photoinduced binding to the protein bovine serum albumin was also 
seen, and implicated in a potential role as an antimetastatic agent. The analogous 
iron complex,[114] [FeL(B)], (B = dppz, L = a tetradentate N,O,O,O phenolate-
based ligand) showed photocleavage upon irradiation with red light, also 
involving OH• radicals, and phototoxicity in the human cervical cancer cell line 
(HeLa) and human keratinocyte cell line (HaCaT); upon UVA irradiation, IC50 
values were in the nanomolar range. 
 
1.5.3 Photoactivated PtIV Complexes 
The idea of administering a prodrug which becomes activated upon irradiation has 
recently been applied to platinum chemotherapy, and could potentially lead to a 
novel class of photoactivated anticancer agents which do not rely upon the 
presence of oxygen. Many PtIV complexes are known to be inert in vivo and 
activated by reduction to PtII; and it is known that such a reduction can occur 
photochemically. Therefore, it was hypothesised that a non-toxic, PtIV prodrug 
could be designed which, upon site-selective irradiation, could be reduced in the 
region of the tumour to yield a cytotoxic PtII species. Since such complexes are a 
focus of this project, these are discussed in detail below. 
Initial studies in this area employed PtIV complexes containing equatorial iodido 
ligands[115] (Figure 1.14), since the Pt–I ligand-to-metal charge transfer (LMCT) 
band is of sufficiently low energy to allow photolysis by visible light. The nature 
of the axial ligand was found to greatly influence both the photochemistry and the 
dark stability of the complexes; that with axial chlorido groups being too unstable 




in serum for further study. In nucleobase and DNA binding experiments, the 
complex with axial acetato groups showed no reaction to 5'-GMP in the dark, but 
formed the bisadduct Pt(en)(5'-GMP)2 upon irradiation;
[116] similarly, little DNA 
platination occurred after 24  the dark, but rose to 60% after 6 h irradiation. The 
hydroxyl analogue was also photolabile, however the predominant photoproducts 
were believed to be PtIV species, and were unreactive to 5'-GMP upon irradiation; 






Figure 1.14  Photoactivatable PtIV prodrugs containing equatorial iodido ligands. 
 
In additional experiments, the hydroxyl analogue was found to react rapidly with 
glutathione, forming a ring-opened PtII species via initial attack of the thiol on an 
iodido ligand.[117] Since poor stability towards thiols such as glutathione leads to 
rapid deactivation of such complexes in vivo, these complexes were deemed 
unsuitable for further study. 
 
It was believed that replacement of the equatorial iodido ligands with a more 
strongly-binding ligand could produce a more stable PtIV species, however it was 
also necessary to retain photoactivity. The pseudo-halogen group azide (N3) was 
chosen which, being a nitrogen donor, can form strong bonds to platinum; 
additionally, the photoactivity of metal-azide complexes is well documented.[118]  
Initial studies on the PtIV azido complexes cis,cis,trans-[Pt(NH3)2(N3)2(OH)2] and 
cis,trans-[Pt(en)(N3)2(OH)2] showed them to be remarkably stable in the dark in 
the presence of glutathione and 5’-GMP, with no observable reactions over a 




period of many weeks. Upon irradiation with visible light (457.9 nm), however, 
rapid binding to the N7 atoms of 5'-GMP and d(GpG) was observed.[119] 
Subsequent transcription mapping studies of plasmid DNA treated with cis,trans-
[Pt(en)(N3)2(OH)2] and visible light revealed platination sites similar to those of 
cisplatin, occurring mainly at GG sequences; HPLC analysis of a 40-bp DNA 







Figure 1.15  The structures of two photoactivatable PtIV azido complexes   
 
However, cell morphology studies suggested these complexes may have a 
different mode of action to drugs such as cisplatin.[121] Cis,cis,trans-
[Pt(NH3)(N3)2(OH)2] and cis,trans-[Pt(en)(N3)2(OH)2] were both found to show 
negligible toxicity in the dark, but were phototoxic to both the 5637 and 5637 
cisplatin-resistant human bladder cancer cell lines upon irradiation with UVA 
light (365 nm). Morphology studies showed that, in contrast to cisplatin, treated 
cells showed “ballooning” after 6 h irradiation, and 17 h after the irradiation 
period cellular shrinkage and loss of contact with neighbours was observed, as 
well as significant nuclear packing. After 90 h, cells were shrunken and most 
lacked a nucleus. These results were markedly different from those of cisplatin 
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Figure 1.16 Phase contrast microscopy images of 5367 bladder cancer cells 
following exposure to cis,cis,trans-[Pt(NH3)(N3)2(OH)2]. From reference 121. 
 
An interesting discovery was that complexes with the azide ligands in a trans 
geometry appear to show higher activity than their cis analogues, which is 
surprising since the cis complexes could be regarded as a prodrug for cisplatin, 
and the trans complexes would presumably be unable to form 1,2-d(GpG) cross-
links with DNA. Nevertheless, irradiation studies of trans,trans,trans-
[Pt(NH3)2(N3)2(OH)2] in the presence of 5'-GMP showed rapid formation of the 
bisadduct trans-[Pt(NH3)2(5'-GMP-N7)2]
2+, and phototoxicity tests revealed this 
complex to be as cytotoxic as cisplatin upon irradiation with UVA light, whilst 
non-toxic in the dark.[122] A range of trans-azido complexes has since been 
synthesised and shown good phototoxicity,[123,124] with one in particular, 
trans,trans,trans-[Pt(NH3)(py)(N3)2(OH)2] (py = pyridine), showing cytotoxicity 
between 13 and 80 times greater than cisplatin upon irradiation, dependent upon 
cell line.[123] This complex appears to have a novel mechanism of action, forming 
trans azido/guanine and trans diguanine PtII adducts; both intrastrand and 
interstrand, and DNA–protein, cross-links were detected. DNA damage was found 
to be different from that induced by cisplatin or transplatin, and repair synthesis 
also markedly lower.  
 
 




Work is continuing to elucidate the mechanism of action of these PtIV azido 
complexes and their degradation pathways upon irradiation. A reductive 
elimination was initially proposed, in which the two azido ligands leave as 
radicals and rapidly combine to form molecular nitrogen, resulting in cytotoxic 
PtII species. However, recent experiments have suggested this is an 
oversimplification, with photoproducts highly dependent upon solvent and pH. 
Various photoproducts have been detected upon UVA irradiation of cis,cis,trans-
[Pt(15NH3)2(N3)2(OH)2], including N2, N3
–, 15NH3, unlabelled NH3 (presumably 
arising from N3), and O2, as well as Pt
IV photoisomerisation products, several PtII 
species, and an insoluble precipitate thought to be a polymeric hydroxo-/oxo 
bridged platinum species; nitrene intermediates have also been implicated.[125] 
Rapid photoreductions have been found in the presence of biomolecules; for 
example, during the irradiation of trans,trans,trans-[Pt(NH3)2(N3)2(OH)2] in the 
presence of 5'-GMP, the bisadduct trans-[Pt(NH3)2(5'-GMP-N7)2]
2+ was detected 
after only one minute.[122.126] However, irradiation studies of cis,cis,trans-
[Pt(NH3)2(N3)2(OH)2] with 1-methylimidazole, in a 1:1 ratio, gave rise to a 






1.6 The Aims of this Work 
The general aims of this work were to further investigate the chemistry of 
platinum azido complexes as potential photoactivatable anticancer agents, in 
particular to explore routes to their functionalisation and for shifting the 
wavelength of activation further into the visible region. 
The functionalisation of cytotoxic complexes with bioactive ligands, such as a 
fluorescent probe or a cancer-cell targeting species, could aid elucidation of their 
mechanism of action or improve specificity for cancer cells. Therefore one aim of 
this work was to develop platinum azido complexes with functional groups to 




which bioactive ligands could be attached, and to investigate the attachment of 
such species to these complexes.  
The ideal wavelengths of activation for a photoactivatable drug are between 700–
1000 nm, the region in which light can penetrate deepest into tissue, however the 
PtIV azido complexes currently studied absorb in the UV region. A further aim 
was to investigate the incorporation of ligands absorbing strongly in the visible 
region, which may allow the possibility of activation upon irradiation in this 
region, and lead to novel photochemical pathways. 
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This chapter describes the main experimental methods used in this work. Details 
relating to individual experiments can be found in subsequent chapters where 
relevant. 
 
2.1 Nuclear Magnetic Resonance (NMR) Spectroscopy[1,2,3] 
NMR spectroscopy is among the most powerful tools available for the structural 
determination of compounds. 1H NMR was routinely used in this work to 
characterise the compounds synthesised, to investigate their stability over time, 
and to follow reactions in solution. The following paragraphs give a background 
to the technique and the NMR methods used in this work. 
 
2.1.1 Overview of Technique 
Certain nuclei possess spin, a property related to the number of unpaired protons 
and neutrons within the nucleus. This is characterised by the nuclear spin quantum 
number I, which can take integer and half-integer values. Spin-½ nuclei are the 
most favourable for NMR observation; those for which I = 0 have no overall spin 
and are NMR silent, and nuclei for which I > ½, termed quadrupolar nuclei, can 
give unfavourable spectra and are less commonly studied. 
Nuclei possessing spin have associated with them a weak magnetic field. When 
placed in an external field (B0), they begin to precess about the axis of this field, 
known as Larmor precession. This occurs at the Larmor frequency (ν), which is 
proportional to the strength of the applied field with proportionality constant γ, the 
magnetogyric ratio. This is characteristic to each nucleus, and an indication of 
how “strongly magnetic” the particular nucleus is. 
A nucleus of spin I can adopt 2I+1 orientations, which are degenerate in the 
absence of an external magnetic field. When such a field is applied the degeneracy 
is removed, hence a spin-½ nucleus can align in two ways, parallel (α) or 




antiparallel (β) to the external field, with the former of slightly lower energy. 
Application of electromagnetic radiation at the appropriate energy (the Larmor 
frequency) can induce excitation of the lower energy state to the higher; this is 
nuclear magnetic resonance.  
Considering nuclei in bulk, a slight excess of spins will be present in the low 
energy orientation, resulting in a bulk magnetisation vector, M, along the +z axis, 
parallel to the applied field. The application of a second field, B1, at the Larmor 
frequency rotates the magnetisation away from the +z axis; in the case of a 90˚ 
pulse, which equalises the population of the α and β states, it is rotated into the x-y 
plane, generating an oscillating voltage in the transmitter coil. As the 
magnetisation gradually returns to the +z axis (the equilibrium state) by the 
process of relaxation, the oscillating voltage decays producing the free induction 
decay (FID), which is then subject to a Fourier analysis to obtain an NMR 
spectrum. 
 
2.1.2 Chemical Shift 
The electron cloud surrounding the nucleus will also circulate in the applied field, 
generating a small field of its own which acts in opposition. This shields the 
nucleus to some extent from the applied field, changing the rate of precession and 
the frequency required to induce resonance. Differences in chemical environment 
and thus electron cloud density will provide different levels of shielding, hence 
resonance will be induced at different frequencies. This variation in frequency is 
known as the chemical shift, with symbol δ and units of ppm. 
 
2.1.3 Resonance Intensities 
The intensity of a peak (the total area beneath it, obtained by integration) is 
proportional to the number of protons giving rise to it. Although the accuracy is 
generally low, and can vary between resonances in the spectrum, it is usually 




sufficient to compare ratios and determine the number of protons giving rise to 
each particular signal, and for this reason is also of use in structure determination. 
 
2.1.4 Spin-spin Coupling 
The small magnetic field influencing a nucleus will also affect the electrons in the 
bond; thus the orientation of one nucleus can be relayed to another through 
chemical bonds. The two possible orientations of a 1H nucleus will result in two 
slightly different local fields at another, so resonance occurs at two different 
frequencies. The signal is split into a doublet, with the frequency difference 
between the two lines known as the coupling constant, J. Multiplicities resulting 
from coupling reflect the 2nI+1 rule; for spin-½ nuclei, the relative intensities of 
the lines are given by the coefficients of Pascal’s triangle. Coupling is generally 
seen over two or three bonds (geminal and vicinal coupling respectively), 
although certain factors can increase the magnitude of coupling over a longer 
range. Protons that are equivalent will show no coupling to each other. Coupling 
thus aids assignment of peaks in the NMR spectrum by indicating which nuclei 
are joined by chemical bonds.  
As well as to each other, protons can also show coupling to other NMR-active 
nuclei close in the bonding network. Since 13C is only 1.1% abundant, 13C–1H 
couplings are rarely apparent in 1H NMR spectra, although 13C satellites can be 
seen on either side of strong peaks, each comprising 0.5% of the total peak 
intensity. In this work, 3J(195Pt–1H) couplings were often observed in 1H NMR 
spectra, since this NMR active isotope of platinum, 195Pt, is 33.8% abundant. In 
PtII complexes, these satellites are often significantly broadened by chemical shift 
anisotropy relaxation, although are sharper in the more symmetrical, octahedral 
PtIV complexes.[4] The geometry change also accounts for the reduced magnitude 
of coupling constants seen in PtIV complexes compared with PtII (ratio around 
1 : 1.5), attributed to a decrease in s character of the resulting hybridised 
orbitals.[5] 




2.1.5 Water Suppression 
The spectra of many samples in this work were recorded in aqueous solutions in 
order to be of biological relevance. In certain cases 90% H2O/10% D2O was 
chosen over 100% D2O; this allows for peaks of exchangeable protons (such as 
those of amines and hydroxyl groups) to be seen. In such cases, a large HOD peak 
dominates the spectrum and requires suppression. Two main techniques can be 
used to achieve this. Presaturation uses a weak, continuous wave at the water 
frequency during the relaxation delay, so as to saturate the water resonance; 
however, exchangeable protons may also be saturated by this method.[6] Other 
techniques involve the use of magnetic field gradients, such as Excitation 
Sculpting (also known as Double Pulsed Field Gradient Spin Echo (DPFGSE) or 
Shaka water suppression).[7] However, in this case, signals close to the water peak 
can also be suppressed and therefore reduced in intensity. 
 
2.1.6 13C NMR 
13C NMR is routinely used for the characterisation of organic compounds, despite 
the low natural abundance (1.1%) and poor sensitivity of the nucleus. Spectra are 
typically recorded with broadband decoupling of protons to remove 13C–1H 
splittings; this results in a simplification of the spectrum so that a single line is 
observed for each chemically distinct carbon. Unlike in 1H NMR, the integral of a 
peak is not generally proportional to the number of carbons contributing to it, so 
signals cannot be reliably integrated. Signal strength can be enhanced by the use 
of experiments such as Polarisation ENhancement During Attached Nucleus 
Testing (PENDANT),[6] in which polarisation transfer from 1H to 13C is 
employed.  In these experiments, the pulse sequences are designed such that 
signals display positive or negative intensities depending upon the number of 
protons directly attached to the carbon, to aid in the assignment of the spectrum. 




2.1.7 Two-dimensional Techniques  
Two-dimensional NMR techniques involve the addition of a second frequency 
axis and give information on how spins are related in a molecule. Homonuclear 
(1H–1H) or heteronuclear (for example 13C–1H) correlation experiments can be 
performed. 
COrrelation SpectroscopY (COSY) is a homonuclear experiment, allowing two or 
three bond couplings to be identified. Following application of a 90˚ pulse and a 
delay, a second 90˚ pulse is applied to transfer magnetisation partially from one 
spin to its J-coupled partner. During the following time delay (known as mixing 
time), magnetisation evolves partially with the frequency of the second nucleus. A 
plot of the two frequency axes reveals cross peaks, indicating which nuclei have 
exchanged magnetisation during the experiment and hence which are J-coupled to 
each other.  
Nuclear Overhauser Effect SpectroscopY (NOESY) exploits the transfer of 
magnetisation from one spin to another close in space through dipolar 
interactions, upon irradiation at the resonant frequency of one of them. This 
homonuclear 1H–1H experiment consists of three 90˚ pulses; during the delay 
between the second and third, magnetisation is transferred between neighbouring 
spins via the NOE. This allows for the identification of protons that are spatially 
close, which is of great importance in structural elucidation of proteins or other 
molecules with stereochemical differences. 
Heteronuclear Multiple Quantum Coherence (HMQC) is a two-dimensional, 
heteronuclear inverse detection experiment correlating, in this case, 13C and 1H 
resonances by the J-coupling interactions between them. As with the experiments 
described previously, these are observed as cross peaks on a two-dimensional 
spectrum. HMQC is selective for direct, 1J(13C–1H) couplings, so correlates 
protons only with the carbons to which they are directly bound. Since this 
experiment relies on inverse detection, quaternary carbons, to which no protons 




are bound, are invisible to this technique. These experiments aid in the complete 
assignment of 1H and 13C signals. 
 
2.1.8 Experimental 
NMR spectra were recorded on the following Bruker Spectrometers: DMX 
500 MHz, DPX 360 MHz or AV 800 MHz (University of Edinburgh), and DPX 
400 MHz, AV 400 MHz or DRX 500 MHz (University of Warwick).  1D and 2D 
spectra were recorded using standard Bruker pulse sequences modified by Dr 
Juraj Bella or Dr Dusan Uhrin (University of Edinburgh), and Dr Adam Clarke or 
Dr Ivan Prokes (University of Warwick). Unless otherwise stated, spectra were 
acquired in 5 mm quartz NMR tubes at 298 K. 1H chemical shifts were referenced 
to residual protio-solvent resonances:[8] δ = 7.26 (chloroform), 2.50 (DMSO), 3.31 
(methanol) and 2.92 (DMF). For D2O and H2O/D2O solutions, 0.7–4 µL of a 1% 
dioxane solution was added as an internal calibrant (δ = 3.75). Spectral data were 
processed using either XWIN-NMR (Version 2.0 or 3.6, Bruker UK Ltd) or 
MestReC (Version 4.9.9.9, Mestrelab Research, Spain).   
 
2.2 Ultraviolet-Visible (UV-Vis) Spectroscopy 
As a more detailed discussion of the theory behind UV-Vis spectroscopy can be 
found in Chapter 1, this section describes only the methods and instrumentation 
used. Further details of individual experiments can be found in the appropriate 
Chapters. 
Spectra were acquired on a Varian Cary 300 spectrophotometer with a Cary 
temperature controller; the temperature was set to 298 K or 313 K depending on 
the experiment. Spectra were recorded from 800–210 nm, at 1 nm intervals at a 
rate of 420 nm/min. Hellma® self-masking, black walled quartz cuvettes (1 cm 
pathlength, 0.7 mL volume) were used for standard absorption measurements; 




transparent cuvettes were used for irradiation studies as described in section 2.3. 
HPLC grade methanol, UV grade dioxane or deionised water were used as 
solvents. Spectra were processed using Varian Cary WinUV software (Version 
3.00, Varian Inc., USA). 
Molar extinction coefficients (ε) were calculated according to the Beer-Lambert 
law, A = εcl.  For a given compound, spectra at five different concentrations were 
obtained, and for each absorption band the resulting plot of absorbance at λmax 
against concentration is linear; the value of ε is obtained by calculating the 
gradient of the line. 
 
2.3 Irradiation Studies 
The majority of the irradiation studies, using both UVA and visible light, were 
carried out using a photoreactor designed for drug photostability testing (Figure 
2.1, A). Additionally, Light Emitting Diodes (LEDs) were also used for the 
irradiation of certain complexes. All irradiations were carried out in either 5 mm 
precision grade NMR tubes or Hellma® transparent UV quartz cuvettes (1 cm 
pathlength, 3.5 mL volume). 
 
2.3.1 Photoreactor 
UV irradiations were performed using a Luzchem LZC-ICH2 photoreactor 
equipped with 16 LZC-UVA lamps (Hitachi), delivering almost pure (>95%) 
UVA light centred at 365 nm (Figure 2.1, B). Typically only four lamps were 
used during each experiment to give power levels in the range of 1.7–
2.2 mW cm-2.   
 
 





























Figure 2.1  A: The photoreactor in operation, showing both UVA and visible 
lamps, B: the spectral output of LZC-UVA lamps, C: that of LZC-VIS lamps.  
Obtained from http://www.luzchem.com. 




For visible irradiation studies, the photoreactor was equipped with 16 LZC-VIS 
lamps (Sylvania cool white). These lamps are regarded as a broadband visible 
light source; although small amounts (<6%) of UV light are present according to 
the spectral output (Figure 2.1, C), power levels in the UV region were measured 
prior to use and determined to be negligible. These lamps were subsequently used 
without any source of light filtration. All 16 lamps were used to give power levels 
in the range of 0.27–0.29 mW cm-2.   
 
Power levels were measured using the appropriate probe window (UV or visible), 
calibrated against an OAI-306 power meter from Optical Associates Inc.  
Irradiations were carried out at either 300 K or 310 K depending upon the 
complex studied; further details can be found in subsequent chapters. 
 
2.3.2 Light Emitting Diodes (LEDs) 
For certain complexes, irradiations in the visible region were also carried out 
using LED light sources, as these have a much narrower emission profile than the 
visible lamps and can be chosen according to the absorption bands of the 
complex.   
Green LEDs (λmax = 525 nm) were obtained from Farnell UK Ltd, the spectral 
output of these is shown in Figure 2.2. A typical setup involved four LEDs 
soldered in series, irradiating a UV cuvette in a blackened box. Power levels were 
measured as 0.19 mW cm-2 using a ILT1400-A radiometer photometer from 
International Light Technologies, equipped with F/W windows as appropriate for 
visible light. Irradiations were carried out at room temperature, with no significant 
heating effect noted during the experiment. 
 















Figure 2.2 The spectral output of the green LEDs. Obtained from 
http://uk.farnell.com. 
 
2.4 Fluorescence Spectroscopy 
As a discussion of fluorescence can be found in Chapter 1, this section describes 
only the methods and instrumentation used. 
Fluorescence spectra were acquired at room temperature on a JASCO FP-6500 
spectrofluorimeter, running Spectra Manager for Windows 95/NT software, 
version 1.53.06 build 1. Samples were placed in a Hellma® fluorescence cuvette 
(pathlength 1 cm, volume 3.5 mL). The excitation wavelength (λex) and scan 
range were varied depending upon the complex under investigation; further details 
are given in subsequent chapters where relevant. Unless otherwise stated, the band 
widths for excitation and emission were set to 5 nm, with spectra averaged over 
five acquisitions. 
 




2.5 X-ray Crystallography[9] 
Single crystal X-ray diffraction is used for the determination of atomic positions, 
bond lengths and angles in molecules in the crystalline state. 
The technique exploits the fact that X-rays are diffracted by electrons when 
passed through a crystal, since their wavelengths are comparable to the spacing 
between the lattice planes of the crystal. This scattering can be recorded as a 
pattern of spots of varying intensity: a diffraction pattern. The geometry of the 
pattern is related to that of the unit cell, and can give information on the repeat 
distance between molecules. The symmetry is related to the crystal system and 
space group, and the intensities of the spots give information as to the positions of 
the atoms within the unit cell. The structure is then solved using, for example, 
Patterson or direct methods, to give approximate atom positions. This is then 
further refined to give more accurate atom positions and displacement parameters.   
Certain diffraction data were collected and refined by Professor Simon Parsons 
and colleagues at the University of Edinburgh, on a Bruker (Siemens) Smart Apex 
CCD Diffractometer using Mo Kα radiation equipped with an Oxford 
Cryosystems low-temperature device operating at 150 K. Other data were 
collected and refined by Dr Guy Clarkson at the University of Warwick, using 
Mo Kα radiation on an Oxford Diffraction Gemini four-circle system, with Ruby 
CCD area detector, at 296 K. 
All structures were solved by Professor Simon Parsons and colleagues, or by Dr 
Guy Clarkson, using direct SHELXS-97[10] methods, with additional light atoms 
found by Fourier methods, and refined against F2 using SHELXL-97.[11]  
Hydrogen atoms were added at calculated positions, and anisotropic displacement 
parameters were used for all non-H atoms. 
 




2.6 Elemental Analysis[12] 
Elemental analysis is one of the most definitive ways of analysing the purity of a 
compound, by determining the percentages of elements in a sample and 
comparing the result to a theoretical value.  Several elements can be analysed, 
although carbon, hydrogen and nitrogen (CHN) analyses are the most common, 
and are the only type used in this work.  
A known mass of sample is subject to high temperature oxidation in a pure 
oxygen environment, producing a gaseous mixture of CO2, CO, H2O, N2 and 
various oxides of nitrogen. These are passed into a furnace in which nitrogen 
oxides are reduced to nitrogen, oxygen is removed, and CO is converted to CO2. 
The mixture is then analysed by a series of detectors; nitrogen content is 
quantified from the gaseous element, hydrogen from the water content, and 
carbon from the carbon dioxide present. 
Analyses were performed by the CHN service staff at the University of Edinburgh 
or at Warwick Analytical Services, both using an Exeter Analytical Elemental 
Analyser (CE440). Analyses were also carried out at the University of St 
Andrews, using a Carlo-Erba CHNS Analyser.   
 
2.7 Mass Spectrometry[1,12]  
Mass spectrometry allows the mass of the molecule of interest to be determined, 
and also gives information on its construction and isotopic distribution.  
This technique separates gaseous ions on the basis of their mass-to-charge ratio 
(m/z), hence requires that the molecule of interest is charged and in the gas phase. 
Various ionisation methods are available in order to achieve this; in this work 
electrospray was used, which is among the softest of ionisation techniques. A 
solution is passed through the exit of a fine needle held at an electric potential, 
then dispersed into a mist of droplets, from which solvent is lost to leave an 
aerosol of protonated sample which is desorbed into the gas phase. 




Ion analysis was performed using either an Ion Trap or Time of Flight (TOF) 
mass analyser. The ion trap consists of a ring electrode, to which a voltage is 
applied inducing the ions to circulate in the cavity. Scanning the voltage causes 
the ions to be destabilised and leave the cavity at varying rates depending upon 
their m/z, where they then pass to a detector. In a TOF analyser, ions are 
accelerated into a field-free drift tube, where lighter particles will accelerate faster 
than heavy ones and have a shorter time of flight along the tube; they are thus 
analysed by their arrival time at the detector. 
Electrospray ionisation mass spectra were obtained either on a Micromass 
Platform II Mass Spectrometer (University of Edinburgh), a Bruker Esquire2000 
Spectrometer or a Bruker MicroTOF Spectrometer with the help of Dr Lijiang 
Song (University of Warwick). Samples were prepared either in water or a 
methanol/water mixture, and the cone voltage and source temperature varied 
depending upon the sample.  Data were processed using DataAnalysis 3.3 (Bruker 
Daltonics). 
 
2.8 pH Measurements 
All pH values were measured at room temperature, using a Hydrus 500 pH meter 
equipped with glass semi-micro combination electrodes from Thermo Scientific.  
The electrodes were filled with either KCl or KNO3 solutions, and were calibrated 
with standard buffer solutions from Sigma-Aldrich at pH 4, 7 and 10. The pH 
values of NMR samples in D2O were recorded without correction for the effect of 
deuterium on the glass electrode, and are termed pH*. 
 
2.9 Fast Protein Liquid Chromatography (FPLC)[13] 
FPLC is a chromatographic technique used for the separation and purification of 
proteins. The sample to be separated is loaded onto a column packed with a 
stationary phase; the means by which separation is achieved is dependent upon the 




type of stationary phase. In this case Sephacryl was used, a gel filtration medium 
that separates molecules based on their size. This consists of small porous 
polymer beads with pores of different sizes. Larger particles cannot readily enter 
pores, so have less volume to traverse and elute from the column more quickly. 
Smaller particles can enter into the pores (to various extents depending upon their 
size), hindering their progress down the column and resulting in a longer retention 
time. The grade of Sephacryl employed here was S-200, which is suitable for 
proteins and macromolecules with molecular weights in the range of 5–250 kDa. 
FPLC was performed on a BioCAD 700E Perfusion Chromatography workstation 
(PerSpective Biosystems), running BioCAD Perfusion Chromatography 
Workstation software, version 3.01. An XK16 Pharmacia Biotech column was 
used, packed with Sephacryl S-200. Samples were concentrated to < 2 mL in 
1X PBS prior to injection, and products were eluted with 1X PBS (pH 7.4). 
 
2.10 Inductively Coupled Plasma Mass Spectrometry (ICP-MS)[14] 
ICP-MS combines the ionisation power of an inductively coupled plasma (ICP) 
with the high sensitivity of mass spectrometry, to give a technique capable of 
quantifying metals and non-metals in concentrations as low as parts per trillion.  
Plasma is generated from the ionisation of argon gas by free electrons, and 
maintained at a high temperature (7500 K). Samples to be analysed are passed 
through a nebuliser into the plasma chamber, where they are atomised and ionised 
by loss of an electron. The resulting ions are extracted into another chamber 
containing a quadrupole mass analyser which separates the ions based on their 
mass-to-charge ratio; since all ions are singly charged, this ratio is equal to the 
mass of the ion. The magnitude of each peak is directly proportional to the 
concentration of an element in a sample; quantitative results are therefore 
generated by comparing signal intensities to those from calibration standards. 




ICP-MS was carried out using an Agilent 7500 series machine with the help of Dr 
Ana Pizarro. Standard solutions were prepared in 3% nitric acid from 
commercially available stock solutions (typically 1000 ppm, Sigma Aldrich) of 
Cd, Se, Zn, S and Pt. These were analysed to give a calibration curve from which 
unknown concentrations of the element could be determined. 
 
2.11 Cytotoxicity Studies 
Cytotoxicity testing was carried out by Dr Ana Pizarro and Miss Soledad 
Betanzos Lara at the University of Warwick. Complexes were tested against the 
A2780 human ovarian cancer cell line, according to a previously published 
protocol.[15] 
The A2780 human ovarian cancer cell line was obtained from the ECACC 
(European Collection of Cell Culture, Salisbury, UK). Cells were grown as 
monolayers in RPMI 1640 medium with L-glutamine (Gibco BRL, Paisley, UK) 
supplemented with 5% foetal calf serum and penicillin (110 U mL-1) and 
streptomycin (100 µg mL-1) and were maintained under standard tissue culture 
conditions of 310 K and 5% CO2. Experiments were performed on cells within 10 
passages of each other. 
After plating, human ovarian A2780 cancer cells were treated with the complexes 
on day 2, at concentrations ranging from 0.1 to 200 µM. Solutions of the 
complexes were made up in 0.5% DMSO (v/v) to assist dissolution. Each 
concentration was added in triplicate and cisplatin control was added to the plate 
as a reference. Cells were exposed to the complexes for 24 h, washed with PBS, 
supplied with fresh medium, allowed to grow for three doubling times (72 h), and 
then the protein content measured (proportional to cell survival) using the 
sulforhodamine B (SRB) assay.[16] 
 




2.12 Phototoxicity Studies 
Phototoxicity testing was carried out by Dr Julie Woods and Kim Robinson from 
the Photobiology unit of the Department of Dermatology, University of Dundee, 
at Ninewells Hospital, Dundee, Scotland. Complexes were tested against HaCaT 
keratinocytes, a human skin cell line. 
Phototoxicity was assessed using the neutral red phototoxicity assay; a test 
designed to compare the toxicity of a drug plus light, compared with the drug 
alone. Complexes were dissolved in Earle’s balanced salt solution and sterile 
filtered (0.22 µm) before being applied to cells. All experiments were carried out 
in a specially adapted photobiology laboratory, with ambient light levels <1 lux 
(Solatell). Cells were seeded at a density of ~7 x 104 cells per cm2 and left to 
adhere overnight. After washing cells with PBS, test compounds were added in 
Earle’s solution and incubated for 1 h (310 K/5% CO2). After this time, cells were 
irradiated by a bank of 2 ft x 6 ft Cosmolux RA Plus (Cosmedico) 15500/100 W 
UVA light sources (5 J cm-2, λmax = 365 nm), each filtered to attenuate UVB/UVC 
wavelengths. The total irradiation time was 50 min, to give a dose equivalent to 
~15–60 min sunlight received on a typical UK midday, and reflects the clinical 
conditions used for light-activated drugs. Following irradiation, the salt solution 
was removed, the cells thoroughly washed, and then returned to the incubator in 
complete growth medium. Phototoxicity was determined 24 h later using neutral 
red uptake.[17,18] The amount of test compound required to inhibit dye uptake by 
50% (IC50 value) was determined by nonlinear regression (GraphPad Prism). 
Experiments were performed in triplicate and each repeated two to three times, 
with chlorpromazine as positive control.  
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Platinum Azido Complexes and 
Routes to Functionalisation 




3.1 Introduction  
PtIV azido complexes, of the general formula [Pt(amine)2(N3)2(OH)2], have 
recently emerged as potential photoactivated anticancer agents.[1] Such complexes 
are stable and non-toxic in the dark, yet upon irradiation can show cytotoxicity up 
to 80 times greater than cisplatin.[2] Work is continuing in our laboratory to further 
elucidate their mechanism of action, and to design new complexes with enhanced 
phototoxicity. 
These appear to be the only examples of platinum azido complexes investigated 
for cytotoxic activity. In the years following the discovery of cisplatin, numerous 
PtII analogues were synthesised and tested, varying the nature of the amines and 
leaving group, and in 1973 Cleare and Hoeschele published a set of structure-
activity relationships aimed at focusing future design onto complexes with the 
most promising features.[3] Regarding the nature of the leaving group, Cl– was 
considered optimal, since experimental evidence had shown that very labile 
groups (H2O, NO3
–) gave complexes with high but indiscriminate toxicity, whilst 
complexes with strongly bound ligands (I–, SCN–, NO2
–) showed little to no 
activity.[3] These findings were correlated with the order of leaving ability for X in 
the reaction [Pt(dien)X]+ + pyridine, which had been experimentally determined 
as NO3
– > H2O > Cl
– > Br– > I– > N3
– > SCN– > NO2
– > CN–.[4] Therefore, 
although PtII azido complexes had seemingly never been tested, they were likely 
predicted to be inactive in line with experimental evidence from iodido and 
isothiocyanato complexes.  
Nevertheless, the severe side effects associated with cisplatin therapy later led to 
the study of complexes with a more stable leaving group, in the belief that side 
reactions may be hindered and toxicity lowered, but antitumour efficacy retained. 
This concept was validated by carboplatin, a second-generation drug containing 
cyclobutanedicarboxylate, a bidentate oxygen donor ligand. The rate of hydrolysis 
of carboplatin is approximately 100 times lower than that of cisplatin, and DNA 
adduct formation at least 10-fold slower,[5] resulting in the need for higher doses 




to achieve a therapeutic effect. However, due to the substantial decrease in 
toxicity, such doses can be tolerated and carboplatin has largely replaced cisplatin 
in many cases of platinum chemotherapy. This theme of enhanced stability 
continued with the development of oxaliplatin, containing the bidentate oxalato 
group; indeed many new platinum complexes in recent clinical trials contain 
bidentate oxygen donor ligands.[6] 
Moreover, although general trends are often observed, the hydrolysis and 
nucleobase binding rates of metal complexes are not always strongly correlated 
with their cytotoxicity. One example concerning the cytotoxicity of metal azide 
complexes can be found in literature, involving two monofunctional RuII arene 
complexes [(η6-hmb)Ru(en)(N3)][PF6] and [(η
6-bip)Ru(en)(N3)][PF6] (where en = 
ethylenediamine, hmb = hexamethylbenzene and bip = biphenyl).[7] The 
hydrolysis of these complexes (hmb, 21.3 min, bip, 367 min) was found to be 
slower than those containing chloride, bromide or iodide, with a 40-fold rate 
difference in comparison to the chlorido analogues, and the extent of hydrolysis 
was <5% in both cases. A degree of binding to 5'-GMP was also detected, 
although at a slower rate than hydrolysis. Surprisingly, however, both complexes 
showed good cytotoxicity, with IC50 values of 18 µM (hmb) and 4 µM (bip).  
It was therefore decided to investigate a range of PtII azido complexes, with regard 
to their potential cytotoxicity. Additionally, since many transition metal azido 
complexes, including those of PtII, are known to be photoactive,[8] such complexes 
could potentially show phototoxic behaviour. Oxidation of these PtII complexes 
could also generate novel PtIV azido analogues, to add to the library of such 
complexes previously studied. 
In addition to ethylenediamine, which is known to form cytotoxic PtII chlorido[9] 
and phototoxic PtIV azido complexes,[10] it was decided to investigate ligands 
incorporating hydroxyl or amine groups, which would remain uncoordinated, or 
“pendant”, upon complex formation; it has been suggested that the hydrogen 
bonding capability of these groups could facilitate interactions with DNA.[11] 
Furthermore, these pendant functional groups could provide a handle with which 




X = Cl:  [Pt(en)Cl2] (1)
X = N3: [Pt(en)(N3)2] (2)
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to functionalise these complexes. This could enable the incorporation of, for 
example, targeting agents or fluorescent probes, to increase affinity for target sites 
or investigate the mechanism of action. This concept is explored in Chapter 4.  
This Chapter describes the synthesis, stability and cytotoxicity of a series of PtII 
chlorido and the corresponding PtII azido complexes, with photoreactions and 



















Figure 3.1 The platinum complexes studied in this Chapter. 






K2[PtCl4] was purchased from Precious Metals Online. 1,4-Diaminobutane, 
2-(2-aminoethylamino)ethanol (L1), ethanolamine, 2-pyridinecarboxaldehyde, di-
tert-butyl dicarbonate and guanosine 5'-monophosphate (5'-GMP) were obtained 
from Aldrich. 1,3-diamino-2-propanol (L3) and silver nitrate were obtained from 
Fluka.  3-(2-aminoethylamino)-1-propanol (L2) was purchased from TCI Europe, 
hydrogen peroxide (30%) from VWR, ethylenediamine and sodium azide from 
Fisher, and reduced glutathione (GSH) from Acros Organics. Other reagents were 
obtained from commercial sources. All reagents were used as received, with the 
exception of ethylenediamine, which was distilled over sodium and stored under 
argon prior to use. 
  
3.2.2 Synthesis 
Caution! Heavy metal azide complexes are known to be unstable and/or 
explosive, especially when subject to friction or high temperatures.[12] Therefore it 
is imperative that care is taken when handling platinum azide complexes in the 
solid form; plastic spatulas are used instead of metal, glass frits are avoided, and 
these complexes are never heated to temperatures exceeding 313 K. 
 
[Pt(en)Cl2] (1)   
K2[PtCl4] (500 mg, 1.20 mmol) was dissolved in water (5 mL), ethylenediamine 
(80 µL, 1.20 mmol) was added, and the solution stirred at room temperature for 
3 h. The yellow solid was removed by filtration, washed with water, ethanol and 
diethyl ether, and dried under vacuum. 




Yield: 277 mg (71%). 
Elemental analysis: Found: C, 7.50; H, 2.31; N, 8.22.  PtC2H8N2Cl2 requires: 
C, 7.37; H, 2.47; N, 8.57%. 
1H NMR (400 MHz, DMSO-d6): δ 5.32 (s, 4H, NH2), 2.23 (s, 4H, CH2). 
 
[Pt(en)(N3)2] (2) 
[Pt(en)Cl2] (250 mg, 0.77 mmol) was suspended in water (15 mL), to this was 
added AgNO3 (254 mg, 1.50 mmol), and the mixture stirred at 328 K in the dark 
for 16 h. The AgCl precipitate was filtered off using an inorganic membrane filter 
(Sartorius Minisart®, 0.2 µm). NaN3 (497 mg, 7.7 mmol) was added, the solution 
immediately filtered again to remove any AgN3, and stirred at room temperature 
in the dark for 3 h. The volume was reduced and the solution stored at 277 K 
overnight, after which a yellow solid was filtered off, washed with water, ethanol 
and diethyl ether, and dried under vacuum. 
Yield: 187 mg (72%). 
Elemental analysis: Found: C, 7.23; H, 2.32; N, 32.75.  PtC2H8N8 requires: 
C, 7.08; H, 2.38; N, 33.08%. 
1H NMR (400 MHz, DMSO-d6): δ 5.27 (s, 4H, NH2), 2.26 (s, 4H, CH2). 
 
[Pt(en)(N3)2(OH)2] (3) 
[Pt(en)(N3)2] (72 mg, 0.21 mmol) was suspended in water (25 mL), to this was 
added H2O2 (903 µL, 8.84 mmol, 30 % solution), and the mixture stirred at room 
temperature in the dark for 16 h. Following this, the solution was passed through 
an inorganic membrane filter to remove any residual AgN3. The volume was 
reduced and the solution stored at 277 K overnight, after which a yellow solid was 
filtered off, washed sparingly with water, ethanol and diethyl ether, and dried 
under vacuum.  




Yield: 32 mg (41%).  
Elemental analysis: Found: C, 6.43; H, 2.60; N, 29.65. PtC2H10N8O2 requires: 
C, 6.44; H, 2.70; N, 30.02%.  
1H NMR (400 MHz, 90% H2O/10% D2O): δ 2.93 (s, 




K2[PtCl4] (1.00 g, 2.41 mmol) was dissolved in water (7.5 mL), and was added 
slowly to a solution of 2-(2-aminoethylamino)ethanol (244 µL, 2.41 mmol) in 
water (1 mL).  The pH was decreased to 7 with 6 M HCl, and then periodically 
readjusted to 7 with 2 M KOH over the course of 3 h, before leaving to stir at 
room temperature overnight.  Following this the pH was readjusted to 7 once 
more, stirred for an additional 30 min, and the pale yellow precipitate isolated. 
Further product could be obtained by adding excess aminoalcohol to the filtrate, 
adjusting the pH to 7 and again stirring overnight before storage at 277 K. The 
product was recrystallised from 0.1 M HCl, washed with small quantities of 
water, ethanol and diethyl ether, and dried under vacuum. Crystals suitable for X-
ray diffraction were obtained from a filtrate stored at room temperature. 
Yield: 583 mg (65%).  
Elemental analysis: Found: C, 12.97; H, 3.19; N, 7.62. PtC4H12N2Cl2O requires: 
C, 12.98; H, 3.27; N, 7.57%.   
1H NMR (800 MHz, DMSO-d6): δ 6.15 (s, NH, 1H), 5.37 (s, NH2, 1H), 5.29 (s, 
NH2, 1H), 4.74 (t, OH, 1H), 3.69 (m, CH2, 1H), 3.61 (m, CH2, 1H), 3.09 (m, CH2, 
1H), 2.78 (m, CH2, 1H), 2.56 (m, CH2, 1H), 2.43 (m, CH2, 1H), 2.36 (m, CH2, 
1H), 2.28 (m, CH2, 1H).  
ESI-MS: [M + H2O]
+ 388, [M – Cl]+ 335 m/z.  
 





[Pt(L1)Cl2] (450 mg, 1.22 mmol) was suspended in water (20 mL), AgNO3 
(407 mg, 2.40 mmol) was added, and the mixture stirred at 328 K in the dark for 
16 h. The AgCl precipitate was then filtered off using an inorganic membrane 
filter. NaN3 (793 mg, 12.2 mmol) was added, the solution immediately filtered 
again to remove any AgN3, and stirred at room temperature in the dark for 4 h. 
The solvent volume was reduced and the mixture stored at 277 K overnight. A 
pale yellow precipitate was filtered off and washed with small quantities of water, 
methanol and diethyl ether, and dried under vacuum. Crystals suitable for X-ray 
diffraction were obtained from a filtrate stored at 277 K. 
Yield: 376 mg (81%).  
Elemental analysis: Found: C, 12.52; H, 3.03; N, 29.52. PtC4H12N8O requires: 
C, 12.53; H, 3.16; N, 29.24%.  
1H NMR (400 MHz, DMSO-d6): δ 5.97 (s, NH, 1H), 5.34 (s, NH2, 1H), 5.24 (s, 
NH2, 1H), 4.77 (t, OH, 1H), 3.66 (m, CH2, 1H), 3.59 (m, CH2, 1H), 2.88 (m, CH2, 
1H), 2.65 (m, CH2, 1H), 2.62 (m, CH2, 1H), 2.39 (m, CH2, 1H), 2.32 (m, CH2, 
2H).  
ESI-MS: [M + Na]+ 406, [M + H]+ 384 m/z.  
 
[Pt(L1)(N3)2(OAc)2] (6) 
[Pt(L1)(N3)2] (50 mg, 0.13 mmol) was suspended in acetic acid (0.75 mL), acetic 
anhydride (115 µL, 1.22 mmol) was added and the mixture stirred for 1 min. H2O2 
(20 µL, 0.19 mmol) was added, after which dissolution of the reagents occurred to 
give a yellow solution; this was stirred in the dark at room temperature for 4 h. 
Methanol (1 mL) was added, the mixture stirred for an additional 30 min, then 
solvent was removed to dryness under vacuum. Very gentle scratching and 
sonication with diethyl ether yielded a yellow solid, which was washed very 
sparingly with water, ethanol and diethyl ether, then dried under high vacuum 
overnight. 




Yield: 19 mg (29%).  
Elemental analysis: Found: C, 19.46; H, 3.52; N, 21.75.  PtC8H18N8O5Pt requires: 
C, 19.17; H, 3.62; N, 22.35%.  
UV-Vis (H2O): λmax 263 nm, ε 17 500 M
-1 cm-1.   
1H NMR (800 MHz, DMSO-d6): δ 9.19 (s, NH, 1H), 8.41 (s, NH2, 1H), 7.48 (s, 
NH2, 1H), 5.06 (t, OH, 1H), 3.73 (m, CH2, 1H), 3.63 (m, CH2, 1H), 3.23 (m, CH2, 
1H), 2.97 (m, CH2, 1H), 2.86 (m, CH2, 1H), 2.80 (m, CH2, 1H), 2.71 (m, CH2, 
1H), 2.61 (m, CH2, 1H), 2.00 (s, CH3, 3H), 1.99 (s, CH3, 3H).  
ESI-MS: [M + H]+ 502, [M + Na]+ 524 m/z.  
 
[Pt(L2)Cl2] (7) 
This complex was synthesised by a similar method to [Pt(L1)Cl2] (4), by using 
3-(2-aminoethylamino)-1-propanol (L2) in place of L1.     
Yield: 32%.  
Elemental analysis: Found: C, 15.62; H, 3.59; N, 7.27. PtC5H14N2Cl2O requires: 
C, 15.63; H, 3.67; N, 7.29%.  
1H NMR (400 MHz, DMSO-d6): δ 6.19 (s, NH, 1H), 5.36 (s, NH2, 1H), 5.30 (s, 
NH2, 1H), 4.52 (t, OH, 1H), 3.41 (m, CH2, 2H), 2.99 (m, CH2, 1H), 2.74 (m, CH2, 
1H), 2.50 (m, CH2, 1H), 2.49 (m, CH2, 1H), 2.35 (m, CH2, 1H), 2.27 (m, CH2, 
2H), 1.89 (m, CH2, 1H), 1.66 (m, CH2, 1H).  
 
[Pt(L2)(N3)2] (8) 
This complex was synthesised by a method similar to that for [Pt(L1)(N3)2] (5), by 
using [Pt(L2)Cl2] (7) as the starting material.   
Yield: 45%.  
Elemental analysis: Found: C, 15.03; H, 3.47; N, 28.07. PtC5H14N8O requires: 
C, 15.12; H, 3.55; N, 28.20%.  
1H NMR (400 MHz, DMSO-d6): δ 6.02 (s, NH, 1H), 5.35 (s, NH2, 1H), 5.25 (s, 




NH2, 1H), 4.54 (t, OH, 1H), 3.43 (m, CH2, 2H), 2.80 (m, CH2, 1H), 2.59 (m, CH2, 
1H), 2.40 (m, CH2, 1H), 2.25 (m, CH2, 1H), 2.23 (m, CH2, 2H), 1.83 (m, CH2, 
1H), 1.66 (m, CH2, 1H).  
 
[Pt(L3)I2]  (9) 
K2[PtCl4] (300 mg, 0.72 mmol) was dissolved in water (4 mL), to this was added 
a solution of KI (1.21 g, 7.2 mmol) in water (3 mL), and the mixture was stirred 
for 90 min at room temperature. 1,3-diamino-2-propanol (L3) (65 mg, 0.72 mmol) 
was added and the reaction stirred for 3 h, after which volume was reduced and 
the mixture stored at 277 K overnight. A mustard-yellow solid was filtered off and 
washed with water, ethanol and diethyl ether, then dried under vacuum. 
Yield: 345 mg (89%).  
Elemental analysis: Found: C, 6.55; H, 1.74; N, 5.06.  PtC3H10N2I2O requires: 
C, 6.68; H, 1.87; N, 5.20%.  
1H NMR (400 MHz, DMSO-d6): δ 5.63 (s, NH2, 2H), 5.44 (t, OH, 1H), 5.39 (s, 
NH2, 2H), 3.91 (m, CH, 1H), 2.84 (m, CH2, 1H), 2.76 (m, CH2, 1H), 2.54 (m, 
CH2, 1H) 2.45 (m, CH2, 1H).  
 
[Pt(L3)Cl2] (10) 
[Pt(L3)I2] (550 mg, 1.02 mmol) was suspended in water (115 mL), AgNO3 
(338 mg, 1.99 mmol) was added, and the mixture stirred in the dark at 328 K for 
16 h. The AgI precipitate was filtered off using an inorganic membrane filter. 
NaCl (596 mg, 10.2 mmol) was added, the solution immediately filtered again to 
remove any AgCl, and stirred at room temperature in the dark for 4 h. The solvent 
volume was reduced and the mixture stored at 277 K overnight. The product was 
recrystallised from 0.1 M HCl, washed with small quantities of water, ethanol and 
diethyl ether, and dried under vacuum.  




Yield: 220 mg (61%).  
Elemental analysis: Found: C, 10.07; H, 2.72; N, 8.07. PtC3H10N2Cl2O requires: 
C, 10.12; H, 2.83; N, 7.87%.  
1H NMR (400 MHz, DMSO-d6): δ 5.20 (d, OH, 1H), 5.03 (s, NH2, 2H), 4.81 (s, 
NH2, 2H), 3.59 (m, CH, 1H), 2.45 (m, CH2, 2H), 2.29 (m, CH2, 2H).  
 
[Pt(L3)(N3)2] (11) 
This complex was synthesised by a similar method to [Pt(L3)Cl2] (9), but using 
NaN3 in place of NaCl.   
Yield: 70%.  
Elemental analysis: Found: C, 9.71; H, 2.64; N, 30.13.  PtC3H10N8O requires: 
C, 9.76; H, 2.73; N, 30.35%.  
1H NMR (400 MHz, DMSO-d6): δ 5.10 (d, OH, 1H), 4.93 (s, NH2, 2H), 4.72 (s, 
NH2, 2H), 3.54 (m, CH, 1H), 2.44 (m, CH2, 2H), 2.29 (m, CH2, 2H). 
 
2-[(2-pyridinylmethyl)amino]ethanol (L4) 
A solution of aminoethanol (634 µL, 10.5 mmol) in methanol (15 mL) was cooled 
in ice. Pyridine-2-carboxaldehyde (1 mL, 10.5 mmol) was added slowly, and the 
reaction mixture stirred at 298 K for 4 h. NaBH4 (1.19 g, 31.5 mmol) was added 
in small portions and the mixture stirred for a further two hours. Water (55 mL) 
was added, the mixture extracted with chloroform (6 x 20 mL), and the combined 
organic phases dried over MgSO4. Solvent was removed to yield a brown oil, to 
which water (3 mL) was added, the solution filtered to remove undissolved 
material, then the water was removed and the product dried under vacuum. 
Yield: 958 mg (60%).  
UV-Vis (H2O): λmax 258 nm, ε 3715 M
-1 cm-1.  
1H NMR (400 MHz, CDCl3): δ = 8.55 (d, 1H), 7.65 (td, 1H), 7.27 (d, 1H), 7.18 
(td, 1H), 3.95 (s, CH2, 2H), 3.67 (t, CH2, 2H), 2.86 (t, CH2, 2H), 2.44 (s, NH, 1H).  




ESI-MS: [M + H]+ 153 m/z.  
 
Cis-[Pt(DMSO)2Cl2] 
K2[PtCl4] (1.00 g, 2.41 mmol) was dissolved in water (9 mL), and to this was 
added dimethyl sulfoxide (513 µL, 7.22 mmol). The mixture was stirred for 1 h, 
then left to stand overnight. A cream solid was filtered off, washed with water, 
ethanol and diethyl ether, and dried under vacuum. 
Yield: 840 mg (83%).  
Elemental analysis: Found: C, 11.53; H, 2.52. PtC4H12Cl2O2S2 requires: C, 11.38; 
H, 2.86%. 
1H NMR (400 MHz, DMSO-d6): δ 2.54 (s, 6H, CH3).  
 
[Pt(L4)Cl2]  (12) 
Cis-[Pt(DMSO)2Cl2] (403 mg, 0.96 mmol) was dissolved in dichloromethane 
(60 mL) and a solution of L4 (146 mg, 0.96 mmol) in dichloromethane (5 mL) 
was added, upon which the solution became yellow. The mixture was stirred for 
3 h, after which all volume was removed to leave a sticky dark yellow residue. 
Recrystallisation from 0.1 M HCl yielded a fluffy pale yellow solid. 
Yield: 80 mg (20%).  
Elemental analysis: Found: C, 22.93; H, 2.77; N, 6.69. PtC8H12N2Cl2O requires: 
C, 22.98; H, 2.89; N, 6.70%.  
UV-Vis (H2O): λmax 263 nm, ε 6020 M
-1 cm-1.  
1H NMR (400 MHz, DMSO-d6): δ = 9.05 (d, 1H), 8.14 (td, 1H), 7.65 (d, 1H), 
7.50 (td, 1H), 7.02 (s, NH, 1H), 4.77 (t, OH, 1H), 4.38 (dd, CH2, 1H), 4.22 (dd, 
CH2, 1H), 3.73 (m, CH2, 2H), 2.98 (m, CH2, 1H), 2.81 (m, CH2, 1H).  
 





1,4-diaminobutane (7.67 g, 87 mmol) was dissolved in dioxane (30 mL). To this, 
a solution of di-tert-butyl dicarbonate (2.45 g, 11 mmol) in dioxane (30 mL) was 
added dropwise, over the course of 2 h. The resulting mixture was stirred at room 
temperature for 16 h. All solvent was removed under reduced pressure, and water 
(50 mL) was added. The mixture was filtered to yield 106 mg of white solid, the 
diprotected product (3% based on di-tert-butyl dicarbonate). The filtrate was then 
extracted with dichloromethane (3 x 50 mL), and the combined extracts 
backwashed once with water (30 mL) then dried over Na2SO4. Solvent was 
removed and the product dried under high vacuum to yield a colourless oil. 
Yield: 1.42 g (67%).  
1H NMR (400 MHz, CDCl3): δ = 4.65 (s, NH, 1H), 3.12 (d, CH2, 2H), 2.70 (t, 
CH2, 2H), 1.50 (m, CH2, 4H), 1.43 (s, CH3, 9H), 1.27 (s, NH2, 2H).   
 
Cis-[Pt(NH3)2I2] 
K2[PtCl4] (1.00 g, 2.41 mmol) was dissolved in water (20 mL), KI (4.00 g, 
24.1 mmol) was added, and the mixture stirred at room temperature for 30 min. 
NH4Cl (259 mg, 4.88 mmol) was added, and the pH adjusted to 10 with 2 M 
KOH. The pH was monitored every 5–10 min and readjusted to 10 until no further 
decrease was observed; the mixture then was stirred for 30 min and left to stand 
for an additional 30 min. The yellow solid was collected by filtration, washed 
with small quantities of water, ethanol and diethyl ether, and dried under vacuum. 
Yield: 1.10 g (95%).  
Elemental analysis: Found: C, 0.00; H, 1.12; N, 5.74.  PtH6N2I2 requires: C, 0.00; 
H, 1.25; N, 5.80%.  
1H NMR (400 MHz, DMSO-d6): δ 4.65 (br s, 3H, NH3). 
 





Cis-[Pt(NH3)2I2] (1.05 g, 2.17 mmol) was suspended in water (60 mL), AgNO3 
(720 mg, 4.24 mmol) was added, and the mixture stirred at 328 K in the dark for 
16 h. The AgI precipitate was filtered off using an inorganic membrane filter. 
NaCl (2.54 g, 43.4 mmol) was added, the solution immediately filtered again to 
remove any AgCl, and stirred at room temperature for 3 h. The solvent volume 
was reduced and the mixture stored at 277 K overnight. A bright yellow 
precipitate was isolated and recrystallised from 0.1M HCl; the final product was 
then filtered and washed with small quantities of water, ethanol and diethyl ether, 
and dried under vacuum.   
Yield: 546 mg (84%).  
Elemental analysis: Found: C, 0.00; H, 1.90; N, 9.27.  PtH6N2Cl2 requires: 
C, 0.00; H, 2.02; N, 9.34%.  
1H NMR (500 MHz, DMSO-d6): δ 3.94 (br s, 3H, NH3).  
ESI-MS: [M + Na]+ 323, [M – NH3]
+ 283, [M – Cl]+ 263 m/z. 
 
K[Pt(NH3)Cl3] 
Cis-[Pt(NH3)2Cl2] (280 mg, 0.93 mmol) and tetraethylammonium chloride 
(186 mg, 1.12 mmol) were placed in a two-necked round bottom flask, and 
dimethylacetamide (58 mL) was added.  The mixture was heated, under a nitrogen 
flow, to 373 K for 6 h. After cooling to room temperature, hexane : ethyl acetate 
(450 mL, 1:1 v/v) was added and the solution stored at 253 K overnight. The 
organic solvents were decanted to leave an orange oil, which was dissolved in 
methanol (10 mL) then filtered to remove any unreacted cisplatin. The methanol 
was removed under vacuum and the oil redissolved in water (5 mL); this was used 
directly in the preparation of mixed amine complexes without isolation. Where 
necessary, the concentration of a methanolic solution of the complex could be 




calculated from the absorption spectrum, with reference to a published extinction 
coefficient. 
UV-Vis (MeOH): λmax  345 nm, ε 115 M
-1 cm-1.  
ESI-MS: [M]– 318, [M – NH3]
– 301 m/z.   
 
Cis-[Pt(L5)(NH3)Cl2] (13) 
To an aqueous solution of K[Pt(NH3)Cl3] was added L5 (351 mg, 1.86 mmol), 
and the mixture stirred at room temperature for 2 h. A cream precipitate was 
isolated and washed with water, ethanol and diethyl ether, then dried under 
vacuum.  
Yield: 228 mg (52% based on cisplatin).  
Elemental analysis: Found: C, 22.56; H, 4.61; N, 8.86.  PtC9H23N3Cl2O2 requires: 
C, 22.94; H, 4.92; N, 8.92%.  
1H NMR (400 MHz, DMSO-d6): δ = 6.79 (br s, NH, 1H), 4.74 (br s, NH2, 2H), 
3.99 (br s, NH3, 3H), 2.90 (m, CH2, 2H), 2.50 (CH2, 2H, obscured by solvent 
peak), 1.53 (m, CH2, 2H), 1.37 (s, CH3 and CH2, 11H).  
 
Cis-[Pt(L5)(NH3)(N3)2] (14) 
Cis-[Pt(L5)(NH3)Cl2] (150 mg, 0.32 mmol) was suspended in methanol (35 mL), 
and to this was added a solution of AgNO3 (105 mg, 0.62 mmol) in water 
(15 mL).  The mixture was stirred at 328 K in the dark for 14 hours. The solvent 
was evaporated to dryness and the residue re-suspended in water; the AgCl 
precipitate was then removed by filtration with an inorganic membrane filter. To 
the filtrate was added NaN3 (207 mg, 3.18 mmol) and the mixture stirred for three 
hours, followed by a further filtration.  The solvent volume was reduced and the 
solution stored at 277 K for three hours, after which a yellow precipitate was 
collected by filtration and washed with water, a small quantity of ethanol and 
diethyl ether, then dried under vacuum. 




Yield: 166 mg (38%).  
1H NMR (400 MHz, DMSO-d6): δ = 6.79 (br s, NH, 1H), 4.61 (br s, NH2, 2H), 
3.86 (br s, NH3, 3H), 2.89 (m, CH2, 2H), 2.40 (m, CH2, 2H), 1.45 (m, CH2, 2H), 
1.38 (s, CH3 and CH2, 11H). 
 
Cis,cis,trans-[Pt(L5)(NH3)(N3)2(OH)2] (15) 
Cis-[Pt(L5)(NH3)(N3)2] (35 mg, 0.072 mmol) was suspended in water (20 mL). 
H2O2 (295 µL, 2.88 mmol, 30 % solution) was added and the mixture stirred for 
14 h at room temperature in the dark. Following this, additional water (20 mL) 
and H2O2 (295 µL) were added and the mixture stirred for a further 6 h, then 
filtered through an inorganic membrane filter. The solvent was removed and 
acetone was added to the residue to isolate a pale yellow precipitate. 
Yield: 9 mg (25%).  
1H NMR (400 MHz, DMSO-d6): δ = 6.81 (br s, NH, 1H), 5.63 (br s, NH2, 2H), 
5.06 (br s, NH3, 3H), 2.91 (m, CH2, 2H), 2.52 (m, CH2, 2H), 1.55 (m, CH2, 2H), 









3.2.3.1 X-ray Crystallography 
The crystal structure of 3 was solved by Professor Simon Parsons and colleagues 
at the University of Edinburgh, and that of 4 by Dr Guy Clarkson at the University 
of Warwick. Data were collected and refined as described in Chapter 2. 
 
3.2.3.2 Stability Studies and Reactions with Glutathione and 5'-GMP 
The stability of several PtII and PtIV complexes under various biologically relevant 
conditions was monitored by 1H NMR spectroscopy, with stability under ambient 
laboratory lighting conditions also investigated. Details for all experiments are 
given in subsequent sections.   
 
3.2.3.3 Cytotoxicity Testing 
The cytotoxicity of several PtII complexes towards the human ovarian A2780 
cancer cell line was investigated. Experiments were performed by Dr Ana Pizarro 
and Miss Soledad Betanzos Lara at the University of Warwick, according to the 
procedure outlined in Chapter 2.  
 
3.2.3.4 Photoreactions 
Photoreactions of several complexes, both alone in aqueous solutions and in the 
presence of 5'-GMP, were studied and monitored by 1H NMR and, in certain 
cases, UV-Visible spectroscopy. Irradiations were performed using a LZC-ICH2 
photoreactor equipped with LZC-UVA lamps (λmax = 365 nm, P = 1.7–
2.2 mW cm-2) and LZC-VIS UV-Visible light lamps (λ = 400–700 nm, P = 0.27–
0.29 mW cm-2); further details and the spectral outputs of these light sources can 




be found in Chapter 2. Specific details for each experiment are given in 
subsequent sections. 
 
3.2.3.5 Phototoxicity Testing 
Phototoxicity testing of complexes 2, 5, 6, and 8 was performed using the HaCaT 
keratinocyte human skin cell line. This was undertaken by Dr Julie Woods and 
Kim Robinson at the Photobiology Unit in Ninewells Hospital, Dundee, as 
described in Chapter 2. 
 
3.3 Results 
A series of PtII azido complexes has been synthesised and characterised, 
containing ligands with a pendant hydroxyl or protected amine group. Two such 
PtIV azido complexes were also prepared. The dark stability of one PtII and one 
PtIV azido complex in aqueous and 100 mM chloride solutions was investigated, 
as well as dark reactions with glutathione and 5'-GMP. The photoreactions of 
these two complexes upon irradiation with UVA and visible light were monitored, 
as well as in the presence of 5'-GMP, irradiating with UVA light. Finally the 
cytotoxicity and phototoxicity of several complexes were determined.  
  




+     K2PtCl4
H2O,pH 7
16 h, RT
n = 1, L1
n = 2, L2
n = 1, [Pt(L1)Cl2] (4)
n = 2, [Pt(L2)Cl2] (7)
3.3.1 Synthesis and Characterisation  
Complexes 1, 2 and 3, containing ethylenediamine as a chelating ligand, were 
prepared according to published methods,[13] and their synthesis will not be 
discussed here. The following sections describe the synthesis of complexes 
containing pendant hydroxyl or protected amine functionalities. 
 
3.3.1.1 Platinum Complexes Containing a Pendant Hydroxyl Group 
3.3.1.1.1 Pt
II
 Chlorido Complexes 
It was not possible to prepare PtII chlorido complexes of all four aminoalcohol 
ligands using the same synthetic route; described below are the three different 
methods used in the preparation of these complexes. 
PtII chlorido complexes of L1 and L2 were prepared in good yields from reaction 










Scheme 3.1  The synthetic route to PtII chlorido complexes of L1 and L2 
 
It has been previously reported that the reaction of L3 with K2[PtCl4] does not 
yield [Pt(L3)Cl2], but instead produces the salt [Pt(L3)2][PtCl4].
[15] Hence an 















alternative route was employed, in which the aminoalcohol ligand was first 
reacted with K2[PtI4] to obtain [Pt(L3)I2] (9).
[16] The iodides were then abstracted 
with silver nitrate to yield the aquo species, followed by addition of NaCl to form 













Scheme 3.2  The synthetic route to the PtII chlorido complex of L3 
 
Attempts to synthesise the new complex [Pt(L4)Cl2] (12) by the method shown in 
Scheme 3.1 were unsuccessful. The reaction mixture rapidly darkened upon pH 
adjustment, yet little reaction was apparent when the pH was unaltered. The most 
successful synthesis of this complex involved reaction of the aminoalcohol ligand 
L4 with cis-[Pt(DMSO)2Cl2] in dichloromethane, however yields were still 
relatively low, and only one suitably pure batch was prepared. 




All chlorido complexes were purified by recrystallisation from 0.1 M HCl, and 
characterised by 1H NMR spectroscopy, CHN analysis and, in the case of 




 Azido Complexes 
The corresponding PtII azido complexes were formed from the chlorido precursors 
according to published methods for similar complexes.[13] Silver nitrate 
abstraction of the chlorides forms the aquo species, which react rapidly upon 
addition of excess NaN3 to yield the desired Pt
II azido complexes, in a similar 
reaction to that shown in Scheme 3.2. The azido complex of L3 could be formed 
in this way from either the PtII chlorido or the iodido precursor. 
Recrystallisation was not attempted for the azido complexes due to their 
sensitivity to temperatures exceeding 313 K. However, purity was confirmed by 





 Azido Complexes 
Attempts were made to oxidise [Pt(L1)(N3)2] (5), via a well documented 
procedure using hydrogen peroxide in aqueous solution, to yield a PtIV azido 
complex containing hydroxyl ligands in the two axial positions.[13] However, 
although evidence of the required complex was seen by mass spectrometry, 
impurities were invariably evident in 1H NMR spectra. In addition, the product 
was very sticky and difficult to isolate and handle; consequently no further work 
was carried out with this complex.  
However, the PtIV complex containing two axial acetato groups was successfully 
synthesised, following a published route for oxidation of the PtII chlorido 








[Pt(L1)(N3)2] (5) [Pt(L1)(N3)2(OAc)2] (6)
precursor,[17] to yield [Pt(L1)(N3)2(OAc)2] (6). This complex was analysed by 
1H 









Scheme 3.3 The oxidation of [Pt(L1)(N3)2] to yield a Pt
IV complex with axial 
acetato groups. 
 
3.3.1.1.4 X-ray Crystallography 
The X-ray crystal structures of [Pt(L1)Cl2] (4) and [Pt(L1)(N3)2] (5) were obtained 
in this work and are discussed below. The structure of 4 has been reported 
previously,[18] whilst that of 5 is novel. 
[Pt(L1)Cl2] (4) crystallised in a monoclinic system with the space group P21/c, 
containing two symmetry independent molecules in the asymmetric unit. All data 
are consistent with the structure previously reported.  
Intermolecular hydrogen bonding is observed between the secondary amine 
hydrogens and the chlorido ligands of complexes stacked vertically in the 
structure (2.35 Å, Figure 3.2, A). Additionally, the hydroxyl groups are involved 
in a chain of hydrogen bonds (1.86 Å, Figure 3.2, B), and do not participate in 
intermolecular interactions with any other groups.  














































Figure 3.2  A: Intermolecular hydrogen bonding between the secondary amine 
hydrogens and the chlorido ligands of [Pt(L1)Cl2] (4). B: Hydrogen bonding 
between the alcohol groups of neighbouring complexes, forming an extended 
chain.  




The structure of [Pt(L1)(N3)2] (5) is shown in Figure 3.3. This complex also 
crystallised in the monoclinic system, but with the space group P21/n. Unlike in 
the case of 4 there is only one molecule in the asymmetric unit, although four are 
present in the unit cell. Further crystallographic data and solution refinements are 
given in Table 3.1. 
 
Table 3.1  Crystallographic data and solution refinements for [Pt(L1)(N3)2] (5).  
 




Crystal Size (mm) 
Crystal System 
Space Group 




Density, calculated (mgM-3) 
F(000) 






0.20 x 0.02 x 0.02 
Monoclinic 
P21/n 
a = 8.3389(2), b = 7.9447(2) 
c = 15.2700(4) Å 








Selected bond lengths and angles are listed in Table 3.2, with the numbering 
scheme corresponding to that in Figure 3.3. 
  





























Table 3.2  Selected bond lengths and angles for [Pt(L1)(N3)2] (5).  
 




































121.6(2)            




The bond lengths are similar to those of previously reported PtII azido 
complexes.[22,31] The Pt(1)–N(8) and Pt(1)–N(11) bond lengths, 2.035 and 2.036 Å 
respectively, are significantly shorter than the analogous Pt–Cl bonds of 4 (2.309 
and 2.320 Å); consistent with the fact that azide is a stronger donor ligand towards 
platinum than is chloride. However, comparing the platinum-amine nitrogen bond 
lengths, there are no significant differences between complexes 4 and 5. 
The structure of the coordinated azido group can be described as a resonance 
hybrid in which the bond between bound (α) and central (β) nitrogens has a lower 
bond order than that between central and terminal (γ). This is reflected by the 
longer length of the Nα–Nβ bonds compared with Nβ–Nγ, for example N(8)–N(9) 
at 1.221 Å, and N(9)–N(10) at 1.151 Å. The azido ligands show Nα–Nβ–Nγ angles 
of 175˚ and 176˚ and as such are essentially linear. The Pt–Nα–Nβ angles of 119.6˚ 
and 121.6˚ are also comparable with those reported for similar PtII azido 
complexes.[22,31] 
The geometry around platinum is essentially square planar, with the N(8)-Pt(1)-
N(11) angle at 90.77˚. The N(1)–Pt(1)–N(4) angle formed within the chelate ring 
is 84.07˚, smaller than that in the related ethylenediamine complex, which was 
determined as 95.7˚.[22]  
The molecules form many inter- and intramolecular short contacts, more so than 
those of the chlorido analogue due to the involvement of the azido nitrogens. Of 
particular interest is an intramolecular hydrogen bond (2.04 Å) between the H of 
the hydroxyl group and a bound azido nitrogen (Figure 3.4). There is also an 
intermolecular hydrogen bond (2.05 Å) between a hydrogen of the primary amino 
group and the hydroxyl oxygen of a neighbouring molecule. Unlike in the 
chlorido analogue, the hydroxyl groups do not form intermolecular contacts with 
each other. The nitrogens of the azido groups also form several longer-range 
intermolecular contacts, involving the primary and secondary amino groups on 
adjacent molecules. 










H NMR Spectroscopy 
1H NMR experiments were carried out in DMSO-d6 for all complexes, since 
spectra generally showed greater clarity in this solvent than in aqueous solutions, 
where many peaks were found to overlap. 
There are several notable features of the spectra of these complexes, which shall 
be discussed with reference to complexes of L1. Firstly, although peaks resulting 
from exchangeable protons are typically broad, that of the OH proton is very 
sharp and presents as a triplet. Evidence for the assignment of this peak is 
provided by 2D [1H, 1H] COSY NMR experiments, in which cross peaks are seen 
with the adjacent methylene protons. A D2O shake results in the disappearance of 
this peak, confirming it arises from an exchangeable proton. A previous study of 
[Pt(L1)Cl2] (4) reports this signal to be sharper than those of the amino protons, 
although it is stated to be a singlet and the spectrum is not shown.[17]  
Additionally, as DMSO is a very good ligand, PtII–Cl bonds readily undergo 
exchange of the chlorido ligands for this solvent over time.[19] In the case of 4, the 













mono- and bis-DMSO adducts, [Pt(L1)(DMSO)Cl]+ and [Pt(L1)(DMSO)2]
2+, are 
believed to be formed. It is interesting to note that exchange results in a 





















1H NMR spectra of [Pt(L1)Cl2] (4) over time in DMSO-d6, illustrating 
the sharp nature of the OH peak, and its significant shift upon exchange of the 
chlorido ligands for DMSO. 
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The spectra also reveal the inequivalence of the protons within each methylene 
pair. At a high magnetic field, it is possible to observe an individual peak for each 
of the eight methylene protons of [Pt(L1)(N3)2(OAc)2] (6). Through 2D [
1H, 1H] 
COSY and NOESY experiments, these peaks were assigned as shown in Figure 
3.6. The two axial acetato groups of this complex are also inequivalent, and their 











Figure 3.6  A: The 1H NMR spectrum of [Pt(L1)(N3)2(OAc)2], B: The aliphatic 
region of the 2D [1H, 1H] NOESY spectrum, showing the assignment of the eight 
methylene protons.  C: The two singlets arise from each inequivalent acetato 
group. 
 

























































3.3.1.1.6 UV-Vis and Fluorescence Spectroscopy of 
 2-[(2-pyridinylmethyl)amino]ethanol (L4) 
 
2-[(2-Pyridinylmethyl)amino]ethanol, (L4), was found to display yellow-white 
fluorescence upon excitation with UVA light. Emission spectra were recorded in 
water, with excitation at two different wavelengths (278 nm and 365 nm), with a 









Figure 3.7  Normalised absorption and emission spectra of L4 in water.  
 
The PtII chlorido complex of this ligand, [Pt(L4)Cl2] (12), displayed orange 
fluorescence in the solid state when placed under a UVA light source. However, 
upon dissolution this fluorescence appeared to be quenched, and emission spectra 
recorded in water and DMF, again with excitation at 278 nm and 365 nm, 
revealed the complex to be non-emissive in solution. 















3.3.1.2 Platinum Complexes Containing a Protected Amine Group 
In addition to complexes containing a pendant hydroxyl group, those containing a 
protected amine were also investigated. PtII chlorido and azido complexes, and the 
PtIV azido derivative, of the ligand N-tert-butoxycarbonyl-1,4-diaminobutane (L5) 
were prepared according to the scheme below. K[Pt(NH3)Cl3]
[20] and L5[21] were 













Scheme 3.4  The synthetic route to a PtIV complex containing a BOC-protected 
amine. 
 
The mixed amine PtII chlorido complex 13 was prepared in moderate yield using 
an excess of L5, and recrystallised where necessary from 0.1 M NaCl. The azido 
complex 14 was prepared via a silver nitrate abstraction of the chlorido ligands, in 
a similar manner to that reported in Scheme 3.2. However yields were relatively 




low as, despite a number of attempts using various conditions, this reaction 
frequently resulted in the formation of a grey-black solid believed to be Pt0.  
Oxidation to the PtIV complex was achieved through the use of hydrogen peroxide 
in aqueous solution, although again was low-yielding due to the formation of a 
similar dark precipitate. All complexes were characterised by 1H NMR 
spectroscopy and, in the case of complex 13, by CHN analysis. 
 
 
3.3.2 Stability Studies 
3.3.2.1 Stability in Aqueous Solutions 
Solutions of 2 and 5 (1.5 mM), and 3 and 6 (3 mM), were prepared in 90% 
H2O/10% D2O, with 0.1 % dioxane (δ = 3.75 ppm) added as an internal calibrant. 
1H NMR spectra were acquired after 0 h, 6 h, 12 h, 24 h, 48 h, 72 h, 5 d, 7 d, 13 d, 
22 d and 50 d. Samples were stored at 310 K in the dark between measurements.  
 
a) [Pt(en)(N3)2]  (2) 
This complex was found to undergo a degree of oxidation in aqueous solution, 
forming a PtIV species identified as [Pt(en)(N3)2(OH)2] (3). 
Small amounts of this new species were apparent after 6 h, with a new peak at 
2.93 ppm accounting for 1% of the total signal in this region. The proportion grew 
steadily, reaching around 17% after 7 d, after which no further increase was seen. 
Evidence for the identity of this species was given from comparisons of the 
chemical shift and coupling constant with those of an authentic sample of 3. 
Quantification of 3 was hindered by the appearance of a broad peak in the 
spectrum at 72 h, centred around 2.84 ppm, which continued to grow throughout 
the remainder of the experiment, indicating multiple new species which could not 
be identified. 






































Figure 3.8  1H NMR spectra of [Pt(en)(N3)2] (2) at various time intervals in 
aqueous solution, showing formation of the oxidised species [Pt(en)(N3)2(OH)2] 
(3). 
 




To further investigate the formation of 3, the experiment was repeated with a 
degassed sample of [Pt(en)(N3)2] (2). Oxidation occurred to a lesser extent, with 
the peak of 3 comprising <5% of the total en-CH2 signal intensity after 5 d, 
compared with 15% in the non-degassed sample over the same time period. 
Evidence of an oxidised product was also found in the spectra of 100 mM NaCl 
solutions of [Pt(en)Cl2] (1), the signal for which comprised 7% of the total after 
5 d. However, despite firm NMR evidence of a PtIV species, attempts to detect 
such a complex by mass spectrometry were unsuccessful. 
 
b) [Pt(en)(N3)2(OH)2] (3) 
The spectrum remained unchanged throughout the course of the 50-day 
experiment, implying that 3 is stable under these conditions. This is in accordance 
with previous findings for similar PtIV azido complexes.[22,31]  
 
c) [Pt(L1)(N3)2] (5) 
Evidence for the formation of new product(s) is seen, however these cannot be 
readily assigned. 
Due to the inequivalence of the eight methylene protons of this complex, the 
spectrum of 5 in aqueous solutions is inherently more complicated than that of 
[Pt(en)(N3)2] (2), rendering any formation of new species harder to follow. After 
6 h, two new doublets appeared at 3.48 and 3.51 ppm and increased in intensity 
until around 48 h, comprising around 10% of the total species. Although it was 
not possible to identify these peaks, they may result from a hydrolysis product, or 
a PtIV species should the complex undergo oxidation as in the case of 2. 
Throughout the remainder of the NMR spectrum, a loss of signal resolution and 
intensity over time indicated the formation of multiple species, which could not be 
readily assigned. 
 




d) [Pt(L1)(N3)2(OAc)2] (6)  
Free acetate was released from this complex over time, with a concurrent decrease 
in pH from 7.92 to 5.03. 
A small amount of free acetate (2% of the total acetate signal) was present in the 
initial spectrum; however the proportion increased to a total of 7% after 50 d. 
Associated with the decrease in pH was an increase in the chemical shift of free 
acetate (from 1.90 to 1.97 ppm), and the appearance of peaks corresponding to the 
amine protons. This is consistent with a previous investigation of the NMR 
spectra of 3 at various pH values, which found the NH2 protons to be visible only 
at pH values below 6.[22] The remainder of the spectrum showed little change 
throughout the experiment, with a small loss of resolution over time. 
 
3.3.2.2 Stability Towards Chloride 
Solutions of 2 and 5 (1.5 mM), and 3 and 6 (3 mM), were prepared in 90% 
H2O/10% D2O containing 100 mM NaCl, with 0.1% dioxane added as an internal 
calibrant. 1H NMR spectra were acquired after 0 h, 6 h, 12 h, 24 h, 48 h, 72 h, 5 d, 
7 d, 13 d, 22 d and 50 d. Samples were stored at 310 K in the dark between 
measurements.  
 
a) [Pt(en)(N3)2]  (2) 
As in the case of aqueous solutions, this complex was found to undergo oxidation 
to form a PtIV species. 
The rate and extent of oxidation was found to be similar to that in aqueous 
solution (14% oxidised species after 7 d), with other changes to the spectrum also 
similar. The oxidised product was again assumed to be [Pt(en)(N3)2(OH)2] (3); it 
is unlikely that Cl– could replace an axial hydroxyl group, and such PtIV azido 
complexes have previously been found stable to 100 mM NaCl solutions. 




c) [Pt(en)(N3)2(OH)2] (3) 
The spectrum remained unchanged throughout the course of the 50-day 
experiment, implying that 3 is stable under these conditions. Again, this is in 
agreement with previous findings for similar complexes.[22,31] 
 
b) [Pt(L1)(N3)2] (5) 
The spectral changes were very similar to those seen for the complex in aqueous 
solutions, with two new doublets appearing at 3.48 and 3.51 ppm after 6 h, and an 
overall loss of signal resolution over time. 
  
d) [Pt(L1)(N3)2(OAc)2] (6) 
Free acetate was again released from this complex over time, with a decrease in 
pH from 7.84 to 5.42. 
The proportion of free acetate again increased from around 2% to 7% over the 
course of the experiment. The pH change was smaller in this case, resulting in a 
smaller downfield shift of the free acetate peak (1.90 to 1.93 ppm). Again, peaks 
corresponding to the amine protons became more visible with the decrease in pH. 
  




3.3.3 Reactions with Glutathione and 5’-GMP 
3.3.3.1 Reactions with Glutathione 
Samples of [Pt(en)(N3)2] (2) (1.5 mM) and [Pt(L1)(N3)2(OAc)2] (6) (3 mM) were 
prepared in D2O, with 2 µL of a 1% acetone solution (δ = 2.22 ppm) added as an 
internal calibrant. A solution of reduced glutathione (GSH) was degassed under 
nitrogen, the pH* was altered to 7.0–7.2 with NaOD, degassing was repeated and 
2 mol equivalents were added to each sample. The pH* of the samples was then 
re-recorded as 7.50 and 7.12 respectively, and the samples briefly degassed once 
more in the NMR tube. 1H NMR spectra were acquired after 0 h, 3 h, 6 h, 12 h, 
24 h, 48 h, 72 h, 5 d, 9 d and 16 d. Samples were stored at 310 K in the dark 
between measurements. 
 
a) [Pt(en)(N3)2] (2)  
Evidence of multiple species was seen, including the sulfur-bridged complex 
[{Pt(en)(µ2-SG)}2]
2+.   
After 3 h, a new peak was apparent at 2.74 ppm (2a). As the en-CH2 peak 
(2.60 ppm) was found to overlap with a glutathione resonance, reliable integration 
was not possible, although the new peak increased in intensity over time with 
concomitant decrease of the en-CH2 resonance. This likely corresponds to the 
monoadduct [Pt(en)(N3)(SG)]. After 48 h a broad peak dominated this region of 
the spectrum, and much signal intensity in this region was lost thereafter, 
indicating formation of multiple products. After 12 h, a new peak appeared at 
3.36 ppm which increased in intensity throughout the remainder of the experiment 
(Figure 3.9). This may arise from the cys-β CH2 protons of a stable Pt-GSH 
complex (2b). Two small doublets at 3.28 and 3.31 ppm, visible after 3 h, arise 
from a small quantity of oxidised glutathione (GSSG), likely oxidised by air.  The 
pH decreased from 7.50 to 6.68 during the course of the experiment. 
 








































Figure 3.9 1H NMR spectra recorded at various intervals during the reaction of 
[Pt(en)(N3)2] (2) with glutathione.  




A mass spectrum of the solution showed a peak at m/z 561, corresponding to the 
sulfur-bridged dimer [{Pt(en)(µ2-SG)}2]
2+, typically the major product of the 
reaction of glutathione with diam(m)inoplatinumII complexes.[23]  
 
b) [Pt(L1)(N3)2(OAc)2] (6) 
Little reduction of 6 was seen throughout the course of the reaction with 
glutathione.  
Changes in the spectra were difficult to identify and quantify, since the spectra of 
both oxidised and reduced glutathione, and PtIV and PtII complexes of L1, 
contained overlapping peaks. However, the appearance of two doublets at 3.28 
and 3.31 ppm clearly indicated formation of oxidised glutathione (GSSG). First 
apparent at 3 h, these peaks increased in intensity slightly throughout the 
experiment, however their reliable quantification was not possible. It is easier to 
follow the fate of the PtIV complex by monitoring the peak of free acetate, which 
is released upon reduction. Although there was an increase in intensity of this 
peak (from 2% to 6% of the total acetate region), the magnitude was similar to 
that seen for the complex alone in aqueous solutions, indicating little reduction 
had taken place. In the remainder of the spectrum, slight changes to peak shapes 
were apparent after 5 days, indicative of new species. The pH* was also found to 
decrease from 7.12 to 5.54.  
A mass spectrum of this solution at the end of the experiment revealed peaks 
corresponding to reduced glutathione at m/z 307.08 [M]+, and complex 6 at 524.09 
[M + Na]+, with no other platinum containing species found. 
 
3.3.3.2 Reactions with 5'-GMP 
Samples of [Pt(en)(N3)2] (2) (1.5 mM) and [Pt(L1)(N3)2(OAc)2] (6) (3 mM) were 
prepared in D2O with 2 µL of 1% dioxane added as an internal calibrant. 2 mol 
equivalents of 5-guanosine monophosphate (5'-GMP) were added to each sample, 




and the pH* of the samples was then adjusted to 5.5–5.7 with NaOD. 1H NMR 
spectra were acquired after 0 h, 3 h, 6 h, 12 h, 24 h, 48 h, 72 h, 5 d, 9 d and 16 d. 
Samples were stored at 310 K in the dark between measurements. 
The interaction of platinum complexes with guanine typically occurs via binding 
to N7,[24] and is followed by the change in chemical shift of the H8 proton. 
However, this proton can undergo exchange for deuterium over time in D2O,
[25] a 
process which appears to be accelerated upon platinum binding,[26] and hinders its 
reliable quantification. To estimate for how long integration of these peaks is 
reliable, the total integral of the H8 region was compared with that of a non-
exchangeable proton, H1', over time. Good agreement was found until 24 hours, 
after which values differed by >10%, therefore integrals of the H8 region were 
deemed unreliable after this point and quantification was based, in the case of 2, 
on the en-CH2 peaks. 
 
a) [Pt(en)(N3)2] (2)  
Formation of a 5'-GMP monoadduct was evident after 3h, with detection of the 
bisadduct at 24 h. Mass spectral evidence of the latter species was obtained. 
Significant oxidation of 2 was also found. 
After three hours a new peak at 8.60 ppm was apparent, the low-field shift of the 
H8 proton consistent with platinum binding to N7 of 5'-GMP. An additional peak 
was also present in the aliphatic region at 2.70 ppm arising from the en-CH2 
protons. Both were attributed to a monoadduct of 5'-GMP (2c), comprising 12% 
of the total platinum species after 3h and rising to 17% after 12 h. 
After 24 h there was evidence of a new product, assigned as the bisadduct 
[Pt(en)(5'-GMP-N7)2]
2+ (2d) comprising 6.5% of the detectable platinum species. 
In the H8 region, the new peak (8.57 ppm) showed a characteristic upfield shift 
from that of the monoadduct,[27] but in the aliphatic region a downfield shift was 
seen (2.82 ppm). Throughout the remainder of the experiment the proportions of 
both mono- and bisadducts increased at the expense of [Pt(en)(N3)2]. However, 

























whilst the monoadduct appeared to stabilise at 25% after 5 days, the proportion of 
bisadduct continued to increase, reaching 41% after 16 days (Figures 3.10 and 
3.11). Evidence of the bisadduct was provided by mass spectrometry, showing a 
peak at m/z 490.58 [M]2+.  
A significant amount of a PtIV species, presumably [Pt(en)(N3)2(OH)2] (3), was 
also formed, as found in the aqueous stability studies. After 24 h this comprised 
13% of all platinum species detected, rising to 15% after 16 d. A graph showing 






















Figure 3.10 The speciation over time during the reaction of 2 with 5’-GMP. 
2 [Pt(en)(N3)2], 2c [Pt(en)(N3)(5’-GMP-N7)]

































































Figure 3.11  Selected regions of the 1H NMR spectra recorded at various 
timepoints during the reaction of [Pt(en)(N3)2] (2) with 5'-GMP. 




b) [Pt(L1)(N3)2(OAc)2] (6) 
There were no changes in the 1H NMR spectrum over a period of 16 days, 
indicating no reaction between complex 6 and 5'-GMP under these conditions. 
 
3.3.3.3 Stability of Pt
II
 Azido Complexes to Ambient Laboratory Lighting 
An initial aim of this work was to test a series of PtII azido complexes for 
cytotoxic activity against a human cancer cell line. However, these tests are 
performed in a standard cell culture laboratory with no control over light levels, 
and many metal azido complexes are known to be photoactive.[8] It was therefore 
necessary to test the stability of the complexes synthesised under ambient lighting 
conditions, to which solutions are exposed for approximately twenty minutes 
during the testing procedure. 
Light levels were monitored with a power meter inside the fume hood in which 
cell testing is carried out, and found to be 0.27 µW/cm2 for UV and 950 µW/cm
2 
for visible. Solutions of [Pt(en)(N3)2] (2) and [Pt(L1)(N3)2] (5) were prepared and 
an initial 1H NMR spectrum acquired. The samples were left in an area of the 
laboratory with stronger light levels (0.40 µW cm-2 UV and 1150 µW cm
-2 visible) 
and for a longer time period (60 min) than they would experience during testing, 
after which a final 1H NMR spectrum was acquired.  
No change was detectable in the spectra of either complex following the 
experiment, suggesting negligible decomposition under these light conditions. 
Therefore it was concluded that these cytotoxicity experiments are appropriate for 
this class of complexes. The PtIV azido complexes were not tested in this way.  
Their high sensitivity to light, particularly in the presence of biomolecules,[2] plus 
their sole intended use as photoactivated agents, renders them suitable for 
controlled phototoxicity testing only. 
  





Several PtII complexes were tested for cytotoxicity against the A2780 human 
ovarian cancer cell line. Both PtII chlorido and azido complexes of each ligand 
were tested, to investigate the differences upon the change of leaving group.   
 
Table 3.3 IC50 values of several Pt
II complexes synthesised in this work, against 


















a The IC50 value is defined as the concentration required to achieve 50% growth inhibition 
Complex IC50 / µM (A2780)
a 
[Pt(en)Cl2] (1) 3.4 
[Pt(en)(N3)2] (2) 33 
[Pt(L1)Cl2] (4) 11 
[Pt(L1)(N3)2] (5) 31 
[Pt(L2)Cl2] (7) 11 
[Pt(L2)(N3)2] (8) 47 
[Pt(L3)I2] (9) >100 
[Pt(L3)Cl2] (10) 3.3 
[Pt(L3)(N3)2] (11) 21 
[Pt(L4)Cl2] (12) 27 
Cisplatin 1.3 




All of the PtII chlorido complexes showed good to moderate cytotoxicity in these 
tests. The high activity of complexes 1 and 10 is consistent with previous 
literature reports,[9,28] as is slightly lower activity for complex 4,[11,18] containing a 
pendant hydroxyl group. Extending the linker to this hydroxyl group from 2 to 3 
carbons apparently has no effect on the cytotoxicity, since the same IC50 values 
are found for complex 4 and the new complex 7. The previously unreported 
complex 12, containing a pyridine ring, shows lower toxicity than the other PtII 
chlorido complexes tested. 
The PtII iodido complex, 9, has an IC50 value greater than 100 µM and is therefore 
deemed inactive; this is consistent with previous findings of such complexes.[3] 
It is interesting to note that all of the PtII azido complexes were moderately 
cytotoxic at the concentrations tested.  From the initial data of this small sample, it 
appears there is little correlation between the cytotoxicity of the PtII chlorido 
complexes and their azido analogues, however this would need to be further 
investigated with a wider range of complexes. 
  





The photoactivity of PtII azido complexes is well documented.[8] It is therefore of 
interest to explore the photoreactions of the complexes produced in this work, 
especially with regard to their potential phototoxicity. The light sources and 
power levels were as described in section 3.2.3.4.  
 
3.3.5.1 Photoreactions of Pt
II
 Chlorido Complexes 
Saturated solutions of [Pt(en)Cl2] (1) and [Pt(L1)Cl2] (4) were prepared in 90% 
H2O/10% D2O, with 0.1% dioxane added as an internal calibrant, and the initial 
pH values recorded. Samples were irradiated in an NMR tube with either UVA or 
visible light for 120 min, with 1H NMR spectra acquired prior to and immediately 
following irradiation. pH values were then re-recorded at the end of the 
experiment.  
 
3.3.5.1.1 [Pt(en)Cl2] (1) 
No changes were seen in the 1H NMR spectrum of this complex following 
irradiation with either UVA or visible light. The pH also remained effectively 
constant (7.3 ± 0.1). This complex can therefore be regarded as stable under these 
conditions. 
 
3.3.5.1.2 [Pt(L1)Cl2] (4)  
Again no changes were seen in either the 1H NMR spectra or the pH values 
(6.6 ± 0.1) of this complex following irradiation with either UVA or visible light. 
 




3.3.5.2 Photoreactions of Pt
II
 Azido Complexes 
Saturated solutions of [Pt(en)(N3)2] (2) and [Pt(L1)(N3)2] (5) were prepared in 
90% H2O/10% D2O, with 0.1% dioxane added as an internal calibrant, and the 
initial pH values recorded. Samples were irradiated with either UVA or visible 
light in an NMR tube at 310 K, with 1H NMR spectra recorded after 0, 5, 10, 15, 
20, 25, 30, 45, 60, 90 and 120 min (UVA) and 0, 10, 30, 60 and 120 min (visible). 
pH values were then re-recorded at the end of the experiment. 
 
3.3.5.2.1 [Pt(en)(N3)2] (2)  
a) UVA Irradiation 
After 5 min irradiation, changes to the en-CH2 peak at 2.60 ppm were already 
apparent. The downfield satellite began to broaden, and this increased upon 
continued irradiation. Concurrently, the main peak at 2.60 ppm decreased in 
intensity with a new peak forming under the upfield satellite at 2.54 ppm; by 
45 min these two peaks were of approximately equal intensity. The loss of signal 
intensity and resolution throughout the experiment suggested the formation of 
multiple new species, possibly including hydrolysis products. There was no 
evidence of free ethylenediamine (2.65 ppm), and no platinum-containing species 
could be detected by mass spectrometry, The pH decreased significantly over the 
course of the reaction, from 8.60 to 5.50; such a change will likely traverse the 
pKa values for any aqua adducts present, further complicating the spectrum.  The 
spectra can be seen in Figure 3.12. 
 
  













b) Visible Irradiation 
Changes to the spectral profile were similar upon irradiation with visible light; a 
significant loss in signal intensity and resolution was seen, although at a slower 
rate than with UVA light. The concomitant decrease in pH was also smaller, from 

































Figure 3.12  1H NMR spectra recorded at various timepoints during the 
irradiation of [Pt(en)(N3)2] (2) with UVA light (λmax = 365 nm), in 90% H2O/10% 
D2O at 310 K. 




3.3.5.2.2 [Pt(L1)(N3)2] (5) 
a) UVA Irradiation 
A loss of signal resolution and intensity was again seen over the course of this 
experiment. As previously noted, the eight methylene protons of this complex are 
magnetically inequivalent, resulting in many overlapping 1H NMR peaks in the 
aliphatic region of the spectrum and rendering the identification of new species 
difficult. However, two new doublets, at 3.48 and 3.51 ppm, were identified after 
10 min irradiation and appeared to grow in intensity slightly throughout the 
experiment, although reliable integrals could not be obtained. These signals were 
also seen in the stability study of this complex in aqueous solution (section 
3.3.2.2), suggesting they could result from a hydrolysis product, the rate of 
formation of which is increased upon irradiation. The pH increased slightly during 
the experiment, from 8.62 to pH 8.97. 
 
b) Visible Irradiation 
As for [Pt(en)(N3)2] (2), it appears that similar changes occurred upon irradiation 
of 5 with visible light as with UVA, although at a slower rate. The pH change was 
of a similar magnitude, increasing from 8.41 to 8.70. 
 
  




3.3.5.3 Photoreactions of a Pt
IV
 Azido Complex, [Pt(L1)(N3)2(OAc)2] (6) 
3.3.5.3.1 
1
H NMR Spectroscopy 
3 mM solutions of 6 were prepared in D2O, with 2 µL of a 1% dioxane solution 
added as an internal calibrant, and the pH recorded. The sample was irradiated in 
an NMR tube with UVA or visible light at 310 K, with 1H NMR spectra recorded 
after 0, 1, 2, 3, 5, 7, 10, 15, 20, 30, 45, 60, 90 and 120 min. For the UVA 
irradiation, the pH value was recorded at the end, whilst for the visible light 
irradiation the pH was measured after each irradiation timepoint, prior to 
acquiring the NMR spectrum. 
 
a) UVA Irradiation 
The two singlets of the bound acetato groups rapidly decreased in intensity upon 
irradiation, with the concurrent growth of a peak corresponding to free acetate. 
Prior to irradiation, a small peak arising from free acetate (1.90 ppm) was 
apparent in the spectrum, comprising 4% of the total acetate signal. After just 
1 min of UVA irradiation, this had increased to 24% and undergone a significant 
downfield shift to 1.99 ppm. Upon further irradiation, this peak continued to grow 
in intensity at the expense of the bound acetato signals, which after 10 min were 
no longer visible in the spectrum. The downfield shift of the free acetate peak is 
consistent with the measured decrease in pH*, from 8.30 to 5.01. The large shift 
after 1 min irradiation, and little change thereafter, suggests the pH* decreases 
rapidly at the beginning of the experiment. Throughout the remainder of the 
experiment, signal intensity and resolution is rapidly lost and no further 








b) Visible Irradiation 
Free acetate was again released, although at a slower rate than upon UVA 
irradiation. Evidence of an additional complex containing a bound acetato group 
was also found. 
Again the peak of free acetate increased in intensity upon irradiation, comprising 
12% of the total acetate signal after 1 min, compared with 24% with UVA light 
(Figure 3.14). The downfield shift was also less pronounced (δ = 1.93 ppm), 
although there was a significant pH change after only one minute (7.70 to 5.60). 
Upon further irradiation the downfield shift and pH decrease continued, 
stabilising after around 20 minutes with values of 1.99 ppm and 4.75, 
respectively, despite the intensity of this peak further increasing throughout the 
experiment.  
Evidence of a new acetato complex was also seen with the appearance of a new 
singlet at 2.14 ppm. First apparent after 5 min, this peak grew in intensity as the 
two singlets at 2.15 and 2.16 ppm decreased, contributing 12% of the total acetate 
signal at the end of the experiment. The chemical shift value is in the region of 
bound acetate, and could potentially arise from a monoacetato intermediate, or a 
photoisomerisation product in which the two acetate groups are magnetically 
equivalent; indeed several smaller peaks in this region suggest multiple species 
may be present. A small peak at 2.14 ppm is also evident following 5 and 10 min 




































































Figure 3.13  
1H NMR spectra recorded at various timepoints during the 
irradiation of [Pt(L1)(N3)2(OAc)2] (6) with UVA light (λmax = 365 nm), in D2O at 
310 K. 

















ppm (t1) 1.902.002.102.201.902.00ppm 2.20 2.10 1.902.00ppm 2.20 2.10
UVA Visible
Figure 3.14  Comparison of the acetate region of the 1H NMR spectra of 
[Pt(L1)(N3)2(OAc)2] (6) upon irradiation with UVA and visible light.  




3.3.5.3.2 UV-Visible Absorption Spectroscopy 
Solutions of 6 (40–50 µM) were prepared in H2O, and irradiated inside a 3.5 mL 
Hellma® UV quartz cuvette with either UVA or visible light. UV-visible 
absorption spectra were acquired after 0, 1, 3, 5, 10, 15, 20, 30, 45, 60, 90 and 
120 min of irradiation.   
The UV-visible absorption spectrum of 6 contains an intense N3→Pt ligand-to-
metal charge transfer (LMCT) band at 263 nm, as found in similar PtIV azido 
complexes.[29,30,31] This band decreases upon irradiation with both UVA and 
visible light, indicating loss of the azide ligands[32] (Figure 3.15). The rate and 
extent of decomposition is greater upon UVA irradiation, as can be expected from 
the greater extinction coefficient at these wavelengths. Indeed, the observation of 
photoactivity upon visible light irradiation, previously seen for similar 
complexes,[31,33] is interesting considering the very low absorbance in this region. 
In both cases, the appearance of bubbles in the UV cuvette indicated the evolution 











































































































Figure 3.15 UV-visible absorption spectra of aqueous solutions of 
[Pt(L1)(N3)2(OAc)2] (6) following irradiation at 310 K with A: UVA 
(λmax  = 365 nm) and B: visible (λ = 400–700 nm) light.   








 Complexes in the Presence of 5’-GMP 
Solutions of 2 (1.5 mM) and 6 (3 mM) were prepared in D2O, with 2 µL of a 1% 
dioxane solution added as an internal calibrant. 2 mol equivalents of 5'-GMP were 
added, and the pH* adjusted with dilute NaOD to 5.68 and 5.59 respectively. 
Samples were irradiated in an NMR tube with UVA light, with 1H NMR spectra 
recorded after 0, 1, 2, 3, 5, 7, 10, 15, 20, 30, 45, 60, 90 and 120 min. The pH was 
also recorded prior to obtaining each spectrum. 
 
a) Pt(en)(N3)2 (2) 
Rapid binding to 5'-GMP occurs upon irradiation to produce mono- and 
bisadducts. Two additional species are formed after 10 min, one of which is 
tentatively assigned to a PtIV species.  
After 1 min of UVA irradiation, a new peak appeared at 8.60 ppm, previously 
assigned to a 5'-GMP monoadduct (2c) (Section 3.3.3.2a). This comprised 10% of 
the total 5'-GMP signal after 1 min, increasing to 20% after 3 min. After 5 min a 
new peak was apparent, slightly upfield from that of the monoadduct. This is 
likely to result from a bisadduct (2d), the peaks of which show this characteristic 
upfield shift. Further evidence was provided from the aliphatic region; the peaks 
at 2.70 and 2.82 ppm having previously been attributed to 2c and 2d respectively 
(Section 3.3.3.2a). The H8 peaks of both 2c and 2d showed a progressive 
downfield shift during the course of the irradiation, from 8.60–8.68 ppm and 
8.61–8.67 ppm respectively. This may result from the gradual increase in pH* 
throughout the experiment (from 5.68 to 6.75), since an increase in chemical shift 
value of the H8 proton of 5'-GMP adducts has previously been seen over this pH 
range.[31] 
Two new peaks appear after 10 min, at 8.84 and 9.17 ppm, arising from two new 
species 2e and 2f. These could not be identified, although are likely to be 
additional Pt–5'-GMP adducts. Over the course of the experiment, clear platinum 
satellites became apparent on the peak of 2f, with 3J(195Pt–1H) = 16 Hz. The high 











chemical shift, small 3J value and clarity of the satellites suggest this peak may 
arise from a PtIV species; furthermore, a previously reported PtIV–5'-GMP adduct 
showed a very similar chemical shift of 9.20 ppm.[34] However, further evidence 
would be needed to confirm the identity of 2f. Subsequent irradiation resulted in 
an increase in the relative proportions of 2d, 2e, and 2f, and a more gradual 
decrease of the monoadduct 2c. Since the decline of the monoadduct was not 
concurrent with a growth in the bisadduct, or a decrease in free 5'-GMP, this 
suggests it does not undergo further substitution. Indeed, its decline more closely 
parallels the growth of 2f, however further evidence would be needed to confirm 
any relationship between the two. Following 120 min irradiation, the speciation 







Figure 3.16  The H8 region of the 1H NMR spectrum of [Pt(en)(N3)2]  (2) and 
5'-GMP (1:2) in D2O, following 120 min irradiation with UVA light 



























































Figure 3.17  1H NMR spectra recorded at various timepoints during the reaction 
of [Pt(en)(N3)2] (2) and 5'-GMP (1:2) in D2O,  upon irradiation with UVA light 
(λmax = 365 nm) at 310 K. 




b) Pt(L1)(N3)2(OAc)2 (6) 
 
Formation of a PtII–5'-GMP adduct occurs rapidly upon UVA irradiation, however 
the peak of this species is subsequently lost and no bound 5'-GMP can be detected 
after 60 min irradiation. 
 
After 1 min irradiation, a new peak was formed at 8.60 ppm, accounting for 3% of 
the total 5'-GMP signal and believed to result from a Pt–5'-GMP monoadduct 
(6a). Further irradiation resulted in the growth of this peak, reaching 20% by 
15 min, followed by a decline and by 60 min no peaks for bound 5'-GMP could be 
seen.  
Little information can be gained from the aliphatic region since, as with the 
complex alone, signal intensity is rapidly lost and no new species can be 
identified. The formation of free acetate seems to occur at a similar rate to that in 
the absence of 5'-GMP, with all signals for bound acetate lost after 15 min 
irradiation. The small increase in chemical shift of the free acetate peak is 






































Figure 3.18  1H NMR spectra recorded at various timepoints during the reaction 
of [Pt(L1)(N3)2(OAc)2] (6) and 5'-GMP (1:2) in D2O,  upon irradiation with UVA 
light (λmax = 365 nm) at 310 K. 





















Figure 3.19  The H8 region of the 1H NMR spectra, recorded at various 
timepoints during the reaction of [Pt(L1)(N3)2(OAc)2] (6) and 5'-GMP (1:2) in 
D2O,  upon irradiation with UVA light (λmax = 365 nm) at 310 K. 





The PtII azido complexes [Pt(en)(N3)2] (2), [Pt(L1)(N3)2] (5) and [Pt(L2)(N3)2] (8), 
as well as the PtIV azido complex [Pt(L1)(N3)2(OAc)2] (6), were tested for 
phototoxicity towards HaCaT keratinocytes upon irradiation with UVA light, as 
described in Chapter 2. 
Complexes 5 and 8 were inactive under these conditions, with IC50 values higher 
than the greatest concentrations tested (260.9 and 251.7 µM, respectively) both 
upon UVA irradiation and in sham-irradiated (dark) controls. Complex 2 did show 
a slight increase in activity upon UVA irradiation (IC50 = 222.7 µM, compared 
with >294.8 in the dark), however it is also classified as non-phototoxic in these 
tests. The PtIV azido complex 6 was also found to be inactive, with IC50 values 
>199.6 µM both upon UVA irradiation and in sham-irradiated controls.  
 
3.4  Discussion 
3.4.1 Complex Design 
Considering the design of PtII azido complexes as potential cytotoxic agents, it 
was decided to first use ethylenediamine (en) as a chelating amine ligand. The 
chlorido complex, [Pt(en)Cl2], shows cytotoxicity approaching that of cisplatin
[9] 
and reactions relating to this have been extensively studied, allowing for the 
possibility of comparisons with the azido analogue.  
Aminoalcohol ligands, incorporating hydroxyl groups which would remain 
uncoordinated (or “pendant”) upon complex formation, were also employed. Such 
groups should aid water solubility of the resulting metal complexes, beneficial 
since low solubility is often problematic for cisplatin and related compounds. 
Moreover, platinum complexes of aminoalcohol ligands are of interest due to their 
hydrogen bonding ability, which could potentially assist DNA binding or stabilise 
platinated adducts; it has been suggested the hydroxyl substituents could readily 
hydrogen bond to a phosphate oxygen or the keto oxygen of a platinated guanine 




residue.[11] A number of recent studies have focused on such complexes,[11,18,35,36] 
encouraged by reports of increased activity towards a number of cancer cell lines 
for aminoalcohol complexes compared with their alkyl analogues.[37]  
The PtII chlorido complex of 2-(2-aminoethylamino)ethanol (L1) has previously 
been shown to exhibit good to moderate cytotoxicity in a range of cancer cell 
lines,[11,18,35] hence it was decided to study the azido complex of this ligand. 
3-(2-aminoethylamino)-1-propanol (L2) was also chosen, since the increased 
length of the carbon linker could potentially affect the hydrogen bonding ability of 
the OH group. Similarly, a ligand with no flexibility of the OH group and a 
different chelating amine motif was chosen, 1,3-diamino-2-propanol (L3). A 
recent paper has described the high cytotoxicity of the PtII chlorido complex of 
this ligand.[16] Finally, a ligand containing a pyridine ring was synthesised, to 
investigate the effects of an aromatic, more hydrophobic group in the complex. 
As mentioned in the introduction, further motivation to study such complexes 
arises since the hydroxyl groups provide a handle for functionalisation, for 
example with targeting agents. In this regard, a complex containing a pendant 
amine group could also be useful since, given the differing reactivity of the 
hydroxyl and amine groups, a wider range of targeting compounds could be 
accessible. Hence a complex containing a protected amine group was also 
synthesised, which could be deprotected to allow functionalisation. The concept 
of functionalisation is investigated in Chapter 4.  
 
3.4.2 Synthesis and Characterisation  
3.4.2.1 Platinum Complexes Containing Hydroxyl Groups 
[Pt(L1)Cl2] (4) and [Pt(L2)Cl2] (7) were synthesised according to a published 
procedure for similar complexes, in which the pH was maintained near to 7 
throughout the reaction.[14] This was found to give slightly greater yields than 
when the pH remained unaltered. Although the ligands give basic solutions, the 




pH decreases during the course of the reaction, to values of 3–4. This is likely to 
be close to the pKa of the amino protons; should any unreacted ligand become 
protonated this would render it unavailable for coordination to platinum. Yields of 
complex 7 were consistently only around half those of 4, likely due to the 
considerably greater water solubility of the former complex, hindering its 
isolation from the reaction and recrystallisation solutions. It is possible that 
increasing the length of the carbon linker leads to a significant change in 
intermolecular interactions, affecting the solubility. The NMR spectra, elemental 
analyses and, in the case of 4, crystal structure, confirmed the identities of these 
complexes. In line with previous observations,[11,18,35] the ligands bind in a 
bidentate (N,N) fashion and the OH group remains uncoordinated. This is 
consistent with the preference of PtII for soft donor ligands, with harder donors 
such as oxygen favoured mainly in the PtIV state. 
[Pt(L3)Cl2] (10) could not be prepared from the reaction of L3 with K2[PtCl4], 
since this is reported to yield [Pt(L3)2][PtCl4];
[38] presumably formation of a 
second, stable 6-membered chelate ring drives the coordination of an additional 
ligand. The use of K2PtI4 allows for successful isolation of [Pt(L3)I2] (9), in which 
a second substitution may be hindered by the more strongly bound iodido ligands; 
these can then be removed by abstraction with silver nitrate. Reasons behind the 
problematic synthesis of [Pt(L4)Cl2] (12) are unclear; with decomposition and 
reduction to Pt0 seen in both aqueous and organic solvents. No further reactions 
were carried out with this complex, however the PtII azido complexes of L1, L2 
and L3 were successfully synthesised. 
Attempts to oxidise [Pt(L1)(N3)2] (5) with hydrogen peroxide were unsuccessful, 
resulting in a sticky solid which showed evidence of impurities and was very 
difficult to handle. Given the current interest in PtIV complexes, the oxidation of 
PtII chlorido complexes of several aminoalcohol ligands is documented in 
literature. Although Jolley et al reported the successful oxidation of [Pt(L1)Cl2] 
(4) to form [Pt(L1)Cl2(OH)2],[11] others have found this to be problematic. 
Hambley and co-workers found that, upon heating 4 in an aqueous solution of 




hydrogen peroxide, the OH group of L1 was deprotonated and coordinated to the 
platinum in a tridentate (N,N,O) fashion, forming a complex with just one axial 
hydroxy group, [Pt(L1–H)Cl2(OH)].
[18] Although they suggested the reaction may 
proceed via the trans-dihydroxo complex in the absence of heat, they did not 
isolate this product. Ren et al also failed to achieve the desired product 
[Pt(L1)Cl2(OH)2] by oxidation of 4, although further explanation was not 
given.[17]. They instead prepared a PtIV complex with axial acetato groups by 
oxidation with hydrogen peroxide and acetic anhydride in acetic acid; the OH 
group of L1 remained uncoordinated, leading to suggestions that its coordination 
is facilitated by the presence of axial hydroxyl groups.[18] The same method was 
used in this work, in the oxidation of 5 to produce [Pt(L1)(N3)2(OAc)2] (6). A 
previous study has found the pendant hydroxyl group of L1 is slowly acetylated 
over time (7 d) by acetic anhydride;[11] this was not seen here, although it was 
found that prolonged reaction times (48 h) gave rise to small impurity peaks in the 
NMR spectrum of 6, at 4.40 and 4.25 ppm, which may arise from such a species. 
Although PtIV complexes with axial hydroxyl groups are usually preferred due to 
their greater stability towards reduction,[39] a complex with axial acetato ligands 
may be beneficial in this case for two reasons. Firstly, the methyl protons of the 
acetato groups show strong signals in NMR spectra, which enable the fate of the 
axial ligands upon irradiation to be followed in a way that is not possible with 
hydroxyl groups. Secondly, interference from the axial ligands will be avoided 
during any subsequent reaction of the pendant hydroxyl group.  
The crystal structures of 4 and 5 reveal that these complexes form many hydrogen 
bonds, with the pendant hydroxyl groups involved in both cases. This could 
explain the sharp nature of the OH peaks in the 1H NMR spectrum, since 
involvement in intermolecular interactions will reduce the tendency to exchange. 
Additionally, different hydrogen bonds are found in the case of the chlorido and 
azido complexes 4 and 5, and this is likely the case for 4 and the DMSO adducts, 
causing a significant shift on exchange despite the remoteness of this group from 
the platinum centre. A particularly interesting feature of 5 is the short (2.04 Å) 




intramolecular hydrogen bond between the OH and a bound azido nitrogen, Nα. 
This could have implications for the subsequent functionalisation of the OH, as it 
may show a reduced tendency to react. 
When coordinated to platinum, the protons of each methylene pair in ligands L1–
L4 are found to be magnetically inequivalent with each showing a distinct peak in 
the 1H NMR spectrum. This has been previously noted in spectra of [Pt(L1)Cl2] 
(4).[17] It is likely that the orientation of the ligand, when constrained in the 
complex, is such that each proton resides in a different environment. The pendant 
arm may also be constrained to some extent by the hydrogen bonding interactions 
of the OH group. The two acetato groups of 6 are also inequivalent, with the 
difference in environment arising since one should be in closer proximity to the 
pendant arm than the other.  
An interesting feature of the fluorescence spectrum of the aminoalcohol ligand L4 
is the presence of two distinct bands upon excitation at 278 nm, centered at 
370 nm and 450 nm. The presence of two peaks in this case could correspond to 
the vibrational profile of the ligand. However, whilst the compound was found to 
be satisfactorily pure by NMR, the presence of a highly fluorescent impurity 
cannot be ruled out without further investigation by more sensitive techniques. 
The emission from the platinum complex in the solid state likely arises from a 
low-lying triplet state, which in solution undergoes non-radiative decay, although 
this pathway may be minimised in a glass matrix at 77 K. In order to draw any 
firm conclusions the fluorescence of both the ligand and complex would need to 
be investigated in further detail; both experimentally, by measuring fluorescence 









3.4.2.2 Platinum Complexes Containing a Protected Amine 
The synthesis of platinum complexes containing pendant amine groups is 
synthetically more challenging than those with hydroxyl groups, as the high 
affinity of platinum for amine nitrogens necessitates the use of protecting group 
chemistry. The ligand employed (L5) contained a free amine group for 
coordination to platinum, separated by a carbon chain linker to a BOC-protected 
amine. Linker length could thus be varied; in this case 4 carbons was chosen, to 
give sufficient distance from the platinum centre whilst retaining solubility.   
Yields of the mixed amine PtII chlorido complex [Pt(L5)(NH3)Cl2] (13) were 
relatively low, although were found to be slightly higher when the reaction was 
carried out in water rather than methanol, likely due to the lower solubility of the 
product in water. The synthesis of the PtII azido complex (14) was found to be 
more problematic. The typical route to such complexes, involving chloride 
extraction with silver nitrate in water, gave very low yields, possibly due to the 
insolubility of the starting material. It had previously been found that, in the case 
of poorly soluble complexes, yields were increased upon addition of a small 
quantity (~500 µL) of DMF to the reaction mixture.[31] Here, however, this 
repeatedly led to the formation of Pt0. The direct substitution of chlorido for azido 
ligands in DMF, as described in Chapter 5 and elsewhere,[40] was also 
unsuccessful in this case; after five days mostly starting material was present with 
only a small quantity of required product. This method is apparently more suitable 
for chelating aromatic ligands such as bipyridine or phenylazopyridine (azpy). 
The most successful synthesis of the PtII azido complex involved carrying out the 
silver nitrate reaction in methanol, which was then removed and exchanged for 
water prior to addition of sodium azide. The oxidation of this complex to yield 
[Pt(L5)(NH3)(N3)2(OH)2] (15) was readily achieved using an excess of hydrogen 
peroxide in aqueous solution. 
 




3.4.3 Stability Studies: Aqueous and Chloride Containing Solutions 
Stability in aqueous and chloride containing solutions is an important factor to 
consider in the design of potential platinum anticancer agents. Cisplatin is stable 
to chloride concentrations found in blood plasma (104 mM), however undergoes 
hydrolysis upon entering cells where the chloride concentration drops to 4–
25 mM. The half-life is fairly short, around 2 h, and it is the hydrolysed species 
which are reactive towards DNA. Azide is known to form stronger bonds to 
platinum than does chloride, hence a slower hydrolysis rate would be expected, 
which may have implications for the cytotoxicity of PtII azido complexes. 
Stability in chloride solutions is also important in order to determine if the 
complex could undergo substitution prior to entering the cell, especially 
considering azide loss may result in a loss of photoactivity. 
Additionally, since work in the area of photoactivated PtIV azido anticancer agents 
has thus far focused upon complexes with axial hydroxyl groups, there have been 
no stability studies involving complexes with axial acetato groups, despite the 
synthesis of several[22,31,40] and recent interest in those containing chelating 
aromatic ligands.[40] Therefore, the stability of 6 to aqueous and chloride solutions 
was also examined. 
 
a) [Pt(en)(N3)2] (2) 
The tendency of 2 to undergo oxidation in aqueous and chloride-containing 
solutions is surprising. The involvement of oxygen is suggested, since a reduction 
in the rate and extent of oxidation is seen in degassed solutions. There appear to 
be few previous reports of such a process. Trans-[Pt(MeNH2)(NH3)Cl2] was 
found to undergo oxidation in air during synthesis, which was prevented by 
performing the reaction under nitrogen, although a similar effect was not seen for 
the ethylamine complex.[31] Hydrolysis was found to trigger the oxidation of 
trans-diamine PtII complexes, and was found to be suppressed in an argon 
medium but accelerated in the presence of oxygen.[41] Here, however, oxidation of 




[Pt(en)Cl2] (1) was found to occur in 100 mM NaCl solution (in which hydrolysis 
would be suppressed), although to a lesser extent than for 2. This suggests that 
hydrolysis is not necessary for oxidation, although it may accelerate the process. 
However, a lesser extent of oxidation may be expected for complex 1 compared 
with 2 in any case; azide is more electron donating than chloride, resulting in 
greater electron density on platinum and rendering it more susceptible to 
oxidation. There was no evidence of oxidation over time in DMSO solutions of 2, 
in which oxygen is poorly soluble and hydrolysis would be suppressed. 
Over increasing time in both aqueous and chloride containing solutions there was 
evidence of a mixture of species in the spectra of 2, believed to be multiple 
hydrolysis and degradation products. However, there was little evidence of this 
change in the first five days. A previous investigation of the stability of 
[Pt(NH3)2(N3)2] in 100mM NaCl solution showed substitution of one azido ligand 
by chloride.[22] In this case, such a species may not be detectable by 1H NMR 
spectroscopy since the en-CH2 protons of both 1 and 2 have very similar chemical 
shifts. Further evidence could be provided from 2D [1H, 15N] experiments with a 
15N-labelled complex. 
 
b) [Pt(en)(N3)2(OH)2] (3) 
The stability of this complex over time is in accordance with that of similar PtIV 
azido complexes.[22,31] A previous investigation of cis,trans,cis- and 
trans,trans,trans-[Pt(NH3)2(N3)2(OH)2] in 100 mM chloride solution found 
evidence of free ammonia after 12 d and 6 d respectively,[31] however amine loss 
would be less likely in this case due to the stability of the ethylenediamine chelate 
ring, and no evidence of this was seen. 
 
c) [Pt(L1)(N3)2] (5) 
Any reactions of these complexes are inherently difficult to follow due to the 
inequivalence of the eight methylene protons. As a result, new peaks in the 




spectrum could not be identified, although it appears the same reaction is 
occurring in both aqueous and chloride containing solutions. From analogies with 
complex 2 an oxidised product may be expected. A multiplet at the same chemical 
shift as these new peaks is found in the spectrum of [Pt(L1)(N3)2(OH)2], however 
this does not give conclusive evidence of an oxidised product, and no evidence 
was seen in the mass spectrum. 
 
d) [Pt(L1)(N3)2(OAc)2] (6)  
Free acetate was released from this complex over time. The reduction of 6 to a PtII 
species would likely liberate acetate; however the lack of a suitable reducing 
agent in solution renders this improbable. The starting solution was slightly basic, 
therefore it may be possible that the Pt–OR ester bond undergoes a slow base-
catalysed hydrolysis, forming a Pt–OH species and the observed free acetate.  
 
 
3.4.4 Reactions with Glutathione and 5'-GMP 
The fairly rapid hydrolysis of cisplatin enables binding to DNA, however its 
severe toxicity is attributed to side reactions with other biomolecules. In 
particular, it is highly reactive towards intracellular thiols such as glutathione, 
which can deactivate much of the drug before it reaches its intended site. The 
rationale behind the use of more stable leaving groups is that side reactions may 
be reduced, so it is of interest to investigate the reaction of PtII azido complexes 
such as 2 with molecules such as glutathione. However, it may be important that 
the leaving group is not so stable that it is inactive towards nucleobases.  
PtIV azido complexes containing axial hydroxyl groups were previously shown to 
be unreactive to both glutathione and nucleobases in the dark,[22,31] however 
acetato complexes such as [Pt(L1)(N3)2(OAc)2] (6) have not been investigated. It 
is known that similar PtIV acetato complexes are less stable towards reducing 
agents than their hydroxyl analogues;[42] additionally, certain PtIV complexes have 




been shown to interact with nucleotides without prior reduction.[34] Since 6 is 
designed to be reduced and bind to DNA only upon irradiation, it is important 
such reactions are investigated. 
 
3.4.4.1 Reactions with Glutathione 
a) [Pt(en)(N3)2] (2) 
Reaction was apparent within the first three hours, with the initial product formed 
likely to be the monoadduct [Pt(en)(N3)(SG)]. However, after 12 hours a new 
singlet at 3.36 ppm appeared in the spectrum, which appeared to grow in intensity 
thereafter whilst that of other peaks was lost. Sulfur ligands show a strong trans-
labilising effect and are known to induce the release of amine ligands trans to 
them, as has been recently noted in reactions of cisplatin with cell extracts.[43] 
Although the release of ethylenediamine should be less favourable than ammonia 
due to the stability of the chelate ring, this has been observed in the reaction of 
[Pt(en)(H2O)2]
2+ with L-cysteine based ligands, shown by a peak also at 
3.36 ppm.[44] However the pH* of the reaction solution was 1.6, hence 
ethylenediamine (pKa 3.92) was protonated; in this case the final pH* was 6.68, at 
which pH* the peak of ethylenediamine would appear at 2.65 ppm and was not 
seen in the spectrum. Additionally, in the 2D [1H, 1H] COSY NMR experiment 
the signal at 3.36 ppm showed cross peaks to other regions of the spectrum, where 
signals were weak. It is therefore likely that this peak arises from a stable Pt–GSH 
adduct, likely the sulfur-bridged dimer [{Pt(en)(µ2-SG)}2]
2+
, a major product in 
reactions of Pt-diamine species with glutathione, and the presence of which was 
confirmed here by mass spectrometry. A previous study[23] concerning the 
reaction of [Pt(en)Cl2] (1) with glutathione identified not only the sulfur-bridged 
dimer but also a novel macrochelate, a di-Pt(en) complex containing one 
glutathione ligand. There was no evidence of such a species in this reaction, 
however further NMR studies and HPLC analysis could confirm this.  




Although some reaction of 2 with glutathione was apparent within three hours, it 
is shown to proceed at a much slower rate than with PtII chlorido complexes: the 
half-life for the reaction of [Pt(en)Cl2] (1) with glutathione has previously been 
determined as 0.9 hours.[23] A half-life could not be determined from this 1H NMR 
experiment, since the en-CH2 peak was found overlapping with peaks from 
glutathione and its disappearance could not be quantified. However, it can be 
estimated that the half-life is at least 12 hours; for comparison, the half-life of the 
reaction of carboplatin with glutathione has been calculated as 24.5 hours.[45] 
 
b) [Pt(L1)(N3)(OAc)2] (6) 
The reduction of PtIV complexes generally involves the liberation of the axial 
ligands,[42] with the free acetate formed here providing a useful way of following 
the reaction. The small increase in free acetate observed suggests complex 6 is 
remarkably stable to glutathione, with very little reduction seen over 16 days. 
Although some evidence of oxidised glutathione (GSSG) is seen in the NMR 
spectrum, it is unclear whether this results from autoxidation in air or interaction 
with complex 6. More conclusive evidence of the fate of the PtIV complex could 
be gained from 2D [1H, 15N] NMR experiments, since nitrogens bound to PtII and 
PtIV give signals in distinct regions of the spectrum, although for this purpose a 
complex containing a 15N-labelled ligand would be required.  
The biological reduction of PtIV complexes containing axial acetato groups is 
currently under debate. Reports have shown that cis,trans,cis-
[Pt(NH3)2Cl2(OAc)2] is rapidly reduced in cancer cells, with only 33% remaining 
in the PtIV state after two hours;[46] however, questions are raised as to the role of 
glutathione in this process. Whilst one report correlates the reduction of 
Satraplatin with intracellular GSH levels,[47] two papers have indicated the 
stability of PtIV acetato complexes to glutathione,[48,49] with another suggesting the 
majority of the reduction is carried out by the high molecular weight fractions of 
cell extracts.[50] In addition, other biomolecules such as cysteine and methionine 




are also capable of reducing such complexes,[51] indicating their stability in cells 
cannot be easily predicted. 
 
3.4.4.2 Reactions with 5’-GMP 
a) [Pt(en)(N3)2] (2) 
The binding of 5’-GMP to 2 is apparent after three hours, however is relatively 
slow with the half-life for the disappearance of 2 estimated at around 3 days. As 
an approximate comparison, that for the reaction of cisplatin with 5'-GMP has 
been calculated as 8 hours under similar conditions.[52] The slower rate is to be 
expected given the stronger binding to platinum of azide compared with chloride, 
however would not necessarily imply a lack of cytotoxicity. A much reduced rate 
is also seen in the case of carboplatin, for which the half-life of this reaction is 
420 hours (17.5 days),[52] yet this complex still shows good antitumour efficacy 
along with the desired reduced toxicity. The appearance first of the monoadduct 
followed by the bisadduct of 5'-GMP is consistent with that observed for cisplatin 
and related complexes. The platination site is suggested to be N7 from the shift of 
the H8 peak upon binding, however this could be further confirmed by a 1H NMR 
pH titration. The H8 chemical shift change associated with protonation of N7 of 
free 5'-GMP, at around 2.5, should be absent for the platinum adduct.[31]  
As seen in aqueous solutions of 2, a significant proportion of the oxidised product 
[Pt(en)(N3)2(OH)2] (3) was formed over time, comprising 13% of the total 
platinum species after 24 h with a slight rise thereafter. Although oxidation 
renders a proportion of platinum unable to bind to 5'-GMP, it would be unlikely to 
occur inside cells which typically maintain a reducing environment. 
 
b) [Pt(L1)(N3)2(OAc)2] (6) 
The observed stability of 6 to 5'-GMP is important, since the complex is intended 
not to undergo reduction or reactions with biomolecules until photoactivated. The 




reactivity of PtIV complexes to nucleobases has been shown to increase with their 
reduction potential.[34] During the reaction of [Pt(en)Cl2(OAc)2] with 5'-GMP, 
Choi et al found evidence of a PtII-GMP adduct after 7 days;[34] whilst Galanski 
and Keppler detected a stable PtIV adduct in the reaction of [Pt(en)(OAc)4] with 
5'-GMP.[53] However, no such reactions are observed in the case of 6 up to 16 
days. The reduction potentials of these PtIV azido complexes have not been 
measured, however the greater donating ability of azide compared with chloride 
suggests they may have a lower reduction potential than their chlorido analogues. 
 
3.4.5 Cytotoxicity 
All of the PtII chlorido complexes tested showed good to moderate cytotoxicity 
(IC50 3.3–27 µM), which can be expected given their similarities to cisplatin. The 
moderate toxicity of Pt(L1)Cl2 (4) (11 µM) is consistent with previous 
reports.[11,18,54] It was believed the additional methylene group of [Pt(L2)Cl2] (7) 
may affect the cytotoxicity, possibly by affecting the hydrogen bonding capability 
suggested to be important for such complexes; indeed one report suggests 
flexibility in this linker may influence cytotoxicity.[54] However, the effect 
appeared to be minimal at least in the PtII chlorido case, since the IC50 values of 4 
and 7 are the same. The new complex [Pt(L4)Cl2] (12), containing a pyridine ring, 
is the least cytotoxic of all PtII chlorido complexes tested (27 µM). An imine 
analogue of this complex has been prepared and showed high levels of binding to 
both single- and double-stranded DNA,[55] however no cytotoxicity data was 
reported. 
The moderate cytotoxicity of the PtII azido complexes (21–47 µM) is especially 
interesting. No previous examples of the testing of such complexes could be 
found; they were probably believed to be inactive based upon the known stability 
of the Pt–N3 bond and the observed inactivity of Pt
II iodido complexes;[3] indeed, 
the PtII iodido complex [Pt(L3)I2] was tested for comparison and found to be 
inactive. There appears to be little correlation between the cytotoxicity of the PtII 




chlorido complexes and their azido analogues, although the sample size is too 
small to draw any accurate conclusions. 
The mechanism of action of these azido complexes would need to be further 
investigated. Although the rate and extent of nucleobase binding is low in 
comparison to that of PtII chlorido complexes, the cytotoxicity of metal complexes 
often does not correlate with nucleotide binding ability. In the one example of 
metal-azido complexes previously tested, hydrolysis and DNA binding rates were 
also low yet a complex with high cytotoxicity (5 µM) was obtained.[7] 
Furthermore, nucleobase binding studies in vitro cannot accurately mimic 
conditions in vivo. Whilst a 100-fold greater concentration of carboplatin is 
required to achieve the same rate of DNA platination as cisplatin in vitro, only a 
4–20 fold increase is required to achieve the same platination rates in patients.[5] 
This can be attributed to the reduced deactivation of carboplatin by side reactions, 
as a result of its increased stability. 
Additionally, these complexes release azide anions upon hydrolysis. This anion is 
itself cytotoxic by inhibition of cytochrome c oxidase and subsequent disruption 
of cellular respiration,[56] so it is possible this has an effect on the cytotoxicity of 
these complexes and could be further investigated. 
 
3.4.6 Photoreactions  
The photochemistry of metal azido complexes is well established, with several 
reports concerning PtII and PtIV complexes.[8] Since the hydrolysis of the Pt–N3 
bond has been observed upon irradiation of PtII complexes, it was hypothesised 
that this may lead to an increase in nucleobase binding and cytotoxicity upon 
irradiation. On the other hand, the PtIV diazido analogues are intended to be stable 
and unreactive towards biomolecules in the dark but become activated upon 
irradiation, as is the case for many PtIV complexes previously reported.[2,22,31] 
Hence the photoreactions of [Pt(en)(N3)2] (2) and [Pt(L1)(N3)2(OAc)2] (6) were 




investigated both alone and in the presence of 5'-GMP. The PtII chlorido 
complexes were also included for comparative purposes. 
 
3.4.6.1 Photoreactions in Aqueous Solution 
a) [Pt(en)Cl2] (1) and [Pt(L1)Cl2] (4) 
The lack of change in the 1H NMR spectra and pH values following UVA and 
visible light irradiation indicated that the PtII chlorido complexes 1 and 4 were 
stable under these conditions. Although it has been previously suggested that 
cisplatin is unstable upon irradiation with UVA and prolonged exposure to 
daylight,[57] it has been found to show no change in toxicity upon irradiation with 
UVA light.[2]  
 
b) [Pt(en)(N3)2] (2) 
The decomposition of complex 2 was apparent after 5 min of UVA irradiation, 
however the photoproducts could be not identified. This was also the case in a 
previous study into the photoactivity of this complex in water;[22] although a new 
species was seen by 2D [1H, 15N] NMR experiments, its identity was unknown. 
The same reaction performed in 100 mM NaCl solution gave rise to 
[Pt(en)Cl(N3)], indicating an azido ligand can be substituted upon irradiation. 
Further irradiation resulted in the loss of intensity of peaks in the spectrum and 
formation of a small amount of yellow precipitate. The former was observed in 
the experiment performed in this work, although a precipitate was not observed. 
The photochemistry of coordinated azides is rich and varied, and can involve the 
formation of nitrene intermediates, nitrido complexes and azide radicals, among 
others,[8] hence the identification of photoproducts is not trivial. Furthermore, 
certain photoproducts may not be amenable to NMR observation; for example the 
formation of paramagnetic species would result in significant broadening of NMR 




signals. This experiment is nevertheless useful to gain an idea of the rate of 
decomposition of the starting material. 
 
c) [Pt(L1)(N3)2(OAc)2] (6) 
Very rapid photoreduction of this complex is seen as monitored by the increase in 
free acetate, which comprised 24% of the total acetate signal by 1H NMR after 
just 1 min of UVA irradiation. The rate was reduced somewhat upon irradiation 
with visible light, with 12% free acetate after 1 min. Two previous irradiation 
studies followed by NMR have been carried out with PtIV azido complexes 
containing axial acetato groups, both using visible light. The first involved 
irradiation of [Pt(NH3)2(N3)2(OAc)2] with blue light (457.9 nm, 15 mW)
[22] where 
the photoreduction proceeded much more slowly, with over half of the acetate still 
bound after 4.1 h. The second involved irradiation of three pyridyl complexes 
with green light (514 nm, 60 mW cm-2),[40] in which the percentage of bound 
acetate after 15 min irradiation was 15%, 65% and 76%, highlighting dependence 
upon the nature of the amine ligands. In the present case, 34% of acetate was 
bound after this time. There appears to be little information on the reduction rate 
of PtIV azido complexes containing axial hydroxyl groups, however it appears that 
the reduction proceeds faster with acetato groups. Such complexes have increased 
reduction potentials; however this factor may not be so relevant in the case of 
photochemical reductions. 
Photoreduction was also monitored by UV-visible spectroscopy, following the 
decrease in intensity of the N3→Pt ligand-to-metal charge transfer (LMCT) band; 
again this indicated a decrease in rate with visible compared with UVA light. It is 
interesting that visible light can induce such a reaction given the very small 
extinction coefficients at these wavelengths; however a computational study has 
indicated low-energy transitions of a highly dissociative nature, which can clearly 
induce ligand dissociation.[40] 




It is evident that the major photoproduct(s) do not contain acetate. A previous 
study of [Pt(bipy)(N3)2(OAc)2] (bipy  = bipyridine) suggested the products of 
UVA irradiation included [Pt(bipy)(OH)2] and [{Pt(bipy)(µ-OH)}2], by 
comparison with their UV-visible absorption spectra.[40] However solutions of 6 
rapidly become acidic upon irradiation, in such conditions dimer formation does 
not occur and any hydroxy species would be protonated. Upon visible irradiation 
of 6 a new peak was seen by 1H NMR in the region of bound acetate (2.14 ppm); 
this could potentially arise from a monoacetato intermediate, or an isomerisation 
product in which the two acetato groups are chemically equivalent. This product 
was not observed upon UVA irradiation; the much faster rate of photoreduction 
could render any intermediates difficult to distinguish. 
 
3.4.6.2 Photoreactions with 5'-GMP 
a)  [Pt(en)(N3)2] (2) 
UVA irradiation initially appeared to accelerate the reaction of 5’-GMP with 2, 
with the formation of monoadducts after 1 min and bisadducts after 5 min. 
However, after 10 min there was little change in the proportion of free 5’-GMP, 
and by the end of the reaction, 77% of the total remained unbound.  
The proportion of monoadduct reached a peak at 7 min (22%) and began to 
decrease thereafter, but the concomitant increase in bisadduct was small and did 
not parallel this, suggesting further substitution did not occur. In fact, the decline 
of monoadduct seems to more closely parallel the growth of the new species 2f, 
however this was not confirmed. Although 2f was not identified, it is tentatively 
suggested to arise from a PtIV species, on account of its high chemical shift, small 
coupling constant (3J(195Pt–1H) = 16 Hz) and clearly visible satellites. Choi et al 
have reported a PtIV–5’-GMP adduct with a very similar chemical shift.[34] 
However, in that case the species was an intermediate in the reaction of a PtIV 
complex with 5’-GMP, and subsequently underwent reduction. In this reaction of 
a PtII complex it is not clear how an oxidised species would arise, since there is no 




oxidant present in the reaction solution; an additional question is whether 
oxidation would take place before or after binding. There is no evidence to 
suggest formation of a PtIV species upon the irradiation of 2 alone, although the 
oxidation of 2 over time in solution has been observed. Should the suggested 
relationship between the monoadduct and this species be confirmed, it would 
indicate oxidation taking place when the platinum was bound. Further 
experiments would be needed in order to investigate this. 
Complex 2 appeared to be less reactive towards 5'-GMP on irradiation than are 
the PtIV analogues previously studied.[31] This could be due to the decomposition 
into photoproducts to which 5'-GMP cannot bind. However, little further reaction 
towards 5'-GMP was seen after 10 min, whilst irradiation studies in water alone 
suggest a significant proportion of 2 remains at this time.  
 
b) [Pt(L1)(N3)2(OAc)2] (6) 
Although formation of a PtII–5'-GMP adduct was initially seen, reaching 20% of 
the total 5'-GMP intensity after 15 min of irradiation, signals began to decrease 
thereafter and by 60 min there was no evidence of bound 5'-GMP. This is in 
contrast to other PtIV azido complexes studied. For example upon UVA irradiation 
of trans,trans,trans-[Pt(NH3)2(N3)2(OH)2] with 5'-GMP, the bisadduct accounted 
for 50% of the total 5'-GMP intensity after 20 min and rose to 70% after 60 
min.[31] The reason for the lack of reactivity here is unclear. As also suggested for  
2, it may be that the photoproducts of this irradiation are unable to bind 
significantly to 5'-GMP. A similar rate of reduction and loss of aliphatic signal 
intensity is seen here compared with the irradiation of 6 alone, indicating that the 
decomposition pathway is similar. It is also unclear as to why the adduct formed 
should be unstable to further irradiation. 
 





As stated before, the PtII azido complexes [Pt(en)(N3)2] (2), [Pt(L1)(N3)2] (5) and 
[Pt(L2)(N3)2] (8), and the Pt
IV complex [Pt(L1)(N3)2(OAc)2] (6), were all found to 
be non-phototoxic towards HaCaT keratinocytes upon UVA irradiation. A 
contributing factor to this may be the lack of adduct formation with nucleobases, 
as discussed in section 3.4.6.2. Complex 2, which shows a small degree of adduct 
formation, does show slightly greater toxicity upon irradiation than in the dark, 
however with an IC50 of 222.7 µM it is classified as inactive in these tests. 
Complexes 5 and 8 are inactive at all concentrations tested, and it would be 
interesting to see if any 5'-GMP adducts are formed with these complexes upon 
irradiation. 
The PtIV azido complex 6 showed no evidence of phototoxicity at concentrations 
up to 200 µM. Although a small degree of 5'-GMP binding is seen, the adduct 
formed appears to be unstable and by 60 min irradiation is no longer detected by 
NMR. Since the irradiation time during testing is 50 min, it is possible that any 
adduct that does form would be decomposed upon subsequent irradiation. This is 
the only PtIV azido complex with axial acetato groups tested for phototoxicity, so 
it would be interesting to see if the lack of activity is common to all acetato 
complexes, or if those with a different amine ligand may show different results. 
It is important to consider that DNA binding would not be the only factor 
governing phototoxicity; for example cell uptake and distribution and reactions 




A series of PtII azido complexes with a pendant hydroxyl group was synthesised 
and characterised, along with one PtIV complex with acetato groups in the axial 
positions. The X-ray crystal structure was obtained for one PtII complex and 
indicates the hydroxyl group is involved in intra- and intermolecular hydrogen 




bonding. In addition, PtII and PtIV azido complexes of a ligand containing a 
protected amine group were also prepared. 
Stability studies were carried out on the PtII azido complex [Pt(en)(N3)2] (2), 
which was found to undergo slow reaction in aqueous and 100 mM chloride 
solutions, yielding hydrolysis products and also a significant proportion of a PtIV 
species. Complex 2 was reactive towards glutathione in the dark, although at a 
much reduced rate compared with the PtII chlorido analogue, and also reacted with 
5'-GMP in the dark forming mono and bisadducts, at a rate approximately an 
order of magnitude lower than that of cisplatin. All four PtII azido complexes 
tested showed moderate cytotoxicity against the A2780 human ovarian cancer cell 
line, with IC50 values ranging from 21–47 µM. Similar stability studies were 
performed with the PtIV azido complex [Pt(L1)(N3)2(OAc)2] (6), and showed that 
this complex was stable in aqueous and chloride solutions, and unreactive towards 
glutathione and 5'-GMP in the dark. 
Complex 2 was found to be photoactive in aqueous solution upon irradiation with 
both UVA and visible light, although the identity of the photoproducts could not 
be ascertained, whilst complex 6 underwent a rapid photoreduction with release of 
acetate. The extent of binding to 5'-GMP upon UVA irradiation was low for both 
complexes. In addition to mono and bis PtII–5'-GMP adducts, 2 gave rise to a 
species tentatively assigned as a PtIV–5'-GMP adduct, whilst the small quantity of 
a PtII–5'-GMP adduct produced in the reaction of 6 decomposed upon further 
irradiation. The lack of formation of stable adducts with nucleobases could 
explain the observed lack of phototoxicity of these complexes. 
This Chapter reports the first example of PtII azido complexes investigated for 
anticancer activity. Although such complexes were expected to be inactive due to 
the stability of the Pt–N3 bond, moderate activity was found in all complexes 
tested. These results further support the investigation of poor leaving groups in the 
search for complexes that undergo minimal deactivation reactions but still retain 
cytotoxic activity. 
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4.1 Introduction 
An increasingly popular strategy in the development of metal-based anticancer 
complexes is their functionalisation with biologically-active species. This offers 
the possibility to address several major challenges in drug design; including 
selectivity, either for cancer cells over healthy cells or for specific intracellular 
targets, and the understanding of drug distribution and mechanism of action. 
There have been many examples of this approach, involving a variety of 














Figure 4.1 Examples of the functionalisation of metal-based anticancer 
complexes with biologically-active species. 
 
Several approaches selectively target cancer cells by exploiting their differences 
compared with healthy cells. For example, the rapid proliferation of cancer cells 




elevates their nutritional requirements, and as such the receptors for many 
nutrients are overexpressed on their surfaces. Platinum complexes of folic acid[1] 
and vitamin B12
[2] were thus designed to be selectively taken up into cancer cells. 
In addition, as a result of compromised vasculature, tumour tissue can often 
accumulate large macromolecules and this has been exploited in the use of novel 
drug delivery methods, such as polymers and liposomes. Several examples of this 
strategy were given in the introduction to this thesis (Chapter 1). 
Also discussed in Chapter 1 were several complexes with a dual mode of action – 
for example, PtIV–estradiol complexes designed to sensitise ER(+) cells to the 
cytotoxic platinum species released upon reduction.[3] An additional example is 
that of a Cu–Pt complex with the ability to cleave DNA as well as form cross-
links; the platinum moiety also serves to anchor the complex, resulting in a 
different DNA cleavage profile to that of the copper complex alone.[4] 
Monitoring the cellular distribution and elucidating the mechanism of action of 
potential metal-based drugs is of particular interest, since their biochemistry is 
often rich and varied. Many organic drug molecules are designed to interact with a 
specific receptor or enzyme, however for some metal complexes the mechanism is 
less well defined, and even their intracellular target can be unclear.[5] 
Functionalisation with a fluorescent probe or incorporation of a fluorescent ligand 
can therefore be of great benefit, both in visualising the distribution and in 
monitoring changes in fluorescence to give an indication of possible intracellular 
transformations.[6] 
This Chapter is concerned with the functionalisation of PtII and PtIV azido 
complexes, and is divided into three sections. The first investigates the 
derivatisation of PtII and PtIV azido complexes with organic fluorescent probes. 
The second involves the synthesis of quantum dots, semiconductor nanocrystals 
with superior fluorescent properties, and their functionalisation with platinum 
complexes. The final part of the Chapter is concerned with the synthesis of PtII 
chlorido and azido complexes containing a porphyrin ligand, a moiety which 
shows well established photochemical behaviour. 




4.2 Platinum Complexes Containing Organic Fluorescent Probes 
4.2.1 Introduction 
As discussed in section 4.1, the attachment of a fluorescent probe to a potential 
drug molecule can aid in monitoring cellular distribution and elucidating the 
mechanism of action. Although this strategy has been widely used in the study of 
organic drugs,[7] it has only recently begun to receive interest in application to 
platinum complexes. Reedijk et al reported the cellular distribution and 
processing pathways of cisplatin analogues derivatised with fluorescent probes,[8] 
visualised by digital fluorescence microscopy, as well as a series of 
monofunctional platinum complexes for use as nucleic acid labelling reagents.[9] 
In addition, complexes have been studied in which the fluorescent species are 
directly bound to platinum. Very recently, Hambley et al described a series of 
complexes containing coumarin, in which the fluorescence is sensitive to the 
oxidation state of the platinum and could thus act as a sensor for the PtIV to PtII 
reduction event.[6] Similarly, a complex of 7-azaindole was reported in which the 
fluorescence of the ligand is quenched upon coordination to platinum, but 
increases upon reaction of the complex with sulfur-containing biomolecules due 
to trans-labilisation, and could thus be of use in monitoring intracellular 
transformations of such complexes.[10]  
Chapter 3 of this thesis described the synthesis of PtII and PtIV azido complexes 
containing pendant functional groups suitable for derivatisation, and incorporation 
of fluorescent probes into these complexes could provide valuable knowledge of 
the photoproducts formed upon irradiation and, potentially, the fate of the 
complexes within cells. Previous studies have indicated the PtIV complexes have a 
complicated photodegradation pathway,[11] and a potentially different cytotoxic 
mechanism to cisplatin.[12] Furthermore, the PtII azido complexes are novel and 
their mechanism of action has not yet been investigated.  
Two organic fluorescent probes were chosen for conjugation to the PtII and PtIV 
azido complexes. The first, N-methylisatoic anhydride (MIA), reacts readily with 












alcohol groups to form fluorescent esters, and has found many applications in 
biochemistry ranging from the labelling of nucleotides[13] and small-molecule 
protein inhibitors[14] to proteins and large enzymes such as kinases;[15] however 
only one previous example of its use in the labelling of metal complexes can be 
found.[16] The small size of the probe should minimise any change in properties of 
the complex arising from conjugation; it has previously been found that 
conjugation of a large fluorophore such as fluorescein can affect cellular uptake 
and diffusion rates of labelled complexes.[17] MIA was therefore selected for 
conjugation to the pendant hydroxyl group of the PtII azido complex [Pt(L1)(N3)2] 
(5), and the axial hydroxyl groups of the PtIV complex [Pt(en)(N3)2(OH)2] (3). 
The second probe, dansyl chloride (DnCl), was chosen for the derivatisation of the 
PtII and PtIV complexes containing a protected amine group, [Pt(L5)(NH3)(N3)2] 
(14) and [Pt(L5)(NH3)(N3)2(OH)2] (15). Dansyl chloride itself is non-fluorescent, 
but readily reacts with amine groups to produce fluorescent dansyl sulfonamides. 
It is widely used in protein sequencing, in the determination of the N-terminal 



















Figure 4.2  The four platinum azido complexes   
investigated for derivatisation and two fluorescent probes. 






[Pt(L1)(N3)2] (5), cis,trans-[Pt(en)(N3)2(OH)2] (3), cis-[Pt(L5)(NH3)(N3)2] (14) 
and cis,cis,trans-[Pt(L5)(NH3)(N3)2(OH)2] (15) were synthesised as described in 
Chapter 3. N-Methylisatoic anhydride (MIA, 90%) was obtained from Acros 
Organics, and 4-dimethylaminopyridine (DMAP) and dansyl chloride (DnCl) 
were from Sigma-Aldrich. Anhydrous grade N,N-dimethylformamide (DMF, 




[Pt(L1)(N3)2] (5) (50 mg, 0.13 mmol) was dissolved in anhydrous DMF (1.5 mL). 
Triethylamine (18 µL, 0.13 mmol) and DMAP (3.2 mg, 0.03 mmol) were added, 
followed by MIA (92 mg, 0.52 mmol), and the solution was placed under nitrogen 
and stirred at room temperature for 40 h in the dark. The addition of diethyl ether 
yielded a sandy coloured precipitate, which was isolated by centrifugation and 
washed extensively with diethyl ether to remove excess MIA, until the 
supernatants were non-fluorescent. The precipitate was then dried under vacuum 
overnight. 
Yield: 20 mg (30%).   
1H NMR (400 MHz, DMSO-d6): δ = 7.90 (d, arom-CH, 1H), 7.54 (d, NH, 1H), 
6.72 (d, arom-CH, 1H), 6.59 (t, arom-CH, 1H), 6.33 (br s, NH, 1H), 5.40 (br s, 
NH2, 1H), 5.24 (br s, NH2, 1H), 4.51 (m, CH2, 1H), 4.38 (m, CH2, 1H), 3.16 
(d, CH3, 3H), 2.98 (m, CH2, 1H), 2.67 (m, CH2, 1H), 2.65 (m, CH2, 1H), 2.41 (m, 
CH2, 1H), 2.32 (m, CH2, 2H).  




ESI-MS:  539.1203 [M + Na]+, NaPtC12H19N9O2 requires 539.1202 m/z.   
Fluorescence (DMF): λem 421 nm.  
 
Cis,trans-[Pt(en)(N3)2(OH)(OMIA)] (17) 
Cis,trans-[Pt(en)(N3)2(OH)2] (3) (50 mg, 0.14 mmol) was suspended in anhydrous 
DMF (1 mL). MIA (95 mg, 0.54 mmol) was added and the mixture stirred at 
310 K in the dark for 48 h. A small quantity of yellow-grey solid was removed by 
filtration, and to the brown filtrate was added diethyl ether. A yellow solid 
precipitated, which was isolated by centrifugation and washed extensively with 
diethyl ether, then dried under vacuum overnight. 
Yield: 18 mg (25%).   
1H NMR (400 MHz, DMSO-d6): δ = 7.92 (d, arom-CH, 1H), 7.69 (br s, NH2, 2H), 
7.63 (d, arom-CH, 1H), 7.27 (t, arom-CH, 1H), 6.74 (br s, NH2, 2H), 6.58 (d, 
arom-CH, 1H), 6.48 (t, arom-CH, 1H), 2.79 (d, CH3, 3H), 1.59 (s, CH2, 2H).  
ESI-MS:  529.0994 [M + Na]+, 507.1176 [M + H]+, NaPtC10H17N9O3 requires 
529.0990, PtC10H18N9O3 requires 507.1177 m/z.  
Fluorescence (DMF): λmax 414 nm.  
 
Cis-[Pt(L5-NDn)(NH3)(N3)2]  
Cis-[Pt(L5)(NH3)(N3)2] (14) was suspended in 0.1 M HCl (2 mL) and stirred at 
310 K in the dark for 16 h, after which all solid had dissolved to give a yellow 
solution. The pH was then adjusted to 9.5, the solution cooled to 273 K and dansyl 
chloride (7.7 mg) was added, after which the solution was stirred for 4 h in the 
dark. Work-up attempts included removal of solvent and re-suspension in water, 
and precipitation with various solvents, however it was not possible to isolate a 
clean sample of this complex despite mass spectral evidence of its formation. 
ESI-MS:  616.15 [M – H]+, PtC16H25N10O2S requires 616.15 m/z.   
Fluorescence (H2O): λmax 493 nm. 





The synthetic procedure was as for [Pt(L5-NDn)(NH3)(N3)2], but starting from the 
PtIV complex [Pt(L5)(NH3)(N3)2(OH)2] (15). Again, a clean sample of the desired 
complex could not be obtained, and mass spectral evidence could not be found. 
Fluorescence (DMF): λmax 491 nm.  
 
4.2.2.3 Methods 
4.2.2.3.1 Fluorescence Spectroscopy 
Fluorescence emission spectra of 7 µM solutions of 16, 17 and MIAH were 
recorded at 298 K in DMF, with λex = 316 nm. MIAH was obtained from the 
addition of 5 eq HCl to a 7 µM solution of MIA. Emission spectra of 18 and 19 
were recorded at 298 K in water, with λex = 337 nm. 
 
4.2.2.3.2 Photoreactions 
The change in the fluorescence spectra of 17 upon irradiation with visible light 
was monitored over a 10 min period. A 7 µM solution of 17 in DMF was 
irradiated in a LZC-ICH2 photoreactor equipped with LZC-VIS UV-Visible light 
lamps (λ = 400–700 nm, P = 0.27 mW cm-2), and fluorescence emission spectra 
were recorded every 1 min for a total of 10 min, with λex = 316 nm. 
 
4.2.3 Results 
This section has investigated the conjugation of fluorescent probes to PtII and PtIV 
azido complexes synthesised in Chapter 3. The pendant hydroxyl group of a PtII 
azido complex was derivatised with N-methylisatoic anhydride (MIA); this 
fluorophore was also used in the functionalisation of an axial hydroxyl group of a 















[Pt(L1)(N3)2] (5) MIA [Pt(L1-OMIA)(N3)2] (16)
PtIV azido complex. The fluorescence emission spectra of both complexes were 
obtained and compared with that of an equimolar solution of the fluorophore. The 
change in fluorescence intensity of the PtIV complex upon irradiation with visible 
light was monitored. Attempts were also made to functionalise PtII and PtIV azido 
complexes containing protected amine ligands, via deprotection followed by 
reaction with dansyl chloride to form fluorescent sulfonamides.  
 
4.2.3.1 Functionalising Platinum Complexes with N-methylisatoic 
anhydride 
4.2.3.1.1 Synthesis and Characterisation 
a) Functionalisation of a PtII complex 
The PtII complex [Pt(L1)(N3)2] (5), containing a pendant hydroxyl group, was 
reacted with excess N-methylisatoic anhydride (MIA) to form a fluorescent ester 
(Scheme 4.1). The reaction was carried out in DMF, since it is reported that the 
derivatisation of low molecular weight alcohols with this fluorophore proceeds 
best in aprotic organic solvents,[19] with DMAP and triethylamine used as a 
catalyst and auxiliary base, respectively.[20] The product was obtained in a low 





Scheme 4.1 The functionalisation of the pendant hydroxyl group of a PtII azido 
complex with the fluorescent probe N-methylisatoic anhydride (MIA). 






40 h, 310 K
[Pt(en)(N3)2(OH)2] (3) MIA [Pt(en)(N3)2(OH)(OMIA)] (17)
b) Functionalisation of a PtIV complex 
[Pt(en)(N3)2(OH)2] (3) was reacted with excess MIA in DMF, following a well 
documented procedure for derivatisation of the axial hydroxyl groups of PtIV 
complexes.[21] However, lower temperatures were used in this case due to the 
sensitivity of azido complexes to temperatures exceeding 313 K. Interestingly, 
this reaction formed a complex in which only one hydroxyl group was esterified. 
The 1H NMR spectrum gives integrals consistent with the mono-esterified 
complex; in addition, a separate peak was seen for the protons of each NH2 group, 
their inequivalence resulting from asymmetry at the platinum centre. Mass 
spectrometry showed peaks corresponding only to the mono-esterified product 







Scheme 4.2 The functionalisation of the axial hydroxyl groups of a PtIV complex 

















































λem = 414 nm
4.2.3.1.2 Fluorescence Spectroscopy 
The fluorescence emission spectra of equimolar solutions of [Pt(L1-OMIA)(N3)2] 
(16) and [Pt(en)(N3)2(OH)(OMIA)] (17) were recorded in DMF, along with that 
of the free fluorophore MIAH (Figure 4.3). The ring-opened carboxylic acid 
MIAH was formed from the anhydride MIA by addition of acid, to allow for 












Figure 4.3  Fluorescence emission spectra (λex = 316 nm) of 7 µM solutions of 
MIAH, [Pt(L1-OMIA)(N3)2] (16) and [Pt(en)(N3)2(OH)(OMIA)] (17) in DMF. 
 
MIAH shows relatively broad emission in the blue region, centred at 414 nm. As 
expected, quenching of the fluorescence is observed in the spectra of the platinum 
complexes, due to the internal heavy-atom effect.[22] The PtII complex (16) shows 
a small red shift (~7 nm) and an approximately 12-fold decrease in fluorescence 
intensity compared with MIAH; a similar degree of quenching was also observed 
in the RuII complex of L1-OMIA.[16] The quenching is more pronounced for the 




























































PtIV complex (17), for which fluorescence is almost undetectable at this 
concentration, due to the closer proximity of the fluorophore to the metal centre in 
this complex compared with 16; furthermore the quenching ability of metals is 
also affected by their oxidation state, and it has been previously shown that PtIV 
appears to exert a greater quenching effect than does PtII.[6] However, in order to 
draw quantitative conclusions regarding the reduction in quantum yield, it would 
be necessary to ensure the solutions were of equal optical density (isoabsorbant).  
 
4.2.3.1.3 Photoreactions of [Pt(en)(N3)2(OH)(OMIA)] (17) 
The fluorescence spectra of [Pt(en)(N3)2(OH)(OMIA)] (17) upon irradiation with 
visible light in DMF solution was measured over a ten minute period, with spectra 
acquired every one minute. The fluorescence intensity was found to dramatically 





Figure 4.4  The increase in fluorescence observed upon irradiating a sample of 
(en)(N3)2(OH)(OMIA)] (17)  with visible light in DMF. 





16 h, 310 K
pH 9
4 h, 273 K
[Pt(L5)(NH3)(N3)2] (14) Not Isolated
[Pt(L5-NDn)(NH3)(N3)2] 
DnCl
The increase in intensity upon irradiation indicates the release of MIAH, as the 
axial ligands are lost upon photoreduction to PtII. The rapid increase in intensity at 
the beginning of the experiment indicates that reduction occurs very quickly, and 
the majority of the PtIV complex is reduced after only a few minutes of irradiation. 
 
4.2.3.2 Functionalising Platinum Complexes with Dansyl Chloride  
 
4.2.3.2.1 Synthesis and Characterisation 
Both the PtII and PtIV azido complexes containing a BOC-protected amine were 
investigated for functionalisation with a dansyl group, with the same reaction 
scheme followed for both (Scheme 4.3). Deprotection of the BOC group was first 
carried out by stirring in strong acid; the resulting protonated amine species was 
not isolated, although reaction was evident, especially in the case of the PtII 
complex, by the dissolution of the starting material and formation of a yellow 
solution. The pH was then increased and dansyl chloride added in order to form 
the fluorescent sulfonamide; this latter step was carried out at 273 K to minimise 









Scheme 4.3 The synthetic procedure for the attempted formation of dansyl 
sulfonamide complexes, demonstrated for the PtII complex [Pt(L5-
NDn)(NH3)(N3)2]. 




It was not possible to isolate a clean sample of either the PtII or the PtIV target 
complex. Attempts to precipitate the product gave only very small amounts which 
were found to be impure. However, mass spectral evidence of the PtII complex 
[Pt(L5-NDn-H)(N3)2]
+ was obtained. The apparent formation of the ion [Pt(L5-
NDn-H)(N3)2]
+, in which the target complex appears to have ionised via loss of a 
hydride, is unexpected, although the mass and isotope pattern match this species 
well. It is postulated that this ion could be formed by loss of hydride at the 
dimethylamino group, forming an imine-type species. However, the 
dimethylamino group is a prime site for protonation under mass spectrometry 
conditions, and this would have been expected preferentially to give a complex 
with m/z two units higher. 
  



































4.2.3.2.2 Fluorescence Spectroscopy 
Dansyl chloride itself is not fluorescent, however blue-green fluorescent 
sulfonamides are generated upon its reaction with amines. The fluorescence 
spectra of the reaction solutions were therefore measured, in order to determine if 











Figure 4.5  The fluorescence emission spectra of the reaction solutions of the PtII 
and PtIV complexes 14 and 15 with dansyl chloride. 
 
The broad band centred upon 492 nm is indicative of sulfonamide formation, and 
suggests that the reaction was to some degree successful in functionalising the 
pendant amine group of both PtII and PtIV complexes. However, no further 
information can be gained from the fluorescence spectra, and it cannot be 
ascertained that this fluorescence arises from the target species. For example, the 
dissociation of an amine ligand from the platinum centre under strongly acidic 
conditions, and its subsequent reaction with dansyl chloride, would also generate 
a species with such an emission spectral profile. 




4.2.4 Discussion  
4.2.4.1 Functionalisation Strategies   
The motivation for the attachment of fluorescent probes to platinum azido 
complexes was discussed in the introduction: monitoring the fluorescence could 
provide information on cellular distribution and the mechanism of action of such 
complexes, as well as their fate upon irradiation. Despite this, however, there have 
been relatively few examples in the literature of fluorescent probes conjugated to 
platinum anticancer complexes. An early paper by Lippard et al reported a PtII 
chlorido complex containing an ethylenediamine unit, to which a fluorescent 
dansyl group was tethered.[23] In this case, the organic framework was constructed 
first, followed by the simple addition of a platinum salt to coordinate to the 
ethylenediamine unit and generate the required, functionalised  PtII complex. Such 
a strategy has also been employed, for example, in the synthesis of platinum 
species tethered to intercalators.[24] However, in the case of the PtII, and 
particularly PtIV azido complexes studied in this work, this functionalisation 
strategy is not feasible. Following synthesis of a PtII chlorido complex, the PtII 
azido species is prepared by chloride extraction with silver nitrate, and the PtIV 
complex by oxidation with hydrogen peroxide. The organic framework of many 
fluorescent probes or other biologically active species would be incompatible with 
such reagents, as has been recently demonstrated: the oxidation of PtII chlorido 
complexes containing fluorescent coumarin ligands was reported to be 
problematic and low yielding, and in some cases involved oxidation or labilisation 
of the coumarin moiety.[6] Instead, the preferred functionalisation strategy for PtII 
and PtIV azido complexes involved the preparation of complexes containing a 
reactive functional group, to which biologically active species could then be 
attached. Complexes were chosen to contain either a pendant hydroxyl or a 
protected amine group; the differing chemistries of these two groups allowing for 
a wide range of biologically active species with which to functionalise. Chapter 3 




of this thesis described the synthesis and characterisation of several PtII and PtIV 
azido complexes of this type.  
 
4.2.4.2 Functionalisation of [Pt(L1)(N3)2] (5) with N-methylisatoic 
anhydride, and Reactivity of the Pendant Hydroxyl Group 
The functionalisation of Pt(L1)(N3)2 (5), containing a pendant hydroxyl group, 
with a fluorescent probe was thus investigated. A probe was required which 
would react with the hydroxyl group under mild conditions, hence N-
methylisatoic anhydride (MIA) was chosen, since anhydrides react readily with 
alcohols at room temperature. An additional advantage of this compound is its 
small size, as discussed in section 4.2.1.  
Several observations had led to the suggestion that the pendant hydroxyl group of 
5 may show a reduced reactivity compared with organic primary aliphatic 
alcohols. The NMR spectra of all complexes of L1 synthesised in this work 
showed a sharp triplet arising from the OH proton, indicating that it is not readily 
exchangeable, likely due to involvement in inter- or intramolecular interactions. 
Indeed, the crystal structures of both the PtII chlorido and azido complexes of L1 
(Chapter 3, Section 3.3.1.1.4) showed heavy involvement of the OH group in 
hydrogen bonding: intermolecular in the case of the chlorido complex, and 
intramolecular, involving a nitrogen of the azido group, in the azido complex. 
Such interactions may mask the reactivity of the hydroxyl group and decrease its 
tendency to participate in typical nucleophilic attack. In addition, there have been 
previous reports of the inactivity of the hydroxyl group of this ligand in metal 
complexes,[25] and the functionalisation of a RuII arene complex of L1 with MIA 
was reported to be unsuccessful via derivatisation of the hydroxyl group.[16] 
However, Segal et al performed a successful phosphoramidite coupling with the 
hydroxyl group of a PtII chlorido complex of L1,[26] and Nolan et al reported that, 
during the acetylation of the axial hydroxyl groups of a PtIV complex, the pendant 




hydroxyl group of L1 was acetylated also; however, the yield of this species was 
low (14%) and the reaction time long (7 days).[27] In this work, the use of higher 
temperatures to accelerate the reaction was restricted by the sensitivity of the PtII 
azido complex to temperatures exceeding 313 K. Hence DMAP was used as an 
esterification catalyst with triethylamine as the auxiliary base, and the reaction to 
form [Pt(L1-OMIA)(N3)2] (16) was successful, although fairly low yielding. This 
therefore demonstrates the ability to functionalise this hydroxyl group, and the 
concept could be extended to other bioactive species. 
The significant decrease in fluorescence intensity of MIAH upon complex 
formation results from quenching due to the internal heavy-atom effect.[22] The 
presence of a heavy metal within the same compound as the fluorophore increases 
the spin-orbit coupling in the system, and as a result the excited states are not 
purely singlet or triplet in character. Hence the spin selection rules are relaxed 
somewhat, allowing for an increased rate of (formally forbidden) intersystem 
crossing from a singlet to a triplet excited state. This non-radiative transition 
competes effectively with the emissive S1→S0 relaxation pathway, and results in a 
decrease of the fluorescence quantum yield. However, the fluorescence of this PtII 
complex would still be sufficient to allow for the observation of cellular uptake 
and distribution, and potential monitoring of intracellular reactions. For example, 
the binding of sulfur-containing biomolecules to PtII complexes has been shown to 
induce trans-labilisation of the amine ligands; should this occur in this case, an 
increase in fluorescence intensity would be expected. This strategy has already 
been demonstrated with PtII complexes containing the fluorescent 7-azaindole 
ligand.[10] 
However, in the case of 16 an increase in fluorescence could also result from other 
intracellular transformations, for example hydrolysis of the ester bond linking the 
fluorophore to the ligand L1, which would limit the usefulness of the complex for 
tracking the fate of the platinum moiety. The cytosol contains many esterases 
capable of catalysing such a hydrolysis reaction, and a RuII arene complex, 
containing MIA conjugated to L1, was recently tested for its ability to act as a 




substrate for one such enzyme.[16] The half-life of hydrolysis was approximately 
40 h indicating that, although slow, ester hydrolysis would likely occur inside 
cells and may lead to misrepresentation of the cellular distribution of the complex. 
A similar experiment would need to be performed to assess if this is also the case 
for the PtII azido complex 16. 
However, hydrolysis by esterases is exploited in the activation of several organic-
based prodrugs, such as capecitabine, which upon hydrolysis releases the 
anticancer agent 5-deoxy-5-fluorouridine.[28] The application of this strategy to 
platinum drugs has been suggested,[29] however no examples have yet been 
published. Therefore, now the functionalisation of [Pt(L1)(N3)2] (5) has been 
demonstrated, it may be of interest to further explore this in the design of an 
esterase-activated prodrug delivery system. 
 
4.2.4.3 Functionalisation of the Axial Hydroxyl Groups of    
[Pt(en)(N3)2(OH)2] (3) 
It was discussed in Chapter 1 that the photodegradation pathways and phototoxic 
mechanism of action of PtIV azido complexes are not trivial to establish, although 
it is known that reduction to PtII is necessary for phototoxicity. NMR and UV-
visible absorption experiments indicate that photoreduction of such complexes is 
rapid, particularly in the presence of biomolecules. However it would be of use to 
follow such reactions intracellularly, for example by a change in fluorescence 
intensity of the complex upon reduction. 
Hambley et al have very recently explored this idea with the use of fluorescent 
coumarin ligands as probes of PtIV to PtII reduction, and have monitored such 
reactions in cells using confocal microscopy.[6] Since the fluorescence of these 
ligands is quenched more efficiently by PtIV than by PtII, an increase in 
fluorescence intensity following treatment with a PtIV complex is indicative of 
reduction. However, the ligands must be carefully chosen to ensure the difference 




of fluorescence intensity between the PtII and PtIV complexes is sufficiently large 
to be visualised by microscopy. An alternative strategy was considered in this 
work, involving the functionalisation of the axial groups with a fluorescent probe. 
The loss of the axial ligands upon reduction is well known and has been exploited 
previously,[3] and NMR experiments on PtIV azido complexes with axial acetato 
groups confirm these ligands are rapidly released upon photoreduction.[30] 
Furthermore, the difference in fluorescence intensity of a probe when bound to 
PtIV or unbound following reduction should be very large. However, more suitable 
still would be a system utilising ratiometric imaging, involving a change of 
emission energy upon reduction. The advantage of such a method is the ability to 
normalise for changes in fluorescence intensities which are unrelated to changes 
in concentration of the target species. 
The functionalisation of axial hydroxyl groups of PtIV complexes is well 
established, and has been employed in the synthesis of novel carboxylato 
complexes as potential anticancer agents,[31,32] or for the introduction of bioactive 
species into a PtIV complex.[3,33] Since many synthetic routes use anhydrides in the 
formation of carboxylates, it was believed reaction with MIA may be feasible. 
However, despite the use of excess anhydride, the reaction gave rise solely to the 
mono-esterified PtIV complex, in which only one hydroxyl group was 
functionalised. The reasons for this are not clear, and only a few examples of PtIV 
complexes containing different axial ligands can be found in literature. Lippard et 
al prepared cis,cis,trans-[Pt(NH3)2Cl2(OH)(OEt)], however this was via the 
oxidation of cisplatin in dilute ethanolic hydrogen peroxide; the hydroxyl group 
was then found to undergo subsequent reaction with an anhydride whilst the 
ethoxy group remained intact.[34] Mixed carboxylates have also been formed from 
complexes such as [Pt(dach)(OH)4], with the functionalisation of one OH group 
achieved by addition of one equivalent of anhydride, however, this resulted in 
mixtures that required chromatographic separation.[35] The carboxylation of 
[Pt(dach)(OH)4] with an excess of carboxylic acid formed the tris-carboxylate 
cleanly, where one OH group remained intact, however this could be attributed to 




the differing mechanism of reaction in acidic conditions, in which protonation of 
the OH groups occurs prior to substitution.[36] Functionalisation with bulky 
aromatic anhydrides has been achieved before, so steric constraints are 
unlikely.[32] It is possible that the second hydroxyl ligand is harder to functionalise 
one the first is carboxylated, and the elevated temperatures usually employed in 
such reactions are necessary to ensure reaction of both hydroxyl groups. 
 
4.2.4.4 Irradiation of [Pt(en)(N3)2(OH)(OMIA)] (17) 
The increase in fluorescence intensity upon irradiation is indicative of 
photoreduction and release of MIAH, and is in accordance with previous evidence 
of the release of axial ligands upon reduction. The large contrast in fluorescence 
intensity between that of the free probe and the essentially non-fluorescent PtIV 
complex demonstrates that such a system could be useful in following the 
photoreduction in cells by fluorescence microscopy. 
The large increase in intensity after very short irradiation times indicates that the 
majority of the complex is reduced after only a few minutes, even upon irradiation 
with visible light; this was also the case for the PtIV complex [Pt(L1)(N3)2(OAc)2] 
(6), as shown in Chapter 3. It is known that complexes with axial carboxylates are 
more readily chemically reduced than those containing hydroxyl groups, however 
the extrapolation of this to photochemical reductions may not be valid. The high 
reduction rate in the case of 17 may result in part from the bulky nature of the 
axial ligand, since this is known to destabilise the PtIV state. In any case, rapid 
photoactivation is a desirable quantity for potential drug candidates, however the 
PtIV state must not be so unstable as to undergo spontaneous reduction or reactions 
in the dark.  
Since the rapid release of the axial groups upon irradiation has been demonstrated, 
it may also be of interest to explore the attachment of other bioactive species to 
the hydroxyl group, which could then be selectively released upon irradiation. 




4.2.4.5 Functionalising Platinum Complexes with Dansyl Chloride 
In addition to complexes containing a free hydroxyl group, it was believed that a 
complex with a free amine group would allow access to a wider range of 
functionalising species, given their differing chemistries. Furthermore, the amide 
linkages formed upon reaction are more stable than ester bonds, and do not 
undergo hydrolysis under mild conditions. 
The reactivity of platinum towards amines necessitates the use of protecting group 
chemistry in the formation of such a complex. A ligand was chosen in which the 
protected amine to be functionalised was separated from the coordinating amine 
by four carbons; it has previously been shown that this distance is sufficient to 
minimise quenching from the platinum centre upon attachment of a 
fluorophore.[23]   
There are several functional groups that can react with free amines at room 
temperature, for example isothiocyanate, and fluorescein isothiocyanate is widely 
used in biochemical applications. However, this probe could not be used in this 
case, since metal azido complexes can undergo cycloaddition reactions of the 
coordinated azide with isothiocyanate groups, to give complexes containing S-
coordinated, tetrazole-thiolate ligands.[37] Hence dansyl chloride was chosen, 
which forms fluorescent, stable sulfonamides upon reaction with amines. 
Unfortunately, it was not possible to isolate a clean sample of either the PtIV or the 
PtII sulfonamide complex. The deprotection of the BOC group appeared to be 
successful, however, and provides validation of this functionalisation route. Upon 
addition of dansyl chloride, fluorescent sulfonamide species were clearly formed, 
and in the case of the PtII complex there was evidence of the required product. 
However, the formation of other fluorescent sulfonamides cannot be ruled out, for 
example if the amine ligand L5 were to dissociate from the platinum under the 
strongly acidic conditions of the reaction, this could also combine with dansyl 
chloride to form a product with a similar emission profile. 
  




4.3 Attachment of Platinum Complexes to Quantum Dots 
4.3.1 Introduction[38,39] 
Quantum dots are a class of fluorophore receiving increasing interest for 
biological sensing and imaging purposes, as a result of their superior optical and 
electronic properties compared with traditional organic dyes. They are 
approximately spherical particles of semiconductor materials, typically of the 
II-VI group such as CdSe, vary between 2–10 nm in size and contain around 200–
10 000 atoms; hence they are often termed “semiconductor nanocrystals”. 
In such materials, excitons (electron-hole pairs) are confined in all three spatial 
dimensions, giving rise to the term “dot”, and energy levels are discrete and 
quantised, unlike the continuum of a bulk material. The optical properties result 
from transitions between the valence and conduction bands and are thus 
dependent upon the band gap energy; in such nanocrystals this is a function of 
their size (E α 1/r2), the variation of which allows the optical properties to be 
tuned. With increasing size, the energy levels are greater in number and more 
closely spaced (i.e. more similar to a bulk material), resulting in a red shift in 
absorption and emission. In the case of CdSe dots, emission throughout the entire 
visible spectrum can be obtained by variation of the size, which is readily 
achieved during the synthetic pathway.  
Readily tunable emission is one of many benefits quantum dots show over 
traditional organic fluorophores. When coated with a “shell” of a higher band gap 
material, such as ZnS, CdSe quantum dots are also around 10–100 times brighter, 
due to a larger absorption cross section, and 100–1000 times more resistant to 
photobleaching than organic dyes. Their broad absorbance in the UV-visible 
region allows for a wide range of excitation wavelengths, however they show very 
narrow and tunable emission profiles. Quantum dots have thus found application 
in many areas such as electronics, optics and OLEDs, and are becoming 
increasingly important for biological applications.[40] Although early work in this 




field produced quantum dots which were insoluble in aqueous media, it is now 
possible to modify their surface to impart biocompatibility, generally through 
exchange of the organic ligands with hydrophilic alternatives, or through 
encapsulation of the dots in an amphiphilic polymer. Subsequent conjugation to 
biomolecules can then be performed and is becoming an increasingly popular 
strategy, allowing for targeting of the dots and increasing their potential for 
application in areas such as cellular imaging and diagnostics, and for dual imaging 
and therapy purposes. 
There are numerous examples of the conjugation of biomolecules or biologically 
active species to quantum dots. Several species, such as the TAT peptide, have 
been used to aid the internalisation of quantum dots into cells.[41] Conjugation of 
streptavidin is particularly useful in targeting since the resultant dots readily bind 
to specifically biotinylated molecules,[42] and many small organic ligands have 
been utilised to interact with different cellular receptors and targets.[43] The 
conjugation of photosensitisers has also been explored, using both organic 
compounds[44] and metal complexes;[45] such conjugates represent a dual imaging 
and therapy strategy, having the potential for both singlet oxygen generation and 
fluorescence imaging. Additionally, a very recent report describes the reduction of 
a PtIV complex via photoinduced electron transfer upon irradiation in the presence 
of CdSe–ZnS quantum dots; such a method may have application in the field of 
photoactivated anticancer agents.[46] 
However, there are no reported examples of the covalent conjugation of a 
platinum complex to quantum dots. It was believed that such a conjugate could 
form a novel example of a potential dual imaging and therapy agent, allowing for 
the monitoring of uptake and distribution of a cytotoxic moiety. Furthermore, the 
incorporation of a photoactivated platinum complex could allow for potentially 
novel methods of activation, for example by irradiation at the visible wavelengths 
at which the quantum dots absorb. This section involves the synthesis and 
characterisation of water soluble quantum dots and subsequent investigations into 
the conjugation of a platinum complex.  






Cadmium oxide (CdO, ~1 micron, 99.5%), trioctylphosphine (TOP, 90%), 
trioctylphosphine oxide (TOPO, 99%), tributylphosphine (TBP, 97%), 
hexamethyldisilathiane ((TMS)2S, synthesis grade), N,N-
diethyldiethylenetriamine (L6, 98%), D-(+)-glucosamine hydrochloride (≥ 99%) 
and human apo-Transferrin (apo-hTf, ≥ 97%) were purchased from Aldrich. 
Stearic acid (≥ 98.5%), hexadecylamine (HDA, ≥ 90%), potassium tert-butoxide 
(≥ 97%), diethylzinc solution (~1 M in hexane), (±)-α-lipoic acid (≥ 98%), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, ≥ 98%) and 
N-hydroxysulfosuccinimide sodium salt (sulfo-NHS, ≥ 98.5%) were obtained 
from Fluka. Selenium powder (~200 mesh, 99.8%) was purchased from Chempur, 
Germany. apo-hTf was purified on a Sephacryl 200 column prior to use, with 1 X 
phosphate buffered saline solution (PBS) prepared as previously described,[47] and 
all other reagents were obtained from commercial sources and used as received. 
 
4.3.2.2 Synthesis 
The syntheses of CdSe and CdSe-ZnS quantum dots, and preparation of ZnS stock 
solution, were carried out under an argon atmosphere using standard Schlenk 
techniques; all other syntheses were carried out in air unless otherwise stated. 
 
CdSe Quantum Dots (CdSe QDs) 
CdO (39 mg) and stearic acid (780 mg) were placed in a 50 mL two-necked 
round-bottomed flask equipped with a magnetic stirring bar. The mixture was 
heated to 473 K with stirring until dissolution of CdO was complete (~ 15 min), 
then allowed to cool to room temperature. HDA (3 g) and TOPO (9 g) were 




added, and the mixture heated to 573 K on a heating mantle. A fresh solution of 
Se (240 mg) in TOP (2.5 mL) was then added rapidly by injection. After 30 sec, 
the flask was transferred to a hotplate at 533 K, where it was stirred for another 
2 min before cooling in ice. Once at 333 K chloroform (50 mL) was added, 
followed by methanol (250 mL). The precipitated dots were collected by 
centrifugation (7500 rpm, 8 min) and washed once more with 1:4 CHCl3:MeOH 
prior to drying in air. 
 
CdSe-ZnS Quantum Dots (CdSe–ZnS QDs) 
CdSe QDs (prepared as described) and TOPO (16 g) were placed in a 50 mL two-
necked round-bottomed flask, equipped with a magnetic stirring bar, and heated to 
483 K. Meanwhile, a ZnS stock solution was freshly prepared by mixing 3.5 mL 
of a Zn(Et)2 solution with 6 mL TOP and 0.52 mL (TMS)2S. This was injected 
into the former solution at 483 K, dropwise over a period of 15 min.  Following 
injection, the flask was cooled to 383 K by blowing with compressed air for 
around 10 min, and then heated at 383 K for 5 h. The solution was allowed to cool 
to room temperature, after which CHCl3 (30 mL) and methanol (120 mL) were 
added. The precipitated dots were collected by centrifugation (7500 rpm, 8 min) 
and washed with a 1:4 CHCl3:MeOH mixture, to yield 1.79 g of CdSe-ZnS dots. 
It was also possible to perform the ZnS coating immediately following the 
preparation of CdSe dots. In such syntheses, following the growth of CdSe dots at 
533 K, the flask was transferred to a hotplate preheated to 483 K, and the ZnS 
stock solution added as described. 
 
Dihydrolipoic Acid (DHLA) 
A solution of lipoic acid (3.01 g, 14.5 mmol) in 0.25 M NaHCO3 (70 mL) was 
placed under nitrogen and cooled in an ice bath to 273 K. NaBH4 (2.21 g, 




58.4 mmol) was added in small portions over the course of 1 h; the solution was 
then stirred at 273 K for a further 2 h. The reaction mixture was acidified to pH 1, 
extracted with toluene (3 x 30 mL), and the combined organic phases were dried 
over MgSO4. Solvent was removed to yield a colourless oil, which was stored at 
277 K under nitrogen. 
Yield: 2.72 g (90%). 
1H NMR (500 MHz, CDCl3): δ = 10.64 (br s, 1H), 2.92 (m, 1H), 2.69 (m, 2H), 
2.37 (m, 2H), 1.89 (m, 1H), 1.78-1.42 (m, 5H), 1.35 (t, 1H), 1.31 (d, 1H). 
 
CdSe–ZnS/DHLA Quantum Dots (CdSe-ZnS/DHLA QDs) 
Freshly synthesised and air-dried CdSe–ZnS dots (1.79 g) were placed in a sealed 
vessel, followed by addition of DHLA (2.2 mL), and the mixture heated to 348 K 
for 3.5 h under nitrogen. Upon cooling to room temperature, DMF (20 mL) was 
added and the mixture centrifuged (6500 rpm, 7 min). The dark brown/red 
supernatant was retained, and the precipitate washed twice with additional DMF, 
after which all supernatants were combined and filtered through a 0.2 µm 
hydrophobic syringe filter (Millex-FG), to remove any insoluble impurities or non 
cap-exchanged dots. Potassium tert-butoxide (1.5 g) was then added, the mixture 
stirred for 10 min, and the precipitated dots collected by centrifugation (8400 rpm, 
7 min) and washed with DMF. Water (35 mL) was added to dissolve the dots; the 
solution was then filtered through a 0.2 µm hydrophilic syringe filter (Sartorius 
Minisart®), and this stock solution was stored at 278 K under argon. Prior to 
further use, the dots were purified on a Sephacryl 200 column, eluting with 
100 mM PBS solution at pH 7.4. 
 
QD–L6 
To 6 mL of an 8.3 µM solution of CdSe–ZnS/DHLA QDs in 1 X PBS (pH 7.4) 
was added EDC (58 mg, 50 mM) and sulfo-NHS (6.5 mg, 5 mM), and the 




solution mixed for 20 min at room temperature. 2-Mercaptoethanol (10 µL) was 
added, the mixture shaken for 10 min, then  L6 (1 µL, 0.9 mM) was added and the 
solution placed on a shaker at room temperature for 12 h. Most of the QDs had 
precipitated after this time; these were isolated by centrifugation, washed twice 
with water, and redissolved in 0.1 M NaOD solution with the aid of sonication. 
 
QD–L6–Pt (18) 
1 mL of a 2 µM QD–L6 solution in 0.1 M NaOD/NaCl was added to 
Pt(DMSO)2Cl2 (0.1 mg), and the mixture placed on a shaker for 5 h. The solution 
was exchanged for 0.1 M NaCl in D2O in a 30 kDa molecular weight cut-off 
(MWCO) filter, upon which some precipitation of dots occurred; further 
precipitation was seen upon storage at 278 K. Some solubility could be regained 
upon addition of 0.1 M NaOH. 
 
QD–Glu 
To 3 mL of a 10 µM solution of CdSe–ZnS/DHLA QDs in 1 X PBS (pH 7.4) was 
added EDC (30 mg, 64 mM) and glucosamine (10 mg, 15 mM). The solution was 
stirred gently for 4 h, and washed over a 30 kDa MWCO filter three times with 
1 x PBS. 
 
QD–Tf 
EDC (1 mg) and sulfo-NHS (2.5 mg) were dissolved in 1 mL of 0.1 M MES 
activation buffer (pH 6.0), and added to 400 µL of a 10 µM solution of QDs in 
1 X PBS (pH 7.6). The mixture was placed on a shaker at room temperature for 
30 min. 2-Mercaptoethanol (2.5 µL) was added followed by further shaking for 
10 min. The pH was adjusted to 7.0 with 1M NaOH, apo-hTf (58 µL of a 150 µM 




solution in 1 x PBS) was added, and the pH increased to 7.8 before placing on a 
shaker at room temperature for 2.5 h. The solution was washed with 1 X PBS 
three times through a 100 kDa MWCO filter, and the product purified on a 
Sephacryl 200 column, eluting with 100 mM PBS solution at pH 7.4. 
 
QD–Tf–L6 
To 1 mL of a 1 µM solution of QD–Tf in 1 X PBS was added EDC (9.6 mg) and 
sulfo-NHS (1.1 mg), and the reaction mixture acidified with dilute HCl to pH 6.5 
and shaken for 10 min. L6 (1 µL) was added, upon which the pH rose to 8.5, and 
the mixture was placed on a shaker for 5 h at room temperature. The solution was 
then washed three times in a 30 kDa MWCO filter with 100 mM PBS at pH 8.5. 
 
QD–Tf–L6–Pt (19) 
To 2 mL of a 0.6 µM solution of QD–Tf–L6 was added K2PtCl4 (0.5 mg), and the 
reaction shaken at room temperature for 2 h. Following storage at 277 K for 48 h 
the mixture was washed three times in a 30 kDa MWCO filter with 100 mM PBS 
at pH 8.5. 
 
QD–Tf–Pt 
To 400 µL of a 0.4 µM solution of QD–Tf in 1 X PBS  was added 20 µL of a 
0.7 mM K2PtCl4 solution in H2O. The solution was placed on a shaker for 2 h, 
then washed three times in a 30 kDa MWCO filter with 1 X PBS  at pH 7.4.  
 
 






The concentrations and relative ratios of Cd, Se, Zn and S were determined for 
CdSe, CdSe-ZnS and CdSe–ZnS/DHLA QDs. Cd and Pt concentrations were 
determined for CdSe–ZnS/DHLA QDs, QD–L6–Pt, QD–Tf, QD–Tf–Pt, QD–Tf–
L6 and QD–Tf–L6–Pt. Samples of water-soluble products were prepared to a 
concentration of ~0.1 µM in 3% nitric acid, and digested for 48 h at 343 K. For all 
other products, a sample of the solid was digested in aqua regia, again for 48 h at 
343 K, prior to dilution to give a final acid concentration of 3%. Standard 
solutions (3200–5 ppb) were prepared from stock 1000 ppm solutions of Cd, Se, 
P, S, Zn and Pt (Sigma-Aldrich), and were run to give a calibration curve from 
which unknown concentrations of the elements could be determined. The isotopes 
observed were 111Cd, 82Se, 32S, 66Zn and 195Pt.  
 
4.3.2.3.2 Iron Uptake by QD–Tf 
500 µL of a 0.4 µM solution of QD–Tf was placed in a cuvette, the UV-visible 
absorption spectrum recorded and the value at 470 nm set to zero. To this was 
added 6 µL of an 800 mM NaHCO3 solution, followed by 10 µL of a 4 mM Fe
III 
citrate solution, and the solution gently mixed for 2 min. The change in 
absorbance at 470 nm was then followed, with a reading taken every 30 sec for 
90 min, with the temperature set to 298 K. The experiment was repeated with 
CdSe-ZnS/DHLA QDs to act as a control.  
 
4.3.2.3.3 Cytotoxicity Testing 
The cytotoxicity of QD, QD–Tf and QD–Tf–L6–Pt (19) towards the human 
ovarian A2780 cancer cell line was assessed by Dr Ana Pizarro at the University 
of Warwick, according to the procedure outlined in Chapter 2.  








































CdSe–ZnS quantum dots were synthesised, and rendered water soluble by the 
incorporation of an amphiphilic thiol ligand. The carboxylate groups of these 
ligands were then subject to an amide coupling to incorporate a platinum binding 
chelating amine moiety; subsequent reaction with a platinum complex formed a 
platinum conjugate, with evidence from ICP-MS data. Attempts were then made 
to increase the water solubility and potential tumour targeting properties by initial 
functionalisation of the quantum dots with glucosamine and transferrin; amide 
coupling and platinum binding were then achieved with the transferrin conjugate. 
The water soluble quantum dots, the transferrin conjugate and its platinated 






















Figure 4.6  A diagram illustrating the reactions performed with quantum dots. 



















DHLA – Dihydrolipoic acid
Zn(Et)2 in hexane 
(TMS)2S, TOP
483 K






4.3.3.1 Synthesis of CdSe–ZnS/DHLA Quantum Dots 
The reaction scheme for the synthesis of water soluble quantum dots is displayed 
below in Scheme 4.4. These are synthesised via the initial preparation of organic 



















Scheme 4.4  The synthetic route to CdSe-ZnS/DHLA quantum dots.  
HDA = hexadecylamine, TOP = trioctylphosphine, 
(TMS)2S = hexamethyldisilathiane.  




CdSe quantum dots (CdSe QDs) were synthesised with minor modifications to a 
literature method,[48] by the high-temperature reaction of Cd and Se precursors in 
the presence of a high-boiling organic solvent, TOPO. These dots were typically 
isolated and characterised by UV-visible absorption and fluorescence 
spectroscopy prior to coating with a ZnS shell; however, it was also possible to 
perform the coating directly following CdSe quantum dot growth in situ, without 
prior isolation. Coating was accomplished by addition of appropriate Zn and S 
precursors and allowing growth of the shell for 5 h at a lower temperature than 
that required for nanocrystal growth;[48] this coating yields quantum dots with 
improved photochemical stability and luminescence properties compared with 
their non-coated CdSe precursors. 
The resultant CdSe–ZnS quantum dots are soluble only in organic solvents on 
account of the highly hydrophobic capping ligand TOPO; hence in order to obtain 
aqueous solubility these ligands must be exchanged for more hydrophilic 
alternatives. The commonly-used dihydrolipoic acid (DHLA) was chosen in this 
case, containing two thiol groups to allow for bidentate interactions with the 
quantum dot surface, and a carboxylate group to confer solubility in aqueous 
solutions. Ligand exchange was accomplished by stirring CdSe–ZnS QDs in neat 
DHLA with moderate heating.[49] The resultant CdSe–ZnS/DHLA QDs were then 
purified on a Sephacryl-200 column eluting with 100mM PBS at pH 7.4, with the 
chromatogram shown in Figure 4.7. The first eluted peak consisted of the required 
quantum dots, with a second species eluting at a later timepoint and thus of a 
lower molecular weight. These fractions were neither coloured nor fluorescent, 
and were slightly malodorous; they were thus presumed to arise from high 



















































Figure 4.7  Chromatogram obtained upon purification of CdSe–ZnS/DHLA QDs, 
using a Sephacryl-200 size-exclusion column eluting with 100 mM PBS (pH 7.4). 
 
4.3.3.2 Characterisation of Quantum Dots 
4.3.3.2.1 UV-Visible Absorption Spectroscopy 
CdSe QDs, CdSe–ZnS QDs and CdSe–ZnS/DHLA QDs were characterised by 
UV-visible absorption spectroscopy, and showed an absorption profile typical of 
quantum dots. The red shift of λmax upon ZnS coating results from the partial 
leaking of the exciton into the ZnS matrix, leading to a reduction in quantum 
confinement.[50] There is no change in λmax upon exchange of the capping ligand 
to form water soluble dots, since the core of the dots giving rise to the absorption 
in this region is unaffected. 
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Figure 4.8  Normalised UV-visible absorption spectra of CdSe QDs and CdSe–
ZnS QDs in chloroform, and of CdSe–ZnS/DHLA QDs in aqueous solution. 
 
Several parameters can be obtained from the absorption spectra of the dots; these 
are calculated below for the water soluble CdSe–ZnS/DHLA QDs. 
 
a) Size 
The band gap (and thus the energy required for the transition) is related to the size 
of the emissive core of the quantum dots; thus from the position of the first 
absorption peak, the size can be calculated according to the following polynomial 
equation (where D = diameter and λ = λmax).
[51] 
 
CdSe:  D = (1.6122 x 10-9)λ4 – (2.6575 x 10-6)λ3 + (1.6242 x 10-3)λ2 –  
(0.4277)λ + 41.57. 
Inputting the value of 581 nm as λ yields D = 4.0 nm. 





The extinction coefficient per mole of nanocrystals can be calculated from their 
diameter as follows:[51] 
 
CdSe: ε = 5857(D)2.65 
Inputting the value of 4.1 nm yields ε = 230 750 M-1 cm-1 
 
The absorption spectrum is also an indication of the size distribution of the dots, 
with a broad peak, or more than one maximum, indicative of a broad distribution. 
However, as the dots increase in size and move towards the properties of the bulk 
material the spectra become inherently more structured,[38] and a much more 
reliable way to assess the size distribution is by analysis of the fluorescence 
emission spectrum. 
 
4.3.3.2.2 Fluorescence Spectroscopy 
Fluorescence emission spectra were obtained for CdSe QDs, CdSe–ZnS QDs and 
CdSe–ZnS/DHLA QDs, and show narrow bands with low full-width half-
maximum (FWHM) values (32 nm, 38 nm and 42 nm respectively), indicative of 
a narrow size distribution. Again a red-shift is seen upon ZnS coating, with no 
change upon exchange of the capping ligands.  
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Figure 4.9  Normalised fluorescence emission spectra of CdSe QDs and CdSe–
ZnS QDs in chloroform, and CdSe–ZnS/DHLA QDs in aqueous solution, with 
excitation at 365 nm. 
 
4.3.3.3 Functionalisation of CdSe-ZnS/DHLA QDs with an Organic Amine  
4.3.3.3.1 Binding of an Organic Amine Ligand (QD–L6) 
The carboxylate group of DHLA is amenable to derivatisation by standard 
coupling techniques; such reactions of the capping ligands are a common route to 
the functionalisation of quantum dots.[40] In this case, it was necessary to 
incorporate a ligand capable of binding a platinum moiety. A ligand was chosen 
containing a primary, secondary and tertiary amine group separated by ethylene 
units (L6, Figure 4.6); the primary amine can selectively participate in amide 
coupling reactions, leaving the secondary and tertiary groups available for 
chelation to platinum. 













Amide coupling was thus performed in 1 X PBS at pH 7.4, using an excess of 












Scheme 4.5  The coupling of L6 to the carboxylate groups of DHLA.  
 
The quantum dots precipitated to some extent during the course of the reaction, 
likely resulting from the reduced solubility of the amine capping ligand in the 
buffered reaction medium (pH 7.4); solubility could be restored upon sonication 
of the precipitated dots in a 0.1 M NaOH solution. The solubility change provides 
some evidence of reaction; a 1H NMR spectrum in 0.1 M NaOD in D2O was also 
obtained and compared with that of the ligand alone to obtain further evidence. 
The expected peaks for the ligand appear to be present in the product (QD–L6), 
including the triplet of the two methyl groups which does not appear in DHLA.  




















Figure 4.10  
1H NMR spectra in 0.1 M NaOD/D2O of the ligand L6 and the 
functionalised quantum dots, QD–L6. 
 
4.3.3.3.2 Binding of Platinum (QD–L6–Pt, 18) 
The platination of QD–L6 was carried out using an excess of Pt(DMSO)2Cl2 in 
0.1 M NaOH solution, however during removal of excess starting material and 
exchange for 0.1 M NaCl in D2O in a MWCO filter, the dots began to precipitate, 
with further precipitation seen upon storage. Addition of 0.1 M NaOH dissolved 
the solid to some extent, although not all could be resolubilised.  
Immediately following the reaction, visual observation of the solution under a 
UVA lamp indicated a large degree of fluorescence quenching upon reaction with 
the platinum complex; presumably due to the heavy-atom effect.[22] An attempt 
was made to measure the degree of quenching in the product, QD–L6–Pt (18), by 




































recording fluorescence emission spectra of isoabsorbant solutions of QD–L6–Pt 











Figure 4.11  Fluorescence emission spectra of isoabsorbant solutions of CdSe–
ZnS/DHLA QDs in 1 X PBS, and QD–L6–Pt (18) in 0.1 M NaOH. 
 
The spectra show a decrease in fluorescence intensity for QD–L6–Pt compared 
with the non-platinated dots, however this spectrum may be unlikely to reflect the 
true degree of quenching in the product. To obtain the spectrum it was necessary 
to resolubilise the precipitated QD–L6–Pt in alkaline solution, however as 
mentioned this did not solubilise the entire product. It is likely the dots that were 
solubilised were those that did not react with platinum, or those that were 
platinated to a lesser extent, since the free amines of QD–L6 would be expected to 
show greater solubility than when platinated in QD–L6–Pt. Platination was, 
however, confirmed by ICP–MS, the results of which are discussed in Section 
4.3.3.6. 
 




The aqueous insolubility and quenching of fluorescence observed for QD–L6–Pt 
render these dots unsuitable for biological imaging purposes. It was therefore 
decided to investigate the functionalisation of quantum dots with biomolecules 
prior to platination; to gain the dual benefit of imparting aqueous solubility and 
distancing the platinum from the fluorophore, thereby minimising the degree of 
quenching. 
 
4.3.3.4 Functionalising Quantum Dots with Glucosamine (QD–Glu) 
Glucosamine is a naturally occurring amino monosaccharide, which can be 
derivatised through reactions of the amino group.[52] Attempts were made to 
conjugate glucosamine to CdSe–ZnS/DHLA quantum dots via the coupling of this 
amine to the carboxylate group of DHLA. 
Successful coupling was achieved using an excess (~20 fold) of glucosamine in 
the presence of EDC; a larger excess was found to induce precipitation of the 
quantum dots. The UV-visible absorption and fluorescence spectra of the resultant 
conjugate QD–Glu were unchanged from those of CdSe–ZnS/DHLA quantum 
dots, as expected, and evidence for successful conjugation was provided from the 
NMR spectrum of QD–Glu in comparison with that of glucosamine alone (Figure 
4.12). The presence of a peak at 5.37 ppm, corresponding to the proton on the 
anomeric carbon, was particularly indicative of successful binding. 
Subsequent attempts to derivatise the OH groups were unsuccessful. Reaction 
with bromoacetic acid, to provide carboxylate groups available for subsequent 
amide coupling, led to precipitation of the quantum dots. Although it was believed 
successful derivatisation could be achieved, attention was then turned to 
alternative biomolecules and no further work was carried out with the 
glucosamine conjugate. 
 

















Figure 4.12  1H NMR spectra of glucosamine (in D2O) and QD–Glu (in D2O with 
water suppression). 
 
4.3.3.5 Functionalising Quantum Dots with Transferrin (QD–Tf) 
Human transferrin is an 80 kDa protein involved in the binding and transportation 
of iron in vivo, with cellular delivery of iron achieved upon interaction of 
transferrin with the transferrin receptor (TfR1) and subsequent internalisation by 
endocytosis. TfR1 is overexpressed on rapidly dividing cells, with low expression 
in non-proliferating cells; thus it has become an attractive target for the selective 
delivery of drugs to tumours.[53] It was believed the conjugation of transferrin to 
quantum dots prior to platinum binding would aid water solubility and 
internalisation specifically into tumour cells, and distance the platinum from the 
fluorophore such that quenching of fluorescence is minimised. 
Attempts were made to conjugate human apo-transferrin (metal-free, hereby 
abbreviated Tf) to the carboxylate ligands of DHLA, via the amino groups of 
lysine residues on the protein. Attempts at coupling using EDC alone were 




































unsuccessful, leading to precipitation of the protein. The use of EDC and sulfo-
NHS, previously reported for the conjugation of biomolecules to quantum dots,[54] 
led to successful preparation of a conjugate denoted QD–Tf. This product was 
purified on a Sephacryl-200 column, eluting with 100mM PBS at pH 7.4 (Figure 
4.13), allowing for separation of the conjugate from both unmodified quantum 












Figure 4.13 The chromatogram obtained upon purification of QD–Tf, using a 
Sephacryl-200 size-exclusion column eluting with 100 mM PBS (pH 7.4). 
 
4.3.3.5.1 Iron Uptake by QD–Tf 
Upon addition of an FeIII source to apo-transferrin, along with HCO3
– to act as a 
synergistic anion, the binding of FeIII can be monitored by the increase in 
absorbance at 470 nm, the λmax of the tyrosine oxygen–Fe
III ligand-to-metal charge 
transfer (LMCT) band. This experiment was performed with QD–Tf, to confirm 
conjugation of Tf to the quantum dots. The observed increase in absorbance, up to 






























a saturation point of around 20 min, is indicative of such an iron uptake reaction 
and provides evidence of the successful conjugation of Tf. As a control, the 














Figure 4.14  The change in absorbance at 470 nm following addition of FeIII to 
QD–Tf and CdSe–ZnS/DHLA, as a monitor of iron uptake. 
 
4.3.3.5.2 QD–Tf–L6 and QD–Tf–L6–Pt (19) 
The ligand L6 was conjugated to QD–Tf via an amide coupling reaction involving 
the primary amino group of the ligand and accessible free carboxylates of the 
transferrin. In this case, no precipitation was seen; the transferrin clearly 
imparting enhanced water solubility on the conjugate. 


































Platination was accomplished by addition of an excess of K2PtCl4. Fluorescence 
spectra of equimolar solutions of QD–Tf–L6–Pt (19) and CdSe–ZnS/DHLA QDs 
indicate that platination has very little effect on the fluorescence of the quantum 
dot (Figure 4.15), there is essentially no contact between the two as a result of the 













Figure 4.15  Fluorescence emission spectra of isoabsorbant solutions of CdSe–
ZnS/DHLA QDs in 1 X PBS, and QD–Tf–L6–Pt (19) in 100 mM PBS pH 8.4. 
 
To ensure platination was occurring at L6 with minimal non-specific binding to 
amino acid residues on transferrin, QD–Tf was treated with K2PtCl4 in the same 








4.3.3.6 ICP-MS of Quantum Dots and Conjugates 
The concentrations and relative ratios of Cd, Se, Zn and S were determined for 
CdSe, CdSe–ZnS and CdSe–ZnS/DHLA QDs by ICP-MS. 
 
Table 4.1  ICP-MS data for CdSe, CdSe–ZnS and CdSe–ZnS/DHLA QDs 
















































These results indicate a large excess of selenium in the CdSe quantum dots, when 
more equal concentrations of cadmium and selenium would be expected. Excess 
selenium is no longer present, however, in the CdSe–ZnS dots, and approximately 
equal proportions of Zn and S are seen as expected. The exchange of TOPO for 
the thiol ligand DHLA can also be evidenced by the increase in the proportion of 
sulfur in the CdSe–ZnS/DHLA quantum dots. 
 




To monitor the platination reactions of several quantum dots and conjugates, Cd 
and Pt concentrations were determined for CdSe–ZnS/DHLA QDs, QD–L6–Pt 
(18), QD–Tf, QD–Tf–Pt, QD–Tf–L6 and QD–Tf–L6–Pt (19). 
 
Table 4.2  ICP-MS data for several quantum dot-platinum conjugates and their 
precursors. 



































These results indicate the successful platination of QD–L6, with the platinum 
concentration approximately half that of cadmium. It is evident that some 
platination of transferrin occurred in QD–Tf, however the degree of platination is 
smaller than for conjugates containing the platinum-binding ligand L6. 
Surprisingly, the conjugate QD–Tf–L6–Pt (19) contained a very large proportion 
of platinum compared with cadmium, and compared with QD–L6–Pt (18) in 




which the platinum binding ligand L6 is also present. This could indicate the non-
specific platination of transferrin to some extent, and will be further discussed in 
Section 4.3.4.2.3. 
 
4.3.3.7 Cytotoxicity  
CdSe–ZnS/DHLA QDs, QD–Tf and QD–Tf–L6–Pt (19) were tested for 
cytotoxicity against the A2780 human ovarian cancer cell line, as described in 
section 4.3.2.3.3. The concentrations were calculated based on the results of the 
ICP-MS measurements, and chosen such that the concentrations of Pt 
administered during the testing of 19 were 100, 50 and 5 µM, in line with the 
standard protocol for the screening of platinum complexes. The corresponding 
concentrations of cadmium were determined and, in order to draw comparisons, 
CdSe-ZnS/DHLA QDs and QD–Tf were tested at these cadmium concentrations 
also. 
Screening indicated that both CdSe–ZnS/DHLA QDs and QD–Tf were cytotoxic 
at the concentrations tested, with IC50 values estimated to be in the range of 20–
40 µM (cadmium concentration). However, QD–Tf–L6–Pt (19) was non-toxic, 
with cell survival ≥ 100% at all concentrations tested.  
 
4.3.4 Discussion 
4.3.4.1 Synthesis of CdSe–ZnS/DHLA dots 
Interest in semiconductor quantum dots has grown rapidly in recent years with the 
emergence of numerous potential applications, many of which require a narrow 
fluorescence emission profile and thus a narrow size distribution of dots. Despite 
this, it was found that detailed synthetic information on the preparation of 
quantum dots is somewhat sparse, and literature preparations are not always trivial 
to reproduce. The discussion below includes several observations made during the 




synthesis of quantum dots, some of which are apparently scarcely documented in 
literature. 
Many experimental factors affect the size and size distribution of quantum dots, 
including the Cd:Se ratio, temperature and growth time. In this work, the optimal 
synthesis of quantum dots was achieved via minor modifications to a literature 
method,[48] resulting in orange fluorescent CdSe quantum dots with a narrow size 
distribution, as evidenced from the absorption and fluorescence spectra. This 
method uses a small Cd:Se ratio of 1:10, which is reported to increase the 
quantum yield of fluorescence. A large excess of Se was observed in the CdSe 
QDs by ICP-MS (1:8) when a ratio closer to 1:1 may be expected, or indeed 
excess cadmium,[55] and this may arise from insufficient washing of the product, 
resulting in an excess of Se starting material (or its oxide) in the CdSe quantum 
dots tested.  
Varying the growth time is the simplest way to prepare CdSe quantum dots of 
different sizes; however, since at longer growth times a wider range of sizes will 
be present statistically, it is more difficult to obtain larger dots in a narrow size 
distribution. It was also observed that further growth of CdSe dots following their 
isolation is not possible: an attempt was made to encourage the growth of a batch 
of dots with an uneven size distribution by reheating to 493 K in TOPO, however 
this was unsuccessful and resulted in a loss of fluorescence after heating. 
The solubility of CdSe quantum dots appeared to vary with their size; with 
smaller dots requiring a more polar solvent mixture for solubilisation. In addition, 
it was observed that the total drying of quantum dots renders them insoluble, with 
only extensive sonication aiding redissolution. This is seemingly poorly 
documented in literature and yet was found to be true for all dots synthesised, 
including the water soluble CdSe–ZnS/DHLA QDs; it is likely to result from 
aggregation of the surface ligands upon drying. Therefore, care was taken not to 
completely dry samples of solid dots prior to further use; alternatively they were 
stored in solution under an inert gas.  




The coating of the CdSe core with a “shell” of a higher bandgap material, 
typically ZnS, greatly enhances the luminescence properties and photochemical 
stability of the quantum dot.[56] The shell acts to saturate surface defects, thus 
preventing oxidation or interactions of exposed Se core atoms, and also minimises 
non-radiative recombination of electron-hole pairs, thereby increasing the 
fluorescence quantum yield approximately three-fold.[57] In this work, coating was 
typically performed on pre-isolated samples of CdSe, although coating in situ 
immediately following CdSe growth was also possible. A number of observations 
were made during coating attempts in this work; firstly, it is best to prepare fresh 
solutions of the Zn and S precursors, since storage leads to formation of a white 
film, presumably of ZnS, and the solution becomes ineffective. Secondly, the 
literature description for the reduction in temperature between injection of the 
coating solution (483 K) and growth phase (383 K) is ambiguous. It was found 
that altering the temperature of the hotplate and allowing the flask to cool slowly 
resulted in a loss of fluorescence, whereas rapid cooling with compressed air 
followed by transfer to a hotplate preset to 383 K yielded much better results. 
Additionally, several literature preparations report the use of tributylphosphine 
(TBP) rather than trioctylphosphine (TOP) as the solvent for the ZnS solution;[58] 
attempts in this case found that the viscous liquid TBP persisted and was very 
difficult to remove, preventing precipitation of the dots from the reaction solution 
and, furthermore, quenching the fluorescence. It was believed TOP is a better 
solvent for this reaction since it is readily oxidised to TOPO, which is already 
present in the reaction as the capping ligands for the quantum dots. 
Aqueous solubility is achieved by exchange of the organic capping ligand TOPO 
for amphiphilic alternatives, typically thiols which show a high affinity for the 
ZnS shell. Dihydrolipoic acid (DHLA) is a common choice due to the stability 
provided by its bidentate mode of coordination; in this case exchange was 
achieved by the stirring of TOPO-capped CdSe–ZnS QDs in neat DHLA. 
However, whilst imparting aqueous solubility, thiols such as DHLA are known to 
quench the fluorescence of quantum dots to some degree,[49] hence a balance is 




necessary. However, even in a large excess of DHLA a small proportion of dots 
was found to undergo minimal cap-exchange, as evidenced by their insolubility in 
water at the end of the experiment. 
Sephacryl S-200 was found to be a suitable medium for purification of water-
soluble quantum dots by FPLC, enabling their isolation from what were believed 
to be polymeric thiol species. Such species may have a quenching effect on the 
fluorescence of the quantum dot, or could potentially participate in side reactions 
upon attempts to functionalise CdSe–ZnS/DHLA QDs. Gel filtration 
chromatography is common for the purification of bioconjugates of quantum 
dots,[59] however there appears to be little precedence for the purification of 
CdSe–ZnS/DHLA QDs in this way. 
 
4.3.4.2 Functionalisation Techniques and Platination 
4.3.4.2.1 Small-molecule Amine Ligand 
The carboxylate groups of DHLA are known to participate in common cross-
linking reactions to enable functionalisation of quantum dots.[60] In this work, an 
amide coupling with a small-molecule primary amine was attempted and evidence 
of functionalisation was obtained, although the resulting conjugate showed poor 
aqueous solubility, requiring a strong base for dissolution. It has been previously 
reported that EDC couplings with CdSe–ZnS/DHLA QDs typically result in 
aggregate build-up, due to a lack of affinity for water once the carboxylate groups 
are reacted.[49] Platination was successful as evidenced by ICP-MS, and further 
reduced the solubility; perhaps unsurprisingly so since neutral PtII complexes 
often show poor water solubility, and this rendered the conjugate unsuitable for 
any further testing. It was therefore decided to investigate functionalisation with 
biomolecules, to impart aqueous solubility to the conjugates, to introduce distance 
between the platinum and the fluorophore in order to minimise quenching by the 
metal, and to allow the possibility of selective tumour targeting. 





Conjugation of glucosamine to CdSe–ZnS/DHLA QDs via an EDC-mediated 
amide coupling was successful, as evidenced by 1H NMR spectroscopy. 
Formation of a quantum dot conjugate with monomeric glucosamine is apparently 
unreported, although coupling to chitosan, a glucosamine-based polysaccharide, 
has been previously described.[61] The OH groups of QD–Glu are thus free for 
further derivatisation if required. An initial attempt using bromoacetic acid was 
unsuccessful and led to precipitation of the quantum dots, although it may be 
possible to derivatise these groups successfully via a different route. 
 
4.3.4.2.3 Transferrin 
The conjugation of quantum dots to proteins is of increasing interest in biosensing 
and imaging applications. One strategy exploits electrostatic self-assembly, 
whereby positively charged His-tagged proteins can interact with negatively 
charged DHLA-capped quantum dots, whilst another common approach involves 
binding of biotinylated proteins to streptavidin-coated quantum dots.[49,54] 
Transferrin has been conjugated to quantum dots via the latter method,[42] and 
found to internalise into cells via endocytosis in a manner similar to that of 
transferrin alone. Additionally, covalent binding of the protein to lysine-coated 
CdSe/CdS/ZnS quantum dots has also been reported for the imaging of pancreatic 
cancer.[62] It was believed in this case that the conjugation of transferrin to 
quantum dots, with subsequent derivatisation to incorporate a platinum binding 
ligand, would provide a more successful route to a platinated quantum dot, and 
furthermore aid the internalisation of a platinum-dot conjugate; it has been 
demonstrated previously that the reactivities of many types of biomolecules have 
been found to remain after conjugation to quantum dots.[40] 
 




Initial attempts to conjugate the lysine amino groups of transferrin with DHLA 
employed EDC as a carboxyl-activating reagent and resulted in the precipitation 
of protein. The addition of sulfo-NHS was beneficial; this reagent is typically 
employed to increase the efficiency of the coupling reaction, however in this case, 
and in the case of the organic amine ligand, it was found to circumvent the 
problem of precipitation during the coupling reaction with EDC alone.  
Evidence of transferrin binding was provided by the titration with FeIII resulting in 
the growth of an absorption band arising from the tyrosine oxygen-FeIII LMCT 
transition; this was found to be a simple way to determine conjugation. Other 
methods, such as iron supplementation followed by ICP-MS determination of iron 
content, could be unreliable due to the potential loss of iron from the protein and 
the ubiquitous nature of the metal. 
It was observed that the conjugation of transferrin to form QD–Tf, and all 
subsequent reactions with the product, were best performed at low concentrations 
(1–2 µM) to avoid precipitation of the quantum dots. In particular, the addition of 
sulfo-NHS and EDC led to a fall in pH often sufficient to induce precipitation of 
the dots on larger scales. This was partially overcome by the use of a higher 
strength buffer, however reactions were typically more reliable on smaller scales. 
The decreased stability of the dots once biomolecules were bound was evident, 
necessitating more gentle conditions, such as centrifuging at lower speeds or 
alternatively the use of dialysis. 
The subsequent reaction with the primary amino group of L6 proceeded via a 
sulfo-NHS/EDC coupling as described, followed by platination with an excess of 
K2PtCl4. ICP-MS data indicated a very large degree of platinum binding, the 
reason for which is unclear. The control reaction, in which the platinum salt was 
reacted with QD–Tf directly, showed much lower levels of platinum indicating a 
reduced degree of non-specific binding to transferrin. However it could be 
possible that such binding occurred to a greater extent in the reaction of QD–Tf–
L6; there are typically many potential platination sites available on proteins, and 




binding of platinum to transferrin has previously been established.[63] Further 
work would be necessary in order to confirm this. 
 
4.3.4.3 ICP-MS of Quantum Dots and Conjugates 
The use of ICP-MS to determine elemental concentrations of quantum dots and 
their conjugates was unreported until very recently,[55] but is a very useful method 
for determining not only the ratios of elements comprising the dot, but also, in this 
case, as evidence for and quantification of the conjugation of platinum, which 
would be difficult to determine by alternative analytical techniques. 
 
4.3.4.4 Cytotoxicity of Quantum Dot Conjugates 
The cytotoxicity of quantum dots is a matter of much interest, since it hinders at 
present any potential in vivo application. Toxicity is seen at micromolar levels, 
and although the exact mechanisms are yet to be established, it has been related to 
free cadmium ions and to the generation of reactive oxygen species.[64] It was 
therefore of interest to assess the cytotoxicity of the water soluble CdSe–
ZnS/DHLA QDs alone, as well as QD–Tf, to compare to that of the platinum 
conjugate. Both species showed moderate cytotoxicity, with IC50 values in the 
range of 20–40 µM. Further data would be required to assess any differences 
between the cytotoxicity of the two; it may be expected that the transferrin 
conjugate would be more toxic, since it is more readily internalised into the cell 
via TfR1. 
The inactivity of the platinated transferrin conjugate QD–Tf–L6–Pt (19) is 
surprising, since the majority of PtII chlorido complexes show some degree of 
toxicity at this concentration; furthermore both CdSe–ZnS/DHLA QDs and QD–
Tf show moderate cytotoxicity at equimolar cadmium concentrations. This 
therefore suggests that 19 is unable to enter cells following platination. CdSe–
ZnS/DHLA QDs are known to be able to penetrate the cell membrane via passive 




delivery (although still via endocytosis)[65] and transferrin is readily internalised 
by endocytosis upon binding to TfR1;[53] indeed, the protein has previously been 
employed to increase cellular uptake of drug molecules with selective targeting of 
cancer cells. The ICP-MS data suggest a high degree of platination of the 
transferrin conjugate, and it is likely this would have a great effect on the surface 
properties of the quantum dots, such as charge and hydrophobicity; this may 









4.4 Platinum Complexes with Porphyrins 
4.4.1 Introduction 
Porphyrins are macrocyclic compounds consisting of four pyrrole units connected 
by methine bridges. They are highly conjugated, aromatic systems and as such 
display intense absorption in the visible region. The centre of the porphyrin forms 
a cavity in which metal ions can be accommodated, bound by the four nitrogens 
of the pyrrole rings. Such compounds are termed metalloporphyrins and are 
ubiquitous in Nature. The haem prosthetic group, consisting of an iron porphyrin, 
is essential to many metalloproteins such as haemoglobin, myoglobin and the 
cytochromes, and is involved in oxygen and electron transfer; in addition, many 
related structures carry out similar biological functions. 
Porphyrins have found medicinal applications in photodynamic therapy (PDT), a 
technique involving the selective damage of tissue using a photosensitising drug, 
light and oxygen, which is used in the treatment of certain cancers and skin 
conditions. The majority of photosensitisers are porphyrins or related molecules, 
which can be excited by the wavelengths of light which show the deepest 
penetration through human skin (600–1000 nm).[66] Irradiation of the 
photosensitiser induces excitation to a singlet excited state, 1PS*, which can 
undergo intersystem crossing (ISC) to the triplet excited state, 3PS*; this process 
is relatively efficient in the case of tetrapyrrolic systems. From here, the 
photosensitiser can react in two ways, defined as Type I or Type II processes.[67] 
Type II processes involve the direct interaction of 3PS* with molecular oxygen; 
since this has a triplet ground state the interaction results in triplet-triplet 
annihilation, regenerating the ground state of the photosensitiser and forming 
singlet oxygen, 1O2, which shows high and indiscriminate reactivity with 
biomolecules and is largely responsible for the cytotoxic effects of PDT. Type I 
processes involve either reduction or oxidation of the photosensitiser by biological 
substrates, generating free radicals which react rapidly with molecular oxygen and 




form numerous reactive oxygen species, including O2
•
 
–, OH•, OH– and H2O2; 
these are also expected to contribute to cell death.  
An advantage of porphyrins for this purpose is their selective uptake into tumour 
cells over healthy cells;[68] it is believed porphyrins are transported by low density 
lipoproteins (LDL) which are internalised via receptor mediated endocytosis, and 
cancer cells are known to express elevated levels of LDL receptors.[69] Given the 
success of porphyrins in PDT and their tumour accumulating properties, there has 
been increasing interest in the incorporation of porphyrins into cytotoxic PtII 
complexes, to potentially yield complexes with a dual mode of action.[68] One 
study found significant tumour accumulation of such complexes,[70] and another 
reported a series of Pt-porphyrin conjugates that showed both phototoxicity upon 
irradiation and cytotoxicity due to the platinum fragment.[68] 
It was therefore hypothesised that a PtII azido complex containing a porphyrin 
could show interesting photochemical behaviour, given the rich photochemistry of 
both moieties alone. The azide anion is known to be an efficient quencher of 
singlet oxygen;[71] however this may be negated upon photoactivation if the 
porphyrin were to become dissociated and distant from the platinum moiety, or 
perhaps alternative photoactivation pathways could be induced. Furthermore, 
porphyrins exhibit strong absorbance in the visible region and may therefore 
allow for activation of a PtII azido complex at these wavelengths. In this section, 
the synthesis and photochemistry of a PtII chlorido and a PtII azido complex 




Pyrrole (≥ 97%), 4-pyridinecarboxaldehyde (>96%), propionic acid (99%), and 
5,10,15,20-Tetra(4-pyridyl)porphyrin (97%) were purchased from Sigma-Aldrich.  
Benzaldehyde (>99%), pyridine (anhydrous, reagent grade) and sodium azide 




were obtained from Fisher. cis-[Pt(DMSO)2Cl2] and K[PtNH3Cl3] were 
synthesised as described in Chapter 3. All column chromatography was carried 
out using silica gel (60 Å), and under subdued laboratory lighting conditions in 




4-Pyridinecarboxaldehyde (2.5 mL, 26 mmol) and benzaldehyde (7.5 mL, 
74 mmol) were added to propionic acid (250 mL) in a round-bottomed flask. The 
solution was heated to reflux (423 K), after which pyrrole (7.0 mL, 100 mmol) 
was added dropwise over a 20 min period. The mixture was heated at reflux for 
1 h with vigorous stirring, then cooled for 6 h at room temperature and stored at 
277 K overnight. A purple solid (2.72 g) was collected by filtration, and washed 
with methanol until the filtrate ran colourless. The product was purified by 
column chromatography, with the desired porphyrin eluting as the second band 
with 99% CHCl3/1% EtOH. 
Yield: 0.57 g (3.7%)  
Rf = 0.45 (98:2 CHCl3:EtOH) 
1H NMR (400 MHz, CDCl3): δ 9.03 (d, 2H), 8.90–8.79 (m, 8H), 8.22 (d, 6H), 
8.18 (d, 2H), 7.78 (m, 9H), –2.80 (s, NH, 2H).   
ESI-MS:  616.2499 [M + H]+, C43H30N5 requires 616.2496 m/z. 
 
Cis-[Pt(PyTPP)(DMSO)Cl2] 
5-(4-Pyridyl)-10,15,20-triphenylporphyrin (PyTPP) (64.5 mg, 0.105 mmol) was 
dissolved in dichloromethane (20 mL), and to this was added cis-[Pt(DMSO)2Cl2] 
(48 mg, 0.116 mmol) in dichloromethane (10 mL). The mixture was stirred 
overnight at room temperature in the dark, after which all solvent was removed. 




The crude product was purified by column chromatography, with the required 
product eluting as the main band with 95% CHCl3/5% EtOAc. 
Yield: 75 mg (74%)  
Rf = 0.64 (5:1 CHCl3:EtOAc)  
1H NMR (400 MHz, CDCl3): δ 9.18 (d, 2H), 8.95–8.76 (m, 8H), 8.28 (d, 2H), 
8.22 (d, 6H), 7.78 (m, 9H), 3.62 (s, 6H),  –2.77 (s, NH, 2H).   
ESI-MS:  960.1668 [M + H]+ , PtC45H36N5Cl2OS requires 960.1660 m/z. 
 
Cis-[Pt(PyTPP)(Py)Cl2] (20) 
Cis-[Pt(PyTPP)(DMSO)Cl2] (61 mg, 0.064 mmol) was dissolved in chloroform 
(15 mL), pyridine (6.13 µL, 0.076 mmol) was added, and the mixture heated at 
reflux for 24 h in the dark. Solvent was removed and the crude product purified by 
column chromatography. The required product eluted as the second band using a 
solvent system of 5:1 CHCl3:EtOAc. 
Yield: 15 mg (25%)  
Rf = 0.90 (5:1 CHCl3:EtOAc)  
1H NMR (400 MHz, CDCl3): δ 9.35 (d, 2H), 9.07 (d, 2H), 8.94–8.79 (m, 8H), 
8.22 (d, 6H), 8.18 (d, 2H), 7.87 (t, 1H) 7.79 (m, 9H), 7.42 (t, 2H), –2.80 (s, NH, 
2H).  
ESI-MS:  961.1965 [M + H]+, PtC48H35N6Cl2 requires 961.1943 m/z. 
 
Cis-[Pt(PyTPP)(Py)(N3)2] (21) 
Cis-[Pt(PyTPP)(Py)Cl2] (20) (15 mg, 0.016 mmol) was dissolved in 
dimethylformamide (4 mL), and to this was added a solution of NaN3 (10 mg, 
0.160 mmol) in methanol (1.5 mL). The mixture was stirred in the dark for 48 h, 
after which H2O (50 mL) was added and the solution lyophilised. The product was 




washed with water then purified by column chromatography; the required product 
eluted as the main band with 5:1 CHCl3:EtOAc. 
Yield: 4 mg (26%)  
Rf = 0.85 (5:1 CHCl3:EtOAc)   
1H NMR (400 MHz, CDCl3): δ 9.22 (d, 2H), 9.00 (d, 2H), 8.94–8.78 (m, 8H), 
8.30 (d, 2H), 8.21 (d, 6H), 7.96 (t, 1H) 7.79 (m, 9H), 7.56 (t, 2H), –2.80 (s, NH, 
2H).   
UV-Vis (DMF): λmax 418, 514, 549, 590, 646 nm; ε 290 000, 18 100, 7300, 5400, 
3600 M-1 cm-1. 




Saturated solutions of cis-[Pt(PyTPP)(Py)Cl2] (20) and cis-[Pt(PyTPP)(Py)(N3)2] 
(21) in DMF-d7 were irradiated at 310 K in an LZC-ICH2 photoreactor equipped 
with LZC-VIS UV-Visible light lamps (λ = 400–700 nm, P = 0.27 mW cm-2), 
with 1H NMR spectra recorded after 0, 30, 60 and 120 min in the case of 20, and 
0, 5, 10, 20, 30, 60 and 120 min for 21. 
 
4.4.3 Results 
A porphyrin was synthesised incorporating one pyridyl group to act as a ligand for 
platinum, and subsequently reacted to form novel PtII chlorido and azido 
complexes. The photochemical behaviour of both complexes was investigated 
upon irradiation with visible light. 
 
 








1 h, 423 K
PyTPP
4.4.3.1 Synthesis and Characterisation of PyTPP and Platinum Complexes 
A simple porphyrin, 5-(4-Pyridyl)-10,15,20-triphenylporphyrin (PyTPP), was 
chosen, containing three phenyl rings and one pyridyl ring bound to the methine 
bridges of the porphyrin core. This was synthesised as previously described,[72,73] 
by an Adler-type condensation of pyrrole, benzaldehyde and 









Scheme 4.6  The synthesis of PyTPP. 
  
The crude product consisted of a mixture of at least 5 different porphyrin species 
as shown by TLC. The major product was tetraphenylporphyrin, with small 
quantities of bis-pyridyl species also present as well as the required mono-pyridyl 
product. This was isolated by column chromatography and characterised by 
1H NMR spectroscopy and mass spectrometry. The synthetic routes to the PtII 
complexes of this porphyrin are shown in Scheme 4.7. 
 







































Scheme 4.7  Synthetic routes to PtII complexes of PyTPP. 
 
Coordination of platinum was achieved by the reaction of PyTPP with the PtII 
complex cis-[Pt(DMSO)2Cl2], as previously described.
[75] The 1H NMR spectrum 
showed clear evidence of the retention of one DMSO ligand in the complex. A 
singlet arising from six protons was seen at 3.62 ppm and, in contrast with the 
platinum starting material, platinum satellites were not evident. Satellites can be 
broadened by chemical shift anisotropy relaxation, and large molecules tumble 
slowly, hence relaxation becomes more significant and can result in the 
broadening of satellites beyond detection;[76] the peaks of the pyridyl protons 
closest to the bound nitrogen also showed no visible satellites. The signal 
corresponding to the internal pyrrole protons, appearing at high field (–2.80 ppm) 
as a result of shielding by the ring current, was also still present in the complex 




confirming the platinum was not coordinated inside the porphyrin cavity. 
Replacement of the remaining DMSO ligand of cis-[Pt(PyTPP)(DMSO)Cl2] was 
achieved by reaction with pyridine to form the novel complex cis-
[Pt(PyTPP)(Py)Cl2] (20), although this reaction was low-yielding and significant 
quantities of the free porphyrin were observed.  The chlorido groups were then 
directly exchanged with azide via a well-documented method using NaN3 in 
DMF/MeOH,[77] to form the azido complex cis-[Pt(PyTPP)(Py)(N3)2] (21). 
Attempts were also made to synthesise a multinuclear complex via the attachment 
of platinum to all four pyridyl groups of tetrapyridylporphyrin (TPyP). Reaction 
of this porphyrin with cis-[Pt(DMSO)2Cl2] was attempted in a similar manner to 
that of Scheme 4.7; an alternative method involved reaction with K[Pt(NH3)Cl3], 
in which the porphyrin should replace the chlorido group cis to the ammonia 
ligand. However, all attempts to form a multinuclear complex were unsuccessful. 
Although a purple product was precipitated in all cases, this was invariably 
insoluble in most common solvents, with DMF-d7 the only solvent in which NMR 
spectra could be obtained. Whilst the spectra did indicate reaction had taken place, 
the products were not clean and could not be identified, and the poor solubility in 
any solvents suitable for column chromatography prevented purification attempts. 
  
4.4.3.2 UV-Vis Spectroscopy of cis-[Pt(PyTPP)(Py)(N3)2] (21) 
The UV-visible absorption spectrum of cis-[Pt(PyTPP)(Py)(N3)2] (21) in DMF is 










































Figure 4.16  The UV-visible absorption spectrum of [Pt(PyTPP)(Py)(N3)2] (21), 
with (inset) an expansion of the Q band region. 
 
The intense band at 418 nm is known as the B band, or Soret band, and arises 
from a π-π* transition from the ground state to the second excited singlet state.[78] 
The bands in the lower energy region are known as Q bands, the number and 
relative intensity of which depends upon the substituents on the pyrrole or meso 
carbons and whether or not the porphyrin is metallated; in free base porphyrins 
such as this, four bands are seen. Their intensity is much lower than that of the 
Soret band, since they arise from pseudoparity forbidden transitions to the first 
singlet excited state. The absorption bands of the platinum complexes are virtually 
unchanged from those of the uncoordinated porphyrin, hence platinum 
coordination to the pyridyl ring does not seem to significantly perturb the 
electronic properties of the porphyrin system.[75] 
 




4.4.3.3 Photoreactions of [Pt(PyTPP)(Py)Cl2] (20) and [Pt(PyTPP)(Py)(N3)2] 
(21) with Visible Light 
 
a) [Pt(PyTPP)(Py)Cl2] (20) 
After 30 min a new singlet had emerged at 10.41 ppm, which increased in 
intensity upon further irradiation (Figure 4.17). This was believed to arise from 
hydrogen peroxide, with evidence provided by the growth of this peak upon 
spiking the irradiated sample with 4 µL of a 30% H2O2 solution. Hydrogen 
peroxide is known to be among the reactive oxygen species potentially formed 
upon irradiation of porphyrins, and unlike others is detectable by 1H NMR 
spectroscopy. 
There was little change in the aromatic region throughout the experiment, except 
for a slight decrease in intensity of the signals. However, several smaller peaks 
were formed at low field. After 30 min a singlet was apparent at 11.50 ppm, 
however this decreased in intensity upon further irradiation. Conversely, a peak at 
12.09 ppm steadily increased in intensity throughout the experiment. It was 
thought the latter peak could arise from the pyridyl protons of a PtIV complex, 
formed upon oxidation of the PtII species by the hydrogen peroxide generated in 
situ. An NMR spectrum was thus run 36 h after spiking the irradiated sample with 
H2O2, however there was no increase in intensity of the peak at 12.09 ppm. To test 
if an oxidation reaction could be facilitated by irradiation, the spiked sample was 
irradiated for 30 min, however again no increase in this peak was found, 
suggested the assignment as a PtIV species may be incorrect. 
Irradiation of the free porphyrin PyTPP produced only a very small quantity of 
H2O2 after 30 min (not illustrated). It is suggested that the increased yield in the 
case of the PtII chlorido complex could be due to the heavy-atom effect. Singlet 
oxygen production, upon which formation of H2O2 is likely dependent, arises 
from the interaction of oxygen with a triplet excited state of the photosensitiser; 
this triplet state is produced via intersystem crossing from a singlet excited state. 









A heavy metal in the molecule can increase the rate of intersystem crossing (the 



































Figure 4.17  1H NMR spectra recorded in DMF-d7 at various timepoints during 
the irradiation of [Pt(PyTPP)(Py)Cl2] (21) with visible light. 




b) [Pt(PyTPP)(Py)(N3)2] (21) 
In the case of the PtII azido complex changes were seen in the aromatic region 
after 5 min irradiation; notably the emergence of two small peaks around the 
doublet at 8.68 ppm, and new peaks slightly downfield of the pyridyl protons at 
9.37 ppm. It is likely these arise from species which have undergone loss of the 
azido ligands; this is a known photochemical reaction of PtII azido complexes, and 
has been demonstrated in Chapter 3. These new peaks increase in intensity upon 
further irradiation, with a concomitant decrease in intensity of the peaks from the 
initial complex. 
Contrary to the case of [Pt(PyTPP)(Py)Cl2] (21), only very small amounts of 
hydrogen peroxide were detected upon irradiation of the PtII azido complex. It is 
suggested this could be due to the known quenching effect of the released azide 
anions on singlet oxygen (1O2), which is a precursor to the generation of hydrogen 
peroxide upon irradiation of porphyrins. 
There is no evidence of new peaks around 11–12 ppm. This observation suggests 
the peaks seen upon irradiation of the PtII chlorido complex (20) may indeed be 
related to the formation of hydrogen peroxide, although such evidence was not 
found in that particular experiment. 


































Figure 4.18  1H NMR spectra recorded in DMF-d7 at various timepoints during 
the irradiation of [Pt(PyTPP)(Py)(N3)2] (21) with visible light. 




4.4.4 Discussion  
4.4.4.1 Synthesis of PyTPP and Platinum Complexes 
For an initial study of the photochemistry of PtII chlorido and azido complexes 
containing porphyrins, a simple porphyrin was chosen with one pyridyl ligand for 
coordination to platinum (PyTPP). This porphyrin was synthesised according to 
published procedures,[72,73] although was obtained in a typically low yield, since 
reactions to produce mixed aryl porphyrins can potentially form six different 
porphyrin products. One report[72] suggests a higher yield can be obtained by 
using an excess of 4-pyridinecarboxaldehyde compared with benzaldehyde 
(1.18:1). However in this work, whilst this method was found to be successful in 
reducing the proportion of tetraphenylporphyrin in the product, relatively large 
quantities of the two bis-pyridyl porphyrin isomers were also formed. These were 
difficult to separate from the required monopyridyl product by column 
chromatography due to their very similar Rf values; additionally, increases in 
yield were only modest. Hence an alternative method using an excess of 
benzaldehyde was preferred.[73] 
Although the platination of the porphyrin with cis-[Pt(DMSO)2Cl2] proceeded in 
good yield to form cis-[Pt(PyTPP)(DMSO)Cl2], attempts to replace the remaining 
DMSO ligand with pyridine led to significant quantities of free PyTPP. At room 
temperature, detachment of the porphyrin from the platinum centre was found to 
predominate, with only very small quantities of the desired product detected by 
TLC. Heating the reaction to reflux led to a greater proportion of the required 
product cis-[Pt(PyTPP)(Py)Cl2] (20), evidently replacement of the second DMSO 
ligand requires elevated temperatures as previously suggested,[75] although free 
PyTPP was still evident. It is likely that pyridine has an affinity for platinum 
similar to or greater than that of PyTPP, hence is able to readily displace the 
porphyrin. A similar displacement of PyTPP was found upon reaction of 20 with 
sodium azide, although to a lesser extent. This problem could be overcome by the 
use of a different aromatic amine ligand with a lower affinity for platinum, or by 




the coordination of platinum to a chelating amine moiety on a porphyrin, which 
would impart greater stability to the complex. 
It was believed that a complex containing multiple platinum centres bound to one 
porphyrin could show interesting DNA interactions and photochemical properties. 
Indeed, very recent studies of ruthenium and osmium complexes of tetrapyridyl 
porphyrin have found such complexes are both cytotoxic and phototoxic upon 
irradiation with red light, and their fate inside cells can be followed by the 
fluorescence of the porphyrin moiety.[79,80] Attempts were made to form an 
analogous platinum complex in this work, however these were not successful. 
Since it was desirable to retain two chlorido ligands in the product to allow for 
potential cross-linking to DNA, as well as two amine ligands, the target 
complexes were neutral and thus the reaction products showed very poor 
solubility; previous examples of PtII complexes of tetrapyridylporphyrin have a 
high positive charge overall.[81] However, it may also be of interest to prepare a 
charged monochlorido or monoazido complex, since the DNA interactions of such 
a complex are likely to be very different from those of cisplatin-type complexes. 
 
4.4.4.2 Photoreactions of Porphyrin-containing Platinum Complexes 
The apparent formation of hydrogen peroxide upon irradiation of the chlorido 
complex [Pt(PyTPP)(Py)Cl2] (20), but not of the azido complex 
[Pt(PyTPP)(Py)(N3)2] (21), is interesting. Typically, the irradiation of porphyrins 
yields singlet oxygen by reaction of the excited photosensitiser with molecular 
oxygen, and this is believed to be the primary cause of cell death in PDT. The 
generation of many other reactive oxygen species, including hydrogen peroxide, is 
also possible, although these are typically formed as a result of the initial reaction 
of the excited photosensitiser with biological substrates to form radicals, which 
subsequently interact with oxygen.[67] Indeed, there are reports of the detection of 
H2O2 in in vitro experiments of cells treated with photosensitisers and light,
[82,83] 




with biomolecules such as ascorbate[84] and NADPH oxidase[83] implicated in its 
formation. 
The irradiation study of 20 was carried out on the porphyrin alone, however there 
are some studies to suggest the formation of hydrogen peroxide from the 
irradiation of porphyrins in the absence of biological substrates.[85,86] These 
suggest formation is dependent upon the substituents on the porphyrin and 
whether or not it aggregates in aqueous solutions, however the mechanism of 
hydrogen peroxide generation was not discussed. Knör and Vogler report the 
formation of hydrogen peroxide from the irradiation of an aerated ethanolic 
solution of a SbIII porphyrin, with concurrent oxidation of the metal to the SbV 
state;[87] however, since the PtII complex 20 is likely to show markedly different 
chemistry from a SbIII metalloporphyrin, comparisons cannot readily be drawn. It 
is suggested in this work that the hydrogen source could be H2O, which is present 
in significant quantities in the DMF-d7 in which the spectra were obtained. 
It is known that hydrogen peroxide can be produced in relatively small amounts as 
a secondary oxidant after initial singlet oxygen formation.[83] The generation of 
hydrogen peroxide in this way could account for its lack of formation upon 
irradiation of the azido complex 21. It is known that PtII azido complexes can 
release free azide upon photoactivation,[88] and the azide anion is a very efficient 
quencher of singlet oxygen.[89] Should quenching occur, this would minimise the 
amount of singlet oxygen that could subsequently form hydrogen peroxide. 
It is clear that many more studies would need to be performed in order to 
elucidate the photoproducts of the irradiation of 20 and 21. Of all the reactive 
oxygen species that could be produced upon irradiation, 1H NMR can only detect 
hydrogen peroxide, although its presence should ideally be confirmed by another 
method such as the luminol chemiluminescence test.[86] Monitoring changes in the 
UV-visible absorption spectrum may also give valuable information on any 
changes to the porphyrin system. Factors to be determined could include the 
dependence upon oxygen and involvement of singlet oxygen, the role of the 
solvent (although solubility issues would prevent the irradiation of these particular 




porphyrins in aqueous solutions), and the influence of the light source; higher 
energy UV light could give rise to different photoproducts. 
The initial investigation into the photochemistry of these systems is intriguing, 
suggesting that a PtII azido porphyrin complex gives rise to different 
photoproducts from that of a chlorido complex. The question of whether free 
azide quenches the singlet oxygen produced upon irradiation remains to be 
answered. However even if this were the case, it may not necessarily be 
detrimental. Singlet oxygen could react with a variety of biomolecules in vivo, 
where the quenching effect may not be so pronounced; additionally, the rich 
photochemistry of both porphyrins and azido complexes could lead to the 




This Chapter was concerned with the functionalisation of platinum complexes 
with bioactive species.  
The conjugation of the fluorescent probe MIA to [Pt(L1)(N3)2] (5) confirms the 
possibility of functionalisation of the pendant hydroxyl group. The relatively large 
degree of fluorescence quenching in comparison to that of the free probe suggests 
a longer spacer length between the probe and platinum may be desirable in the 
design of complexes for intracellular fluorescence monitoring applications; 
however, the large increase in fluorescence should the probe become detached 
from the platinum may also be of use in monitoring intracellular reactions. 
The reaction of [Pt(en)(N3)2(OH)2] (3) with MIA yielded a complex in which only 
one axial hydroxyl group of a PtIV azido complex was modified. The rapid 
increase in fluorescence upon irradiation of this complex, as a result of loss of the 
axial groups and reduction to PtII, could be a useful monitor of the reduction event 
and not solely applicable to photoactivated complexes. 
Although the functionalisation of the protected amine groups of PtII and PtIV azido 
complexes was unsuccessful in the isolation of a clean product, the formation of a 




fluorescent sulfonamide indicates some degree of success, and suggests the 
deprotection of such groups is feasible and a valid way of introducing an amine-
reactive moiety into the complex. 
The synthesis of water soluble quantum dots was achieved, however the 
subsequent amide coupling and platinum coordination rendered the resulting 
conjugate insoluble in aqueous solutions. The conjugation of transferrin to 
quantum dots was evidenced by iron uptake studies, and subsequent reactions 
prepared the platinum conjugate which showed good water solubility and 
essentially no fluorescence quenching. However, this conjugate was found to be 
non-cytotoxic towards the A2780 human ovarian cancer cell line, likely as a result 
of extensive surface modification due to the high degree of platination, rendering 
the complex impenetrable through the cell membrane. 
PtII chlorido and azido complexes containing a porphyrin were found to undergo 
differing behaviour upon irradiation with visible light in DMF solution. Evidence 
of H2O2 was seen in the case of the Pt
II chlorido complex but was much reduced 
in the case of the azido analogue; it is suggested that H2O2 production may be 
dependent upon singlet oxygen, which could be rapidly quenched by any azide 
ion release from the PtII azido complex upon irradiation. 
This chapter therefore demonstrates the ability to functionalise platinum azido 
complexes, and suggests that conjugation of bioactive species may be of interest 
in the monitoring of reactions or reduction upon photoactivation, or by generating 
complexes with a novel mode of action upon irradiation. 
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Platinum Complexes with  
Azopyridine Ligands 
 




5.1 Introduction  
In the search for photoactive platinum complexes as potential anticancer agents, 
efforts have focused mainly upon PtIV complexes of the general formula 
[Pt(amine)2(N3)2(OH)2].
[1,2,3] These complexes possess a LMCT band (N3→Pt
IV), 
typically centred around 260–290 nm depending upon the geometry of the azide 
ligands (cis or trans respectively). Irradiation with UVA light effects a 
photoreduction from PtIV to PtII, during which the two azide ligands are lost to 
generate reactive, cytotoxic species. 
For phototherapy applications, the use of visible (ideally red) light is preferable to 
UVA, as it penetrates skin to a greater extent and results in minimised damage to 
surrounding healthy cells.[4] However, these PtIV complexes show little 
absorbance in the visible region, and as such irradiation at these wavelengths is 
less effective compared with UVA. For example, although trans,trans,trans-
[Pt(NH3)(py)(N3)2(OH)2] was found to be as cytotoxic as cisplatin towards HaCaT 
keratinocytes upon irradiation at 420 nm, this complex is over an order of 
magnitude more potent when irradiated with UVA light.[3] In addition, TD-DFT 
calculations indicate 476 nm is the longest predicted singlet transition for this 
complex; the longest wavelength at which the absorption of light is formally 
allowed (L. Salassa, unpublished results). 
Shifting the wavelength of activation to longer wavelengths is therefore a key aim 
in the development of new photoactivatable platinum complexes. Photoreduction 
has thus far been achieved by irradiation into the N3→Pt
IV LMCT band; however, 
shifting this band to significantly longer wavelengths may not be feasible and, in 
order to achieve photoactivity in the visible region, it may be necessary to modify 
the design of the complex. It was believed that the incorporation of highly 
coloured ligands could result in a change in the nature of the absorption bands, the 
desired absorbance at visible wavelengths, and the potential for photoactivity in 
this region. For these reasons, it was decided to investigate platinum complexes 
containing azo compounds as ligands. 




Azo compounds are characterised by the presence of the R–N=N–R’ functional 
group (R/R’ = alkyl or aryl). Due to extensive delocalisation of π electrons 
throughout the system, aryl azo compounds are highly coloured and are widely 
used as dyes; it is estimated that around 60–70% of all dyes used in the food and 
textile industries contain an azo linkage.[5] In addition to their intense colours, azo 
compounds show interesting photochemical behaviour, undergoing reversible cis-
trans isomerisation about the N=N bond upon irradiation.[6] The differing 
geometries and spectral properties of the two isomers means these systems find 
application as molecular photoswitches[7] and in optical data storage.[8]  
Compounds such as 2-(phenylazo)pyridine (azpy) are able to act as chelating 
ligands for metals, coordinating via the pyridyl and aza nitrogens. These ligands 
are of interest due to their excellent π-accepting ability; by receiving electron 
density into the azo π* orbital, they are able to stabilise metals in low oxidation 
states.[9] This is demonstrated by remarkably air-stable azo complexes of Mo0, Cr0 
and W0,[10] and the greater stability of RuII azo complexes compared with those of 
bipyridine.[11] Several ruthenium complexes containing such ligands have been 
reported previously, and our group has recently investigated the anticancer 
activity of RuII arene azopyridine complexes with chlorido and iodido ligands. 
The chlorido complexes show hydrolysis of Ru–Cl and Ru–arene bonds to 
varying extents, and their cytotoxicity may result from interactions with DNA.[12] 
The iodido complexes, however, are inert to hydrolysis and their cytotoxicity is 
thought to arise from an increase in reactive oxygen species (ROS); intriguingly, 
these complexes are also able to catalytically oxidise glutathione.[13] In addition, a 
AuIII complex of azpy has recently been reported,[14] which exhibits cytotoxic 
activity as well as an interesting metal-mediated reaction giving rise to an organic 
cation.  
In contrast to other transition metals, platinum complexes of azo dyes are 
relatively scarce. Cyclometallated azobenzene complexes of PtII and PtIV 
containing catecholato ligands have been reported as liquid crystalline 
materials,[15] and the photochemistry of an azobenzene-conjugated PtII–terpyridine 
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complex has been investigated.[16] However, despite reports of PdII analogues as 
early as 1983,[17] PtII complexes of chelating azopyridine ligands remained 
unexplored until 2001, and only two such studies have been reported to date. 
These have focused upon the spectra and electrochemistry of catecholato 
complexes,[18] and aromatic ring amination reactions on the ligand as well as 
oxidative halogen addition to yield PtIV complexes.[19] However, despite the rich 
photochemistry of both azopyridine ligands and complexes such as [Pt(bipy)2]Cl2, 
photochemical studies of PtII azopyridine complexes are apparently absent in 
literature. 
In this Chapter, the synthesis, characterisation and photochemistry of a series of 
PtII chlorido and azido complexes containing phenylazopyridine ligands are 
described.  The structures of the complexes prepared are shown below.  
 
 
        
 






















2-(Phenylazo)pyridine (azpy) and 4-(2-pyridylazo)phenol (azpyOH) were kindly 
donated by Dr Sarah Dougan, and were synthesised as previously described.[12] 
The former was purified by column chromatography prior to use (silica gel, 
eluting with 100% dichloromethane), whilst the latter was used as received. 
4-(2-pyridylazo)-N,N-dimethylaniline (azpyNMe2) was purchased from 
Sigma-Aldrich, and cis-[Pt(DMSO)2Cl2] was synthesised as described in Chapter 
3.  UV grade dioxane (Sigma-Aldrich) and HPLC grade methanol and water 
(Fisher) were used as solvents for UV-visible spectroscopy. All other reagents 




2-(Phenylazo)pyridine (75 mg, 0.41 mmol) was dissolved in dichloromethane 
(5 mL) and added to a solution of cis-[Pt(DMSO)2Cl2] (174 mg, 0.41 mmol) in 
dichloromethane (30 mL). After five minutes the orange solution began to darken; 
it was then stirred at room temperature for 4 h. The solvent volume was reduced 
and the mixture stored overnight at 277 K. A brick-red solid was filtered off, 
washed with dichloromethane, and dried under vacuum. 
Yield: 165 mg (90%). 
Elemental analysis: Found: C, 29.36; H, 1.86; N, 9.12.  PtC11H9N3Cl2 requires: 
C, 29.41; H, 2.02; N, 9.35%. 
1H NMR (500 MHz, CDCl3): δ = 9.89 (d, 
3J(195Pt-1H) 30 Hz, 1H), 8.56 (d, 1H), 
8.39 (td, 1H), 7.99 (m, 3H), 7.61 (t, 1H), 7.55 ppm (t, 2H). 
ESI-MS:  471.97 [M + Na]+, NaPtC11H9N3Cl2 requires 471.97 m/z. 
 





[Pt(azpy)Cl2] (75 mg, 0.17 mmol) was dissolved in dimethylformamide (10 mL), 
and sonicated to ensure dissolution. To this, a solution of NaN3 (109 mg, 
1.7 mmol) in methanol (6.5 mL) was added, upon which there was an immediate 
colour change from orange to deep pink. The solution was stirred in the dark at 
room temperature for 48 h, after which all solvent was removed by rotary 
evaporation. Water (5 mL) was added to dissolve any excess NaN3, and the 
insoluble black product was filtered off, washed with small quantities of water, 
ethanol and diethyl ether, and dried under vacuum. 
Yield: 66 mg (85%). 
Elemental analysis: Found: C, 28.01; H, 1.82; N, 26.50.  PtC11H9N9 requires: 
C, 28.58; H, 1.96; N, 27.27%. 
1H NMR (500 MHz, CDCl3): δ = 9.21 (d, 
3J(195Pt-1H) 27 Hz, 1H), 8.48 (d, 1H), 
8.34 (td, 1H), 8.05 (d, 2H), 7.94 (t, 1H), 7.65 (t, 1H), 7.58 ppm (t, 2H). 
ESI-MS:  485.05 [M + Na]+, NaPtC11H9N9 requires 485.05 m/z. 
 
[Pt(azpyNMe2)Cl2] (24) 
4-(2-Pyridylazo)-N,N-dimethylaniline (100 mg, 0.44 mmol) was dissolved in 
dichloromethane (20 mL), and added to a solution of cis-[Pt(DMSO)2Cl2] 
(185 mg, 0.44 mmol) in dichloromethane (55 mL). Upon mixing, a colour change 
from orange to blue was observed; the solution was then stirred at room 
temperature for 4 h. The solvent volume was reduced and the mixture stored 
overnight at 277 K. A shiny, green-gold solid was filtered off, washed with 
dichloromethane, and dried under vacuum. 
Yield:  195 mg (90%). 
Elemental analysis: Found: C, 31.62; H, 2.79; N, 11.28.  PtC13H14N4Cl2 requires: 
C, 31.72; H, 2.87; N, 11.38%.  
1H NMR (500 MHz, CDCl3): δ = 9.62 (d, 
3J(195Pt-1H) 30 Hz, 1H), 8.39 (d, 2H), 




8.15 (td, 1H), 8.08 (d, 1H), 7.57 (t, 1H), 6.74 (t, 2H), 3.22 ppm (s, 6H). 
ESI-MS:  498.09 [M - Cl + MeCN]+, PtC15H17N5Cl requires 497.90 m\z. 
 
[Pt(azpyNMe2)(N3)2] (25) 
[Pt(azpyNMe2)Cl2] (25 mg, 0.05 mmol) was dissolved in dimethylformamide 
(5 mL) to give a blue solution. NaN3 (33 mg, 0.51 mmol) in methanol (2 mL) was 
added; no colour change was observed. The solution was stirred in the dark at 
room temperature for 48 h, then water (100 mL) was added and the solution 
lyophilised. To the residue, water (5 mL) was added to dissolve any excess NaN3, 
and the insoluble green solid was filtered off, washed with small quantities of 
water, ethanol and diethyl ether, and dried under vacuum. 
Yield: 19 mg (75%). 
Elemental analysis: Found: C, 30.79; H, 2.74; N, 27.42.  PtC13H14N10 requires: 
C, 30.89; H, 2.79; N, 27.71%. 
1H NMR (500 MHz, CDCl3): δ = 9.01 (d, 
3J(195Pt-1H) 32 Hz, 1H), 8.47 (d, 2H), 
8.12 (t, 1H), 8.02 (d, 1H), 7.54 (t, 1H), 6.78 (t, 2H), 3.24 ppm (s, 6H). 
ESI-MS:  528.09 [M + Na]+, NaPtC13H14N10 requires 528.09 m/z. 
 
[Pt(azpyOH)Cl2] (26) 
4-(2-Pyridylazo)phenol (56 mg, 0.28 mmol) was dissolved in methanol (50 mL) 
and added to a solution of cis-[Pt(DMSO)2Cl2] (100 mg, 0.24 mmol) in methanol 
(100 mL). The mixture was sonicated for five minutes to aid dissolution of the 
starting materials, during which time it began to darken from orange to a deep 
red-brown colour. It was then stirred overnight at room temperature. The volume 
was reduced and the mixture stored at 277 K for 4 h. A shiny brown solid was 
filtered off, washed with methanol and collected in a glass vial. To ensure total 
removal of cis-[Pt(DMSO)2Cl2], dichloromethane (8 mL) was added and the 
mixture stirred, sonicated for 10 sec, then filtered off and collected again. 




Yield: 79 mg (68%). 
Elemental analysis: Found: C, 27.81; H, 2.15; N, 8.82.  PtC11H9N3Cl2O requires: 
C, 28.40; H, 1.95; N, 9.03%. 
1H NMR (400 MHz, MeOD): δ = 9.60 (d, 3J(195Pt-1H) 32 Hz, 1H), 8.59 (d, 1H), 
8.48 (td, 1H), 8.03 (d, 2H), 8.00 (t, 1H), 6.91 ppm (t, 2H). 
ESI-MS:  487.96 [M + Na], NaPtC11H9N3Cl2O requires 486.97 m/z. 
 
Na[Pt(azpyO)(N3)2] (27) 
[Pt(azpyOH)Cl2] (25 mg, 0.05 mmol) was dissolved in dimethylformamide 
(5 mL) to give a dark orange solution. NaN3 (35 mg, 0.54 mmol) in methanol 
(2 mL) was added; there was an immediate colour change to deep blue. The 
solution was stirred in the dark at room temperature for 48 h, then water (100 mL) 
was added and the solution lyophilised. To the residue, water (5 mL) was added to 
dissolve any excess NaN3; the product was also partially soluble, however a 
quantity of black product was isolated and washed with small quantities of water, 
ethanol and diethyl ether, and dried under vacuum. 
Yield: 18 mg (65%). 
Elemental analysis: Found: C, 26.61; H, 1.79; N, 23.95.  PtC11H8N9ONa requires: 
C, 26.41; H, 1.61; N, 25.20%. 
1H NMR (500 MHz, CDCl3): δ = 8.63 (d, 
3J(195Pt-1H) 32 Hz, 1H), 8.46 (d, 2H), 
8.05 (t, 1H), 7.76 (d, 1H), 7.30 (t, 1H), 6.49 ppm (d, 2H). 
ESI-MS:  501.04 [M + H], NaPtC11H9N9O requires 501.04 m/z. 
  





5.2.3.1 X-ray Crystallography 
The crystal structure of 22 was solved by Dr Guy Clarkson at the University of 
Warwick. Data were collected and refined as described in Chapter 2. 
 
5.2.3.2 Computational Methods 
TD-DFT calculations on the azopyridine ligands and platinum complexes were 
carried out with the help of Dr Luca Salassa at the University of Warwick. 
Gaussian 03[20] was employed for all the calculations. Geometry optimisation 
calculations of the ground state were performed in the gas phase with the 
gradient-corrected correlation functional PBE1PBE.[21] The LanL2DZ basis set[22] 
and effective core potential were used for the Pt atom and the 6–31G** basis 
set[23] was used for all other atoms, respectively. Ligands were optimised at the 
PBE1PBE/6–31G** level. The nature of all stationary points was confirmed by 
performing a normal-mode analysis.  
Sixteen singlet excited states for the ligands and thirty-two for the complexes 
were calculated with time-dependent density functional theory (TD-DFT)[24,25] 
employing ground-state geometries optimised in the gas phase. 
The conductor-like polarisable continuum model method (CPCM)[26] with 
methanol as solvent was used to calculate all the electronic structure and excited 
states in solution. The electronic distribution and the localisation of the singlet 
excited states were visualised using the electron density difference maps 
(EDDMs).[27] GaussSum 1.05[28] was used for EDDMs calculations and for the 
electronic spectrum simulation. 
 
 




5.2.3.3 Kinetic Studies of Azopyridine Ligands and Pt
II
 Complexes by UV-
Visible Spectroscopy 
The UV-visible absorption spectra of the ligands azpy, azpyNMe2 and azpyOH, as 
well as the complexes 22–27, were monitored over a 12 h period in dioxane at 
298 K. Sample preparation, carried out under subdued laboratory light, involved 
dissolution of the compound in dioxane, filtration, appropriate dilution and, where 
necessary, addition of acid. To allow for this, a delay of five minutes was set 
between dissolution and recording the first spectrum. Spectra were subsequently 
recorded every 2 min for 1 h, every 5 min for a further 1 h, every 10 min for 3 h, 
then every 30 min for the remaining 7 h. In the case of azpyOH and 
[Pt(azpyOH)Cl2] (26), 10 µL (~3 eq) of 0.01 M HNO3 was added to ensure the 
phenolic group remained protonated. For Na[Pt(azpyO)(N3)2]
 (27), the study was 
carried out in methanol due to the insolubility of the complex in dioxane. 
 
5.2.3.4 Stability of Complex 27 in Aqueous Solution and Cell Culture 
Medium 
The stability of Na[Pt(azpyO)(N3)2]
 (27) in aqueous solution was monitored at 
310 K over a 12 h period by UV-visible spectroscopy. Following dissolution of 
27, spectra were recorded every 2 min for 1 h, every 5 min for a further 1 h, every 
10 min for 3 h, then every 15 min for the remaining 7 h. 
The stability of this complex was also assessed under solution conditions similar 
to those employed in cytotoxicity testing. Following dissolution of the complex in 
DMSO, appropriate dilutions were performed so that the final solution comprised 
1% DMSO, 12.5% saline (0.9% solution) and 86.5% RPMI-1640 medium. Since 
the medium is pink in colour, a solution of the same composition but without 
complex was used as a baseline for the UV-visible absorption spectra, so that any 
absorbance observed was solely from the complex.  




5.2.3.5 Stability of Pt
II
 Complexes in Acetone 
The stability of complexes 22–27 was monitored over time by 1H NMR 
spectroscopy. Saturated solutions of the complexes were prepared in acetone-d6 
and a spectrum recorded immediately following dissolution (~5 min); spectra 
were then re-recorded after 1, 3, 6, 18 and 113 d. Samples were stored at ambient 
temperature in the dark between measurements. 
 
5.2.3.6 Cytotoxicity Testing 
Experiments to determine the cytotoxicity of 27 towards human ovarian A2780 
cancer cell lines were performed by Dr Ana Pizarro at the University of Warwick, 
according to the procedure outlined in Chapter 2. 
 
5.2.3.7 Photoreactions 
Photoreactions of complexes 22–26 in dioxane, and complex 27 in methanol, 
were monitored by UV-visible spectroscopy. For all complexes, irradiations were 
performed using a LZC-ICH2 photoreactor equipped with LZC-UVA lamps 
(λmax = 365 nm, P = 1.7–2.2 mW cm
-2) and LZC-VIS UV-Visible light lamps 
(λ = 400–700 nm, P = 0.27–0.29 mW cm-2). For complexes 22 and 23, irradiations 
in the visible region were also carried out using four green LEDs (λmax = 525 nm, 
P = 0.19 mW cm-2). For complex 24, non-irradiated controls were included, as the 
spectral profile of this complex changed over time in the dark. These controls 
were placed in the photoreactor but covered in tinfoil to avoid exposure to light. 
Further details and the spectral outputs of all light sources can be found in Chapter 
2. 
All irradiations were carried out at 298 K unless otherwise stated, with spectra 
recorded after the following total irradiation times: 30 s, 1, 2, 3, 5, 10, 15, 20, 30, 
45, 60, 90 and 120 min. 




5.2.3.8 Phototoxicity Testing 
The phototoxicity of complex 27 towards the HaCaT keratinocyte human skin cell 
line was determined by Dr Julie Woods and Kim Robinson at the Photobiology 
Unit in Ninewells Hospital, Dundee, as described in Chapter 2. 
 
5.2.3.9 Fluorescence Spectroscopy 
Fluorescence spectra of the ligands azpy, azpyNMe2 and azpyOH, and of 
complexes 22–27, were obtained at 298 K in dioxane.  The excitation wavelength 
(λex) was set to the λmax for each absorption band of the compound.   
 
5.3 Results 
PtII chlorido and azido complexes of three azopyridine ligands azpy, azpyNMe2 
and azpyOH were prepared and characterised. The UV-visible absorption spectra 
of the ligands and complexes were calculated using TD-DFT methods, allowing 
the nature of the transitions to be determined. The photochemical behaviour of the 
complexes upon irradiation with UVA and broadband visible light was examined, 
and attempts were made to rationalise the observed changes in the absorption 
spectra with regard to the transitions involved. In addition, the cytotoxicity of the 
water-soluble complex (27) towards A2780 human ovarian cancer cells, and its 
phototoxicity towards HaCaT keratinocytes has been investigated. 
 
 




R = H (22), NMe2 (24), OH (26)




5.3.1 Synthesis of Platinum Complexes of Azopyridine Ligands 
5.3.1.1 Synthesis of Pt
II
 Chlorido Complexes 
The PtII chlorido complexes were obtained by addition of the appropriate 










Scheme 5.1  The synthesis of PtII chlorido complexes with azopyridine ligands 
 
[Pt(azpy)Cl2] (22) and [Pt(azpyNMe2)Cl2] (24) were produced by this method, 
analytically pure in yields of 90%. In the case of [Pt(azpyOH)Cl2] (26), methanol 
was chosen as the solvent due to the low solubility of azpyOH in 
dichloromethane.  However, cis-[Pt(DMSO)2Cl2] is poorly soluble in methanol 
and was commonly observed in the 1H NMR spectrum of the product. Purification 
by column chromatography was unsuccessful; excess starting material was 
therefore eliminated by briefly sonicating the obtained product in a small volume 
of dichloromethane and isolating once more. 
Attempts were made to prepare the PtII chlorido complex of another azopyridine 
ligand, 4-(2-pyridylazo)resorcinol; this ligand is similar to azpyOH, but contains 
an additional OH group on one ortho position of the phenyl ring. The synthesis 




+    NaN3




was carried out as for 26; however, despite 1H NMR evidence of a pure PtII 
product, elemental and mass spectral analyses were inconclusive and this product 
was not identified.  
 
5.3.1.2 Synthesis of Pt
II
 Azido Complexes 
The PtII azido complexes were prepared by direct substitution of the chlorido 










Scheme 5.2  The synthesis of PtII azido complexes of azopyridine ligands 
 
[Pt(azpy)(N3)2] (23) and [Pt(azpyNMe2)(N3)2] (25) were synthesised by the above 
method in yields of around 80%. Complex 27 was isolated as a salt with the 
ligand in its deprotonated form, Na[Pt(azpyO)(N3)2]. In an attempt to isolate the 
protonated product, the complex was dissolved in water and acidified, causing a 
colour change from deep blue to brown. However, although a small amount of 
product was recovered, it was found to be impure and all further studies were 
carried out on the deprotonated complex Na[Pt(azpyO)(N3)2] (27). 
 




5.3.1.3 Investigating the Oxidation of Pt
II
 Complexes 
Efforts to oxidise [Pt(azpy)(N3)2] (23) under a variety of conditions were 
unsuccessful. The use of aqueous solutions of hydrogen peroxide returned 
unreacted starting material. Two methods previously employed for the oxidation 
of PtII complexes of cyclometallated azobenzenes were also attempted. However, 
reaction with I2 in acetone
[15] yielded a mixture of products as seen by NMR 
spectroscopy, and the organic oxidising agent meta-chloroperoxybenzoic acid 
(mCPBA)[29] was found to decolourise the deep pink solution to pale brown, 
suggesting decomposition of the azo chromophore.  
 
5.3.2 X-ray Crystallography 
The structure of [Pt(azpy)Cl2] (22) was determined by single crystal X-ray 
diffraction, and corresponds well with that previously reported in the literature.[18]  
The complex crystallised as orange plates, in the monoclinic system and of space 
group C2/c. The asymmetric unit contains three crystallographically independent 
PtII complexes, differing in the angle of the pendent phenyl group and the distance 
of the chlorido groups from the plane of the platinum and the chelating azo ligand. 
Close contacts between the chlorines and the pyridine hydrogens of a 
neighbouring complex lead to the formation of infinite ribbons (seen for each 
independent complex). Two such ribbons are associated via close Pt-Pt contacts of 












Figure 5.2 A section of the ribbons formed by each crystallographically 
independent complex of [Pt(azpy)Cl2] (22), and the interaction of these ribbons 
via close Pt-Pt contacts (picture courtesy of Dr Guy Clarkson). 
 
5.3.3 Computed Geometries 
According to DFT calculations, similar structural features are observed for all 
three azopyridine ligands. All display planar geometry and have comparable N=N 
distances of around 1.25 Å.  
Upon coordination to platinum, the phenyl ring of the ligand is twisted out of the 
Pt–py–azo plane, by between 29˚ and 39˚ in complexes 22–26. In complex 27, 
however, this twist is reduced to 3˚ and the ligand remains essentially planar.  
Selected calculated bond lengths for complexes 22–27 are tabulated below; in the 
case of 22, the values are compared with those obtained from the crystal structure, 
and show good agreement. In all PtII chlorido complexes (22, 24 and 26), the N=N 
bond lengthens to a similar extent (1.28–1.29 Å) upon coordination. Pt–Cl bonds 
are of a similar length (~2.32 Å) in all complexes, with the two bonds within each 




complex also comparable despite differing ligands in the trans position (one 
pyridyl and one aza nitrogen).  
In the azido complexes, Pt–N3 distances are shorter in all cases than the 
corresponding Pt–Cl, with a concomitant increase in the Pt–N(py) and Pt–N(aza) 
bond lengths. The N=N distances are similar to those in the chlorido complexes, 
with the exception of complex 27 in which this bond is significantly lengthened. 
 
Table 5.1  Selected bond distances (Å) of complexes 22–27 in calculated ground 
state geometries, and comparison with the X-ray crystal structure of 22. 
 






1.275 2.016 2.003 2.316 2.318 
[Pt(azpy)Cl2] (22) 
X-ray 
1.291(9) 2.018(8) 1.965(8) 2.281(2) 2.288(3) 
[Pt(azpyNMe2)Cl2] (24) 1.286 2.012 2.019 2.326 2.324 
[Pt(azpyOH)Cl2] (26) 1.282 2.013 2.002 2.325 2.325 
 
PtII Azido Complex 
 




[Pt(azpy)(N3)2] (23) 1.280 2.021 2.019 2.002 1.989 
[Pt(azpyNMe2)(N3)2]  
(25) 
1.289 2.017 2.049 2.012 1.995 
Na[Pt(azpyO–)(N3)2] 
(27) 
1.327 2.013 2.080 2.039 2.018 







5.3.4 Orbital Analysis 
5.3.4.1 Azopyridine Ligands 
The HOMO of azpy has n character, localised on the nitrogen lone pair, whereas 
HOMO–1 is a π* orbital delocalised over the whole molecule. This order is 
reversed for azpyNMe2 and azpyOH – they both possess π* HOMOs, residing in 
part upon the NMe2 and OH groups, while for both HOMO–1 displays n 
symmetry.  
The LUMO of all three ligands is π* in character and delocalised over the whole 
molecule, with little involvement from the NMe2 and OH groups. LUMO+1 is 
located mainly on the pyridyl ring in each case. The HOMO–LUMO energy gaps 










Figure 5.3  HOMO and LUMO representations of azpy, azpyNMe2 and azpyOH. 
Green indicates a positive phase, and lilac a negative phase. 
 







The HOMO of 22 is a π* orbital delocalised over the whole molecule, with a 
significant part residing on the platinum and chlorido ligands; similarly HOMO–1 
is also of π* symmetry but with a lesser involvement of the Pt–Cl region. In 
contrast, the π* HOMO of 23 is located almost entirely on the platinum and azido 
ligands. HOMO–1 is more delocalised, but still with very little based on the 
phenyl ring of azpy. The HOMOs of 24–27 are alike; π* in character and 
predominately based on the azo ligands, including the NMe2 and OH groups. Each 
HOMO–1 of 24–27 is also similar, and located mainly on the platinum and 
chlorido/azido ligands.  
The LUMOs of complexes 22–27 are similar; π* orbitals delocalised mainly over 
the azopyridine ligand and the metal, with little density based on the chlorido or 
azido ligands. With the exception of 23, the LUMO+1 of all complexes show a 
similar σ* antibonding character towards the Pt–ligand bonds, with small but 
variable degrees of density on the azopyridine ligand, whilst LUMO+2 resides 
mainly upon the pyridyl ring. In complex 23, however, the nature of these orbitals 
is reversed. The HOMO–LUMO energy gaps are 3.54, 2.80, 2.67, 2.69, 2.97 and 













HOMO (22) HOMO (23) HOMO (24)







Figure 5.4  Selected orbitals of platinum complexes. Top: The HOMOs of 22, 23 
and 24. Bottom: The lower unoccupied orbitals, similar for all complexes, are 










5.3.5 UV-Visible Absorption Spectra of Azopyridine Ligands  
5.3.5.1 Absorption and Singlet Excited States of Azpy, AzpyNMe2 and 
AzpyOH 
UV-visible absorption spectra of the three azopyridine ligands were recorded in 
both methanol and dioxane, with the results listed in Table 5.2. 
 
Table 5.2  Wavelength of maximum absorbances and extinction coefficients for 
azopyridine ligands in methanol and dioxane. 
Compound Methanol Dioxane 
 λmax (nm) ε (M






























a Acidified with 3 eq HNO3 
 
 
Electronic absorption spectra of the three ligands in methanol were calculated 
using TD-DFT methods. Figure 5.5 shows these overlain with the experimental 
spectra, and includes the electron density difference maps (EDDMs) of the lowest 
energy singlet transition in each case. Table 5.3 lists the calculated singlet excited 
states for these ligands. 





























































































































































Figure 5.5  Normalised absorption spectra for azpy, azpyNMe2 and azpyOH in 
methanol (black) and calculated spectra (blue). The excited states are shown as 
vertical bars. Inset: Electron density difference maps (EDDMs) of the lowest 
energy singlet electronic transition for each ligand. Electron density migrates from 
magenta to yellow areas. 




Table 5.3  Calculated singlet excited states for azopyridine ligands in methanol.  
Tr = transition number, as obtained in the TD-DFT calculation output; 
f = oscillator strength. 
 
 Tr Ecalc, eV 
(nm) 



























































The results of TD-DFT calculations were used to assign the absorption bands of 
the spectra; these confirm the previous assignment of these transitions based on 
experimental data. The main absorption band of azpy in methanol is centred at 
317 nm, corresponding to a π–π* transition in which electron density migrates onto 
the aza nitrogens. A weak band is also seen at 441 nm in the experimental 
spectrum, resulting from a formally forbidden n-π* transition. AzpyNMe2 
displays a strong absorption band at 432 nm, arising from a mixed π–π*/CT state 
in which charge transfer from the NMe2 group makes a strong contribution. This 




results in the significant red shift of this band compared with the purely π–π* 
transition of azpy. A significant charge transfer contribution is also seen in the 
main transition of azpyOH, although to a lesser extent than in azpyNMe2. Higher 
energy absorptions in both azpyNMe2 and azpyOH can be ascribed to π–π* states. 
Comparing the spectra of these ligands in dioxane and methanol, the transitions 
display solvatochromism as expected from their assigned character. Although 
dioxane is known to show anomalous solvatochromic effects,[30] in this case the 
expected trends are observed. π–π* bands are red-shifted upon changing to the 
more polar methanol, since attractive polarisation forces between the solvent and 
the absorbing molecule lower the energy of the excited state to a greater extent 
than the ground state, decreasing the energy between the two. In contrast the n–π* 
transition of azpy is blue-shifted in methanol; this is due to the increased solvation 
of the lone pair in a more polar solvent, decreasing the energy of the n orbital.[31] 
 
5.3.5.2 Kinetic Studies of Azopyridine Ligands in Dioxane 
The electronic absorption spectral profiles of the ligands azpy, azpyNMe2 and 
azpyOH in dioxane were measured over a 12 hour period, as described in section 
5.2.3.3.   
The spectrum of azpy remained unchanged during the course of the experiment.  
However, the main absorption band of azpyNMe2 (λmax = 418 nm) showed an 
increase in intensity of approximately 7% over 12 hours, with no change in 
energy. Repetition of the experiment found that, although the trend was 








































Figure 5.6  The spectrum of azpyNMe2 in dioxane, showing an increase in 
intensity of the main absorption band over time. 
 
Initial experiments showed that the spectrum of azpyOH also changed over time, 
with an absorbance band growing at 471 nm.  However, further investigation 
suggested this change is related to the protonation state of the phenolic OH group. 
A subsequent experiment, in which ~3  mol eq HNO3 were added to ensure the 









5.3.6 UV-Visible Absorption Spectra of Pt
II
 Complexes 
5.3.6.1 Absorption and Singlet Excited States of Complexes 22-27 
UV-visible absorption data for complexes 22–27, in methanol and dioxane, are 
shown in Table 5.4. 
 
Table 5.4  Wavelength of maximum absorbances and extinction coefficients for 
complexes 22–27 in methanol and dioxane. 
Complex Methanol Dioxane 
 λmax (nm) ε (M
-1 cm-1) λmax (nm) ε (M
-1 cm-1) 


































































a 95:5 methanol/dioxane:DMF. b Acidified with 3 eq HNO3 








































































































































































Figure 5.7  Normalised absorption spectra for complexes 22–24 in methanol 
(black) and calculated spectra (blue). Inset: Electron density difference maps 
(EDDMs) of the lowest energy singlet electronic transition for each complex.  
  






































































































































































Figure 5.8  Normalised absorption spectra for complexes 25–27 in methanol 
(black) and calculated spectra (blue). Inset: Electron density difference maps 
(EDDMs) of the lowest energy singlet electronic transition for each complex. 
  




Table 5.5  Calculated singlet excited states for complexes 22-27 in methanol.  
 Tr Ecalc, eV 
(nm) 




















































































































































































The results of TD-DFT calculations were used to assign the transitions observed 
in the spectra of complexes 22–27. The spectrum of 22 consists of a main band 
centred at 381 nm, with a weaker band at lower energy. The three transitions 
comprising the main band all have mixed character, with electron density 
migrating to the azo group and pyridyl ring. The formally forbidden n–π* band at 
lower energy is more intense here than for azpy. Complex 23 shows a different 
spectral profile. The band centred at 380 nm results from a primarily ligand-
centred (LC) transition with some contribution from the metal, whilst a lower 
energy band at 529 nm arises from a metal-to-ligand charge transfer (MLCT) 
transition with a very strong contribution from the azido ligands.  
The main absorption band of 24 arises from an LC transition in which electron 
density migrates from the NMe2 region to the aza nitrogens, with only a small 
involvement of the metal and chlorido ligands. A lesser contribution to this 
absorption band is made from a transition at slightly higher energy, MLCT in 
character with a strong involvement of the chlorido ligands. The spectrum of 25 is 
similar, with an asymmetric band centred at 614 nm, again comprised of two 
transitions. Although charge transfer (from the NMe2 group to the azo nitrogens 
and pyridyl ring) dominates the main transition, the metal and azido groups also 
contribute. The second transition is MLCT in character, with a strong contribution 
from the azido groups. 
The relatively broad absorption band in the spectrum of 26 results from two main 
transitions, with two others making a lesser contribution. The dominant transition 
is mixed in character, in which electron density migrates to the azo group and 
pyridyl ring; similar to that seen for complex 22 but here with contribution from 
the OH group also. The second transition is MLCT in character, with strong 
involvement of the chlorido groups. Complex 27 shows the poorest agreement 
between theoretical and experimental spectra, however the nature of the 
transitions involved can still be established. Three main transitions are found to 
comprise the absorption band. All are MLCT in character with strong 






























contributions from the azido ligands, with charge transfer from the oxygen 
involved to various extents. 
  
5.3.6.2 Effects of pH on the Absorption Spectra of Complexes 26 and 24 
Solutions of [Pt(azpyOH)Cl2] (26) were found to readily change colour, from 
brown to deep blue, upon addition of certain reagents or solvents, during 
chromatography attempts and, at times, upon filtration. Further investigation 
revealed this to result from deprotonation of the OH substituent of the azopyridine 
ligand. As the protonated forms of the azpyOH complexes are poorly soluble in 
water, an accurate pH titration by NMR spectroscopy could not be performed; 
instead UV-visible absorption spectra were obtained at several pH values. 
Complex 26 was dissolved in a basic NaOH solution and the pH gradually 
decreased by addition of 0.01 M HNO3. The coexistance of both protonated and 











Figure 5.9  The absorption spectrum of [Pt(azpyOH)Cl2] (26) at pH 5.21 and 
6.24. 




Protonation of the NMe2 group of complex 24 was also investigated. Extremely 
acidic conditions (pH ~ 0) were required to effect protonation, which resulted in a 
colour change from deep blue to orange. The resulting spectral profile is similar to 
that of [Pt(azpy)Cl2] (22), confirming the influence of charge transfer from the 
NMe2 group on the absorption properties of 24. The effect of coordination to 
platinum is also demonstrated, since the pKa of azpyNMe2 alone has been 
determined as 2.11.[32] 
  
 
Figure 5.10  The dependence of the absorption spectrum of complex 24 on pH. 
 
5.3.6.3 UV Kinetic Studies of Pt
II
 Complexes in Dioxane 
The electronic absorption spectra of complexes 22–26 in dioxane, and 27 in 
methanol, were measured over a 12 hour period as described in section 5.2.3.3.   
The spectra of [Pt(azpy)Cl2] (22) and [Pt(azpy)(N3)2] (23) remained unchanged 
throughout the experiment. The two complexes of azpyNMe2, however, showed 








































































contrasting behaviour. The main absorption bands of [Pt(azpyNMe2)Cl2] (24), at 
613 nm and 647 nm, showed a 6% decrease in intensity over time, whilst that of 
[Pt(azpyNMe2)(N3)2] (25) (618 nm) increased in intensity by 7%, consistent with 

































Figure 5.11  The change in UV-Visible absorption spectra of complexes 24 and 
25 over a 12 h period. 
 




Initial experiments showed that the spectrum of [Pt(azpyOH)Cl2] (26) also 
changed over time; however, as in the case of azpyOH alone, further investigation 
suggested this was due to the protonation state of the phenolic OH group, the pKa 
of which is decreased upon coordination to platinum (section 5.3.6.2). Repetition 
of the experiment, with the addition of 3 mol eq HNO3 to ensure the phenolic OH 
group remained protonated, showed no change to the spectral profile over 12 
hours. Na[Pt(azpyO)(N3)2] (27), in methanol, showed a 5% decrease in intensity 
of the absorption band at 619 nm, whilst that at 584 nm remained essentially 
unchanged. 
 
5.3.7 Fluorescence Studies 
The fluorescent properties of the three azopyridine ligands and complexes 22–27 
were investigated. All were found to be non-fluorescent under the conditions 
employed (298 K, dioxane). 
 
5.3.8 Kinetic Studies of Complex 27 in Aqueous Solutions and Cell Culture 
Media 
The spectrum of Na[Pt(azpyO)(N3)2] (27) was followed over a 12 hour period in 
aqueous solution. The main absorption bands around 600 nm rapidly decreased 
over time, with A594 decreasing by 16% in the six minutes following the first 
acquisition, followed by the emergence of a new peak at 425 nm. The change was 
also noted visually, as the intense blue colour had been lost at the end of the 
experiment and the solution appeared pale grey-brown. 





































Figure 5.12 The change in absorption profile of 27 over a 12 h period in aqueous 
solution. 
 
Comparing the final spectrum with those obtained during the pH titration 
experiment, it appears that the phenolate group became protonated over time in 
water. This was confirmed by addition of 2 mol eq HNO3, after which the peak at 
425 nm continued to grow and the two peaks around 600 nm decreased in 
intensity further. Conversely, addition of dilute NaOH restored the spectrum to its 
original profile. 
Since 27 is a potential candidate for cytotoxicity and phototoxicity testing, a 
stability study was carried out in buffered (pH 7.3) RPMI cell culture medium, to 
mimic conditions in such experiments, as described in section 5.2.3.4.  A similar 
but much reduced change was seen in this case, indicating the complex remained 
predominantly in its deprotonated form. This is supported by observations during 
the cell tests, in which the blue colour of the solution remained following the 24 
hour exposure of the cells to the drug. 






































Figure 5.13 The change in absorption profile of 27 over a 12 h period in cell 
culture medium. 
 
5.3.9 Stability of Pt
II
 Complexes by NMR in Acetone 
The NMR spectra of complexes 22–27, recorded in acetone, showed no change 
over a period of 113 days following storage at ambient temperature in the dark. It 
can therefore be concluded that these complexes are very stable in solution under 
these conditions, as there is no evidence of decomposition or formation of new 
species. 
 
5.3.10 Cytotoxicity of Na[Pt(azpyO)(N3)2] (27) 
Complex 27 was tested for cytotoxicity against the A2780 human ovarian cancer 
cell line. Although the complex showed moderate cytotoxicity, results were 




variable with the two tests performed giving IC50 values of 62 and 83 µM 
(cisplatin 1.3 µM).  
 
5.3.11 Photoreactions of Pt
II
 Complexes in Dioxane 
The photoreactions of the PtII complexes 22–27 upon irradiation with UVA and 
visible light were followed by UV-visible absorption spectroscopy. Experiments 
were carried out in dioxane due to the increased solubility in this solvent over 
methanol, with the exception of complex 27, for which methanol was used. 
Unless otherwise stated, the power levels and total irradiation times were as 
described in section 5.2.3.7.  
 
5.3.11.1 [Pt(azpy)Cl2] (22)  
A) UVA Light 
The spectral profile of 22 remained essentially unchanged following 120 min 
irradiation, with the main absorption band at 395 nm showing only a small 
decrease of 2%. This decrease continued upon prolonged irradiation, to a total of 
4% after 210 min. However, given such small changes, the complex can be 
regarded as essentially stable under these conditions. 
 
B) Visible Light 
Following 120 min irradiation, no change was seen in the main absorption bands 
of 22. 
 
C) Green Light 
Similarly, no change was seen following 120 min irradiation with green light. 




5.3.11.2 [Pt(azpy)(N3)2] (23) 
A) UVA Light  
Irradiation with UVA light resulted in a decrease in intensity of both main bands 
in the absorption spectrum of 23 (Figure 5.14, A). 
The lower energy band (566 nm) showed the most rapid change in absorbance, 
decreasing to less than half of its initial value by 45 min. Upon further irradiation 
a slight increase was seen, similar to the remainder of the lower energy region of 
the spectrum in which the absorbance increased gradually throughout the 
experiment. The band at 391 nm also decreased upon irradiation; this continued 
throughout the experiment. After 45 min, a new peak became apparent at 325 nm, 
which increased in intensity upon further irradiation. By the end of the experiment 
the sample had decolourised significantly, from deep pink to pale brown. 
 
B) Visible Light 
Irradiation with visible light also led to a decrease in intensity of both main bands 
in the spectrum of 23. Similar changes in the spectral profiles suggest the same 
reaction is occurring upon irradiation with both UVA and visible light; however in 
this case the rate of change is slower compared with UVA. Following 120 min of 
irradiation, the band at 566 nm was still decreasing in intensity and the new peak 
at 325 nm had not clearly resolved.  
 
C) Green Light 
Following 120 min irradiation, no change was seen in the spectral profile of 23. 
 
 
































































































Figure 5.14.  UV-visible absorption spectra of [Pt(azpy)(N3)2] (23) following 
irradiation with A: UVA, B: visible and C: green light, over 120 min in dioxane. 




Attempts to elucidate the photoproducts of these reactions were unsuccessful. No 
platinum containing species could be detected by mass spectrometry, and 
following the reactions by NMR was limited by the poor solubility of the complex 
in many solvents suitable for irradiation experiments. An attempt in dioxane 
showed only weak signals in the spectrum of the initial complex, the intensity of 
which were rapidly lost upon irradiation and no photoproducts could be identified.  
 
5.3.11.3 [Pt(azpyNMe2)Cl2] (24) 
A) UVA Light 
The main absorption bands at 613 and 647 nm showed a decrease in intensity of 
8% following 120 min irradiation, with a smaller decrease (5%) also seen for the 
dark control. A reduction in intensity throughout the higher energy region was 
seen for both samples and was deemed not to be an effect of irradiation. 
 
B) Visible Light 
The decrease of the main absorption bands was, at 3%, smaller than that seen 
following UVA irradiation, however this trend was also seen for the dark control. 
Again, changes in the higher energy region of the spectrum were seen but 
appeared to be independent of irradiation.  
 
Given the variable changes seen in the spectrum of this complex even under dark 
conditions, it is difficult to draw conclusions as to its stability upon irradiation. 
However, it can be concluded that the effect of irradiation is not large, and the 
complex is relatively stable under the conditions employed.  
 
 




5.3.11.4 [Pt(azpyNMe2)(N3)2] (25) 
A) UVA Light 
The irradiation of complex 25 resulted in changes to the main absorption band at 
618 nm. Initially this band decreased in intensity with a broadening of the 
maxima, and after 30 min began to resolve into two separate peaks. Upon further 
irradiation, the peak at lower energy (621 nm) decreased in intensity faster than 
that at higher energy (574 nm). Irradiation was continued beyond 120 min, with 
additional spectra recorded at 180 and 240 min (grey and violet lines, 
respectively). The trend was continued, although the intensity difference between 
the two peaks began to decrease. A decrease in the higher energy absorption band 
at 298 nm was also observed. 
 
B) Visible Light 
Initial changes were similar to those seen upon irradiation with UVA light, 
although again occurred at a slower rate. Irradiation was continued beyond 
120 min, with additional spectra recorded at 150, 180, 210, 240, 300 and 360 min. 
Following 180 min irradiation, the broadened band again began to resolve into 
two separate peaks, both of which decreased in intensity upon continued 
irradiation, although in this case the higher energy peak appeared to decrease at a 
slightly faster rate. Again a decrease in the higher energy absorption band at 
298 nm was observed. 
  


























































































Figure 5.15  UV-visible absorption spectra of [Pt(azpyNMe2)(N3)2] (25) 









5.3.11.5 [Pt(azpyOH)Cl2] (26) 
A) UVA Light 
A 2% decrease in intensity was seen in the main absorption bands of 5 following 
120 min irradiation; again the complex can be regarded as essentially stable under 
these conditions. 
 
B) Visible Light 
Following 120 min irradiation, no change was seen in the main absorption bands 
of 26. 
 
5.3.11.6 Na[Pt(azpyO)(N3)2] (27) 
A) UVA Light 
In comparison to complexes 23 and 25, relatively little change was seen in the 
absorption spectra of 27 upon irradiation. Both peaks at 619 nm and 584 nm 
decreased in intensity by a total of 10% after 120 min irradiation, with an 
accompanying blue shift of 11 nm in each case. Whilst no further blue shift was 
seen after 45 min, the intensity decrease continued throughout the experiment. 
 
B) Visible Light 
Little change was seen in the spectra of the complex upon irradiation with visible 
light. As with UVA, a blue shift of both peaks was again observed, although at 
5 nm was smaller in magnitude in this case. A small (3%) increase in intensity of 
these peaks was seen over the course of the experiment. 
 

















































































Figure 5.16  UV-visible absorption spectra of Na[Pt(azpyO)(N3)2] (27) following 
irradiation with UVA and visible light, over 120 min in methanol.  




5.3.12 Phototoxicity of Na[Pt(azpyO)(N3)2] (27) 
Complex 27 was tested for phototoxicity towards HaCaT keratinocytes, 
irradiating with UVA light as described in Chapter 2. The complex was found to 
be toxic both upon irradiation with UVA light and in the dark (sham-irradiated 
control), with IC50 values of 72.1 and 112.9 µM respectively, which indicate an 
increase in toxicity upon irradiation. 
During testing, it was observed that the intense blue colour caused staining of the 
cells, and thus provided a means of visualising the complex within the cells. This 
staining was evident in the majority of cells in the sample; estimated at around 
80% by visual inspection. Following the 1 h incubation period prior to irradiation, 
the blue colour appeared to be localised in the nuclear region, with only punctate 
staining of the cytoplasm, as shown in Figure 5.17. This suggests that a platinum 
complex reaches the nucleus, since the ligand alone does not give rise to a blue 














Figure 5.17  A microscope image of HaCaT cells prior to irradiation, 1 h after 
addition of complex 27. The staining of the cells by the complex is evident, with 
the blue colouring appearing to be localised in the nuclei.  




During the 24 h development period following irradiation, the blue colour began 
to fade. This seemed to occur to a lesser extent in the irradiated sample than in the 






5.4.1 Synthesis and Characterisation of Platinum Complexes of 
Azopyridine Ligands 
PtII chlorido complexes of several azopyridine derivatives have been reported in 
literature.[18,19] Typically, synthesis has involved reaction of the appropriate 
azopyridine ligand with K2PtCl4 in boiling aqueous acetonitrile, with purification 
in some cases by column chromatography. Attempts were made here to simplify 
this procedure and reduce the need for refluxing and chromatography.  
Cis-[Pt(DMSO)2Cl2] was chosen as the starting material due to the ease of 
replacement of the two DMSO groups by incoming ligands.[33] The synthetic 
methods described here produced, in the case of 22 and 24, analytically pure 
complexes in higher yields and on a shorter timescale than previously reported 
methods. The yield was reduced, however, in the synthesis of 26 due to the need 
for an additional purification step. Solubility constraints led to the use of methanol 
as the reaction solvent in this case, leading to the contamination of the product 
with the poorly soluble starting material cis-[Pt(DMSO)2Cl2]. During column 
chromatography, a colour change from brown to blue was observed. It is likely 
that the phenolic OH of the ligand was deprotonated, and the resulting, more polar 
complex was retained on the silica. 
Attempts to synthesise the PtII chlorido complex of 4-(2-pyridylazo)resorcinol 
were unsuccessful; although evidence of a pure, platinum-containing product was 
obtained by NMR spectroscopy, it could not be identified. The ligand is well 




known for its excellent metal binding ability, and has been used in the 
spectrometric determination of over 40 different metals.[34] Tridentate (N,N,O) 
coordination of this ligand is most common, and may be favoured over bidentate 
(N,N) coordination in a proton-accepting solvent such as methanol.[35]  However, 
mass spectral and elemental analyses suggested the product formed was neither 
the tridentate nor the intended bidentate complex, and its identity could not be 
elucidated. 
Formation of a PtII azido complex is commonly carried out by chloride extraction 
with silver nitrate in aqueous solution, followed by addition of sodium azide as 
described previously.[36] However, the poor aqueous solubility of the PtII chlorido 
complexes, combined with the reported unsuitability of this method for PtII 
bipyridine complexes,[37] led to the use of an alternative method in this case, 
whereby sodium azide was added directly to the complex in DMF. This method, 
previously employed in the synthesis of PtII azido complexes containing 
bipyridines,[38] was found to be equally suitable in this case and the required 
complexes were isolated in good yields. Complex 27 was isolated as a sodium salt 
with the ligand in its deprotonated form, Na[Pt(azpyO)(N3)2]. Subsequent 
experiments indicated that the phenolic OH group of the ligand has a pKa ~5–6 
when coordinated to platinum (section 5.3.6.2), and the methanolic solution of 
NaN3 used in the reaction was sufficiently basic to effect deprotonation. In order 
to isolate the protonated product, it was not possible to acidify the reaction 
solution during synthesis due to the presence of excess sodium azide, since the 
azide anion forms an extremely toxic gas, HN3, upon exposure to acid. Acidifying 
an aqueous solution of the isolated, deprotonated sample was also unsuccessful 
and could be a result of instability to highly acidic conditions, since several metal 
complexes of azpyOH have previously been found to be unstable and sensitive to 
changes in pH.[39] 
Given the interesting photochemistry of PtIV azido complexes previously 
synthesised in our group, attempts were made to oxidise [Pt(azpy)(N3)2] (23) in 
order to investigate the properties of the PtIV derivative. However, attempts using 




a variety of conditions were not successful. The oxidation of [Pt(bipy)(N3)2] and 
similar complexes is difficult to achieve, due to the π-accepting nature of bipy and 
its ability to stabilise metals in their low oxidation states.[40] Azpy is a better π-
acceptor than is bipy, demonstrated by the greater stability of [Ru(azpy)2Cl2] 
compared with [Ru(bipy)2Cl2] with respect to oxidation to Ru
III.[11] Therefore it is 
perhaps not surprising that the oxidation of 23 was problematic, and it may be that 
a stronger oxidising agent and/or reaction conditions would be required than can 
be tolerated by the azo functionality and the azido groups. 
 
5.4.2 UV-Visible Absorption Spectra of Azopyridine Ligands and 
Complexes 22–27 
The experimental absorption spectra of the three ligands azpy, azpyNMe2 and 
azpyOH were compared with those generated by TD-DFT calculations; the results 
of which also enabled the transitions comprising each band to be assigned. 
Each ligand displays a large band arising from a π–π* transition. The charge 
transfer character of this transition increases with the σ-donating ability of the 
para substituent on the phenyl ring (H < OH < NMe2), resulting in a progressive 
red shift of this band in the absorption spectrum. Azpy displays a weak n–π* 
transition at lower energy; the major contribution is presumably from a HOMO–
LUMO transition, since the HOMO of this ligand is of n symmetry. Although 
formally forbidden on symmetry grounds, the selection rules are seemingly 
violated to a small extent and a very weak band resulting from this transition is 
observed.  
The absorption bands of complexes 22–27 are comprised of two or more main 
transitions, generally with LC or MLCT character. The LC transitions typically 
show involvement of the NMe2 or OH group (24–27), whilst the MLCT 
transitions often contain a strong contribution from the chlorido or azido groups. 
In all transitions listed, electron density migrates to the azo group and pyridyl 




nitrogens. The influence of the NMe2 and OH groups of 24–27 can be seen by the 
red shift and increased molar extinction coefficient of the absorption bands 
compared with complexes 22 and 23. σ-Donation from these groups decreases the 
π-accepting capability of the azo group, increasing the energy of the metal-based 
orbitals thus decreasing the energy of the MLCT transitions. A similar energy 
decrease is seen for ligand-centred transitions, due to the increased delocalisation 
of electron density. [Pt(azpy)Cl2] (22) again shows a weak band at lower energy 
(495 nm). Not predicted by singlet excited state calculations, this is likely due to a 
formally forbidden triplet transition. The presence of a heavy metal centre 
increases spin-orbit coupling, allowing for a violation of the spin selection rule 
and a weak band to be observed. 
The agreement between calculated and experimental spectra is generally good, 
although less so for complexes of azpyNMe2 (24 and 25) and for 27, containing 
the deprotonated ligand azpyO–. It has been previously observed that such 
predictions are less valid in the presence of strongly electron-donating or 
withdrawing groups;[41] presumably the calculated energy of the orbitals is less 
accurate in these cases. 
 
5.4.2.1 Kinetic Studies of Ligands and Platinum Complexes by UV-Visible 
Absorption Spectroscopy 
The main absorption band of azpyNMe2 shows an increase in intensity over time; 
the magnitude of which appears to be variable. The same is seen for the PtII azido 
complex of this ligand, 25, whilst the chlorido complex 24 shows the opposite 
trend, with the two main bands decreasing in intensity. The reason for this 
behaviour is unclear. Stacking interactions are common in aromatic π-systems and 
could give rise to such variations in the spectra. Although no significant π-π 
stacking was seen in the crystal structure of [Pt(azpy)Cl2] (22), σ-donation from 
the NMe2 group renders the aromatic system of azpyNMe2 complexes more 
electron- rich in comparison, which could increase the likelihood of such 




interactions. However, the deviation of the ligand from planar geometry in 
complexes 24 and 25 would be expected to hinder stacking, and these spectral 
changes are minimal in complex 27, which is essentially planar according to DFT 
calculated geometries. Additionally, although the aggregation of azo dyes is fairly 
well documented, it is typically favoured in aqueous solutions of high ionic 
strength and not in organic solvents.[42] The phenomenon seen here could be 
further explored by concentration- and temperature-dependent NMR and UV-
visible spectroscopic experiments.   
 
5.4.3 Effects of pH on Complexes 24 and 26 
The effect of charge transfer from the NMe2 and OH groups on the absorption 
properties of these complexes is demonstrated by the UV spectra of 24 and 26 at 
varying pH values. At very low pH (around 0), the NMe2 group of 24 is 
protonated and essentially all donating ability is lost; the solution turns from deep 
blue to orange and the spectral profile resembles that of [Pt(azpy)Cl2] (22). 
Although a pKa value was not determined, it is certainly below that of the free 
ligand, 2.11[32]. The lower tendency towards protonation reflects the greater 
conjugation of the nitrogen lone pair into the π system when the ligand is 
coordinated to platinum. Similarly, the σ-donating ability of the OH group is 
greatly enhanced upon deprotonation, as can be seen by the large red shift in the 
main absorption band of 27 compared with that of 26. An accurate pKa of the OH 
group of complex 26 could not be determined; however at around 5–6 this is 
significantly lower than that of the free ligand at 8.08. A similar effect was seen in 
the ruthenium complex [(η6-p-cym)Ru(azpyOH)Cl]PF6, where the pKa was 
decreased to 6.48 upon coordination to the metal.[32] This suggests that electron 
density from the phenolate group is more readily delocalised in the metal 
complex. Additionally, at physiological pH (around 7.4) the complex will exist 
predominately in its deprotonated form, with an overall negative charge. 
 




5.4.4 Stability Studies of Pt
II 
Complexes 
5.4.4.1 Stability of 22–27 by NMR 
The synthesis and biological properties of the AuIII complex [Au(azpy)Cl2]Cl 
have been recently reported.[14] Intriguingly, the complex was found to undergo a 
metal-mediated reaction to form a cationic, tricyclic organic derivative of azpy 
over 12 days in an acetone solution. This cation showed higher cytotoxicity than 
the parent complex in a number of cancer cell lines. 
Complexes 22–27 were therefore investigated for their tendency to undergo this 
or a similar reaction, with 1H NMR spectra in acetone showing no observable 
changes over 113 days. It was therefore concluded that complexes 22–27 are 
stable over a long time period in solution, and show no tendency to undergo such 
reactions. 
The mechanism of formation of this cation has not been elucidated, though AuIII 
mediated organic transformations are well-known.[43] Although PtII is 
isoelectronic with AuIII, the two display markedly different chemistries. The PtII 
complex of azpy is neutral whilst that of AuIII is cationic, and the electronic 
properties of these complexes will differ significantly.  
 
5.4.4.2 Stability of Na[Pt(azpyO)(N3)2] (27) in Aqueous Solution and Cell 
Culture Media 
The rapid change in the UV-visible spectrum of 27 upon dissolution in water 
appears to result from protonation of the phenolate group. The pKa of this group 
has been determined as 5–6 so at pH values close to this a mixture of the two 
species will be present in solution. The spectral profile will thus change as an 
equilibrium is reached following dissolution of a purely deprotonated sample in 
water. However, the observed rate of change is slower than expected, since 
protonation is typically instantaneous. This reduced rate could indicate the 




involvement of the phenolate group in intermolecular interactions, reducing its 
tendency to protonate. Indeed, an osmium complex of this ligand was recently 
crystallised, in which the phenolate oxygen was found to show a strong hydrogen 
bond to a water molecule (Y. Fu, unpublished results). The stability of this 
complex in methanol also supports the theory, since such a process could not 
readily occur in this solvent. Furthermore, the suppression of this change in RPMI 
cell culture medium, buffered at pH 7.3, provides additional evidence. This 
indicates that, during cytotoxicity testing, the complex should remain 
predominately in its deprotonated form with an overall negative charge. 
  
5.4.5 Cytotoxicity of Na[Pt(azpyO)(N3)2] (27) 
The cytotoxicity of several Ru complexes of azopyridines has been reported, as 
well as that of an AuIII azpy complex.[14] However, despite several reports of PtII 
azopyridine complexes, cytotoxicity studies appear to be absent in the literature. 
The aqueous insolubility of the complexes synthesised here hampered the testing 
of all but complex 27, which is reasonably water soluble due to its isolation as a 
sodium salt. This was found to be moderately cytotoxic towards the human 
ovarian A2780 cancer cell line, although different IC50 values were obtained in 
the two plates tested (62 and 83 µM). The rapid change in the absorption spectrum 
of 27 in aqueous solution, believed to be influenced by its protonation state, 
appears to be reduced upon dissolution in buffered, alkaline cell media. However 
should this occur to any extent (during sample preparation, for example), it would 
result in the testing of two complexes with differing properties and solubilities, 
and in unknown proportions.  
It is also noteworthy that whilst the complex remains predominately deprotonated 
in cell culture media, upon uptake into cancer cells, which typically show pH 
values 0.3 to 0.5 units lower than those of healthy cells,[44] protonation of the 
complex may be more probable. 
 




5.4.6 Photoreactions of Pt
II
 Complexes 
The photoreactions of PtIV azido complexes, and their potential for use as 
photoactivated anticancer agents, are the subject of much current interest. Chapter 
3 was also concerned with investigations of the photochemistry and phototoxicity 
of PtII azido complexes. However, both the PtII and PtIV analogues studied thus far 
show very low absorbance at visible wavelengths of light, which are preferred for 
phototherapy due to their deeper penetration into tissues compared with UVA. 
Therefore photoactivation of these complexes with visible light, whilst sometimes 
achievable, is much less efficient than with UVA.[3] Azo compounds show very 
strong absorbance at visible wavelengths, hence it was believed that their 
incorporation into platinum azido complexes may allow for activation with light 
in the visible region. 
The three PtII chlorido complexes showed little change upon irradiation with UVA 
or visible light, whilst the azido analogues appeared more photoactive but to 
varying degrees. Attempts were made to rationalise the observed behaviour 
considering information from TD-DFT calculations, which predict the nature of 
the transitions and the orbitals involved in singlet excited states. 
The fate of a complex upon irradiation will depend partly upon what transitions 
can be induced by the energy of light, and the nature of the orbitals populated 
during these transitions. For example, the population of strongly antibonding 
orbitals is likely to result in dissociation of the parts of the molecule for which this 
character is seen. Complexes 22–27 all contain an orbital with σ-antibonding 
character towards most of the molecule (Figure 5.4): LUMO+1 for all except 
complex 23 (LUMO+2). The strong antibonding character suggests all transitions 
having contributions from this orbital will be dissociative.  
Complex 23 is perhaps the most photoactive of all three azido complexes, and 
undergoes a rapid decrease in its absorption bands upon irradiation. The strongest 
predicted transition in this complex (386 nm, f = 0.42), has a small (9%) 
contribution from a HOMO→LUMO+2 transition, corresponding to population of 




this strongly antibonding orbital. An additional transition at 372 nm has a much 
smaller oscillator strength (f = 0.08), but a large contribution from the 
HOMO→LUMO+2 transition (59%), and is likely also to be significant. 
Furthermore, there are a number of higher energy states, with low probability but 
some contribution involving LUMO+2. The changes in spectral profile are similar 
upon irradiation of 23 with visible light, although occur at a slower rate. The 
transitions around 386 nm and 372 nm could potentially be accessed by this light 
source, especially since the output spectrum shows spikes of intensity in this 
region. Irradiation with green light (λmax = 525 nm) resulted in no change to the 
absorption spectrum of 23, apparently being of insufficient energy to induce 
dissociative transitions. However, as the power level of the LEDs is very low in 
comparison to the other light sources used, confirmation of this is required by 
repeating this experiment using a more powerful light source, such as a laser, with 
a similar spectral output. 
Since LUMO+2 is σ-antibonding towards most of the molecule, it is likely that 
dissociation of the complex is extensive. The loss of intense colour and rapid 
decrease in signal intensity both in the absorption and NMR spectra is in 
accordance with significant decomposition. However, elucidation of 
photoproducts may be difficult even if dissociation is less extensive. For example, 
were free azopyridine to be released it would undergo cis-trans isomerisation 
upon irradiation, resulting in changes to the spectral profile which would hinder 
its identification. 
Complex 25 also shows a decrease in intensity of its absorption bands upon 
irradiation, although in this case the spectral profiles differ following irradiation 
with UVA and visible light. The transitions involving population of the strongly 
antibonding LUMO+1 have a lesser probability (lower oscillator strength) than 
those of complex 23, with the most accessible at 376 nm (f = 0.006, HOMO–
1→LUMO+1 77%), 345 nm (f = 0.006, HOMO–2→LUMO+1 67%, 
HOMO→LUMO+1 20%) and 317 nm (f = 0.03, HOMO–3→LUMO+1 48%), 
with some additional transitions at higher energy. Although of a low probability, 




the contributions made to these transitions involving LUMO+1 are high. No 
transitions involving this orbital can be found at lower energies accessible by 
irradiation with visible light. However, the complex is photoactive upon 
irradiation in this region, and it is possible that small spikes in the spectral output 
of the visible lamps (at around 370 nm and 320 nm) could induce such changes. 
The resulting spectral profile is different from that produced by UVA light; since 
irradiation with different wavelengths is likely to induce different transitions, 
which can give rise to different photoproducts. 
Complex 27 is much less photoactive than 23 or 25, the absorption spectrum 
showing only a small decrease upon UVA irradiation and a slight increase with 
visible light. Considering the accessible transitions involving the population of 
LUMO+1, a greater photoactivity may be expected. Two transitions (380 nm, 
f = 0.045, HOMO–1→LUMO+1 20%, and 374 nm, f = 0.0245, HOMO–
1→LUMO+1 66%) show fairly reasonably high probabilities and contributions 
from the σ-antibonding orbital, in comparison with 23 and 25. However, it was 
mentioned earlier that the calculation of orbital energies is often less accurate in 
the presence of strongly electron-donating groups such as the phenolate anion, 
which could partially account for the difference between theoretical and 
experimental observations.  
Additionally, whilst TD-DFT calculations can predict the nature of transitions and 
the relevant orbitals involved, they cannot predict their effects on the complex and 
its subsequent fate. For example, the population of a strongly σ-antibonding 
orbital could lead merely to a lengthening of the appropriate bonds and 
destabilisation of the complex, rather than dissociation. This could explain why 
none of the chlorido complexes appear to be photoactive, despite having 
accessible transitions (albeit with low probabilities) involving the population of an 
antibonding orbital. In the case of the azido complexes, dissociation may be more 
probable. The azido group is known to display a rich photochemistry, involving 
the generation of nitrenes and radicals amongst other species,[45] both of which 
could induce further reaction or decomposition of the photoproducts. 




Furthermore, these calculations involve solely the singlet excited state. A more 
thorough analysis would involve triplet states, the contribution of which may be 
significant in these complexes due to the heavy-atom effect. The calculation of 
potential energy surfaces along Pt–ligand bonds would also give insight into 
which ligands are the most likely to dissociate, and which are the most 
dissociative states. 
 
5.4.7 Phototoxicity of [Pt(azpyO)(N3)2] (27) 
The activity shown by Na[Pt(azpyO)(N3)2] (27) is promising in the search for new 
phototoxic complexes. Although toxic in the dark, there is a significant increase in 
activity upon irradiation with UVA light. Furthermore, the strong absorbance at 
visible wavelengths provides the possibility of photoactivation in this region, 
which has been hindered for previous PtIV azido complexes due to their low 
absorbances. Work is now ongoing to investigate the phototoxicity of 27 upon 
irradiation with a broadband red light source.  
Additionally, the intense blue colour of solutions of 27 allows for its presence in 
cells to be clearly visualised, providing information on its localisation. Since the 
colour is characteristic of the complex and not the free ligand, it could also aid in 
identification of the intact complex and any transformations it may undergo. The 
fact that the complex can be visualised alone in this way offers an advantage over 
those to which fluorescent probes are attached. In such cases, incorporation of a 
probe into the complex can significantly alter properties such as cellular uptake 
and distribution, especially since such probes must be located remote from the 
metal centre in order to minimise quenching of the fluorescence.  
Several observations during the testing of this complex warrant further 
investigation. The punctate staining in the cytoplasm could result from 
accumulation in mitochondria as well as in the nucleus, which could be 
determined by co-localisation experiments. It is also interesting that the cells 
appear to retain the blue colour to a greater extent upon UVA irradiation than 




sham irradiation, since a blue colour is indicative of the intact complex. However, 




The PtII chlorido and azido complexes of three azopyridine ligands have been 
studied in this Chapter. All complexes were synthesised in good yields and fully 
characterised. Attempts to oxidise [Pt(azpy)(N3)2] (23) to a Pt
IV derivative were 
unsuccessful, presumably due to the stabilising effect of the π-accepting azo group 
on the PtII oxidation state. 
TD-DFT calculations allowed for an analysis of the frontier orbitals of the ligands 
and complexes. All complexes were found to have a low-lying unoccupied orbital 
with a strong σ-antibonding character towards the majority of the molecule. The 
results of TD-DFT calculations were also used to assign the transitions observed 
in the UV-visible absorption spectra of these complexes; mainly ligand centred or 
MLCT with strong contributions from the chlorido and azido groups. σ-Donation 
from the NMe2 and OH/O
– groups result in a red shift of the main absorption 
bands of 24–27 compared with those of the unsubstituted complexes. 
UV-visible absorption spectra of PtII chlorido complexes showed very little 
change upon irradiation with UVA and visible light. The PtII azido complexes 23 
and 25 were found to be photoactive in both cases, with dissociation likely 
induced by population of a σ-antibonding orbital. Although 23 showed similar 
changes upon irradiation with UVA and visible light, 25 showed differing 
behaviour between the two; it is likely different transitions were induced in each 
case, giving rise to different photoproducts. Complex 27 showed some 
photoactivity upon irradiation with UVA light, but very little was observed with 
visible light. This complex showed moderate, although variable cytotoxicity 
against the human ovarian A2780 cancer cell line (IC50 62–83 µM). It was also 
found to be cytotoxic towards HaCaT keratinocytes, with activity increasing upon 




irradiation with UVA light, with IC50 values of 112.9 and 72.1 µM in the dark and 
upon irradiation, respectively. This complex was also found to stain treated cells 
blue, allowing for its location within the cells to be visualised. 
One of the aims of this work was to synthesise PtII azido complexes with ligands 
exhibiting strong absorbance in the visible region, to investigate whether this 
would lead to photoactivity upon irradiation at these wavelengths. TD-DFT 
calculations suggest dissociative transitions for all complexes occur in the UVA 
region (around 370–380 nm); even so complexes 23 and 25 show photoactivity 
upon irradiation with both UVA and broadband visible light, and work is ongoing 
to investigate if the phototoxicity of 27 shown upon irradiation with UVA light is 
maintained with red light. As well as strong absorbance in the visible region, these 
complexes have a large scope for design by, for example, changing the 
substituents on the phenyl ring, which has been shown here to have a vast 
influence on their properties. These results therefore suggest that further 
exploration of the use of ligands which absorb strongly in the visible region may 
lead to successful attempts to increase the wavelength of photoactivation of 
platinum azido complexes. 
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